*Review*

# Morphinan Alkaloids and Their Transformations: A Historical Perspective of a Century of Opioid Research in Hungary [†]

**János Marton** [1,*], **Paul Cumming** [2,3], **Kenner C. Rice** [4] **and Joannes T. M. Linders** [5]

[1] ABX Advanced Biochemical Compounds Biomedizinische Forschungsreagenzien GmbH, Heinrich-Glaeser-Strasse 10-14, D-01454 Radeberg, Germany

[2] Department of Nuclear Medicine, Bern University Hospital, Freiburgstraße 18, CH-3010 Bern, Switzerland; paul.k.cumming@gmail.com

[3] School of Psychology and Counselling, Queensland University of Technology, Brisbane, QLD 4059, Australia

[4] Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, NIDA and the NIAAA, NIH, Department of Health and Human Services, 9800 Medical Center Drive, Bethesda, MD 20892, USA; kennerr@mail.nih.gov

[5] Johnson & Johnson, Turnhoutseweg 30, B-2340 Beerse, Belgium; jlinders@its.jnj.com

[*] Correspondence: marton@abx.de

[†] Dedicated to the memory of Professor Leendert Maat (1933–2017), a highly esteemed and beloved mentor, collaborator, colleague and friend, and an inexhaustible source of knowledge about morphinans and other alkaloids.

**Abstract:** The word opium derives from the ancient Greek word ὄπιον (ópion) for the juice of any plant, but today means the air-dried seed capsule latex of *Papaver somniferum*. Alkaloid chemistry began with the isolation of morphine from crude opium by Friedrich Wilhelm Adam Sertürner in 1804. More than a century later, Hungarian pharmacist János Kabay opened new perspectives for the direct isolation of morphine from dry poppy heads and straw without the labor-intensive harvesting of opium. In 2015, Kabay's life and achievements obtained official recognition as constituting a «Hungarikum», thereby entering the national repository of matters of unique cultural value. To this day, the study of *Papaver* alkaloids is a focus of medicinal chemistry, the (perhaps unstated) aspiration of which is to obtain an opioid with lesser abuse potential and side effects, while retaining good analgesic properties. We begin this review with a brief account of opiate biosynthesis, followed by a detailed presentation of semisynthetic opioids, emphasizing the efforts of the Alkaloida Chemical Company, founded in 1927 by János Kabay, and the morphine alkaloid group of the University of Debrecen.

**Keywords:** Alkaloida Chemical Company; azidomorphine; biosynthesis; codeine isomers; desomorphine; epimerization; 6,14-ethenomorphinans; Mitsunobu reaction; morphinan alkaloids; morphine; nomenclature; nucleophilic substitution; stereochemistry; University of Debrecen

## Contents

| | |
|---|---|
| „Az ember ezt, ha egykor ellesi, | "Man will certainly learn this by watching |
| Vegykonyhájában szintén megteszi. – | And will simulate it in his kitchen. – |
| Te nagy konyhádba helyzéd embered, | You put into your great kitchen your man |
| S elnézed néki, hogy kontárkodik, | And of his bungling you take no notice, |
| Kotyvaszt, s magát Istennek képzeli." | He brews and fancies himself to be God." |
| Madách Imre: Az ember tragédiája | Imre Madách: Tragedy of the man (translation: Tomschey, O.) |

## 1. Introduction

The word opium has its origin in the ancient Greek ὄπιον (ópion), which originally referred to the juice of any plant, belying the profound importance of the juice of *Papaver somniferum* specifically in ancient and contemporary medicine. The German apothecary and pioneer of alkaloid chemistry Friedrich Wilhelm Adam Sertürner (1783–1841) began working on opium extraction in 1804, first describing a crude preparation that he designated *principium somniferum* and later morphium, after Morphius, the Greek god of dreams. His isolation of pure morphine (**1**, Figure 1) from raw opium was the first of any alkaloid [1,2]. Throughout history, opium, morphine and its semisynthetic derivatives have been double-edged swords, being indispensable in medicine while also bringing crises of dependency and overdose. The touting of oxycodone (14-hydroxydihydrocodeinone) as an

analgesic with a supposedly superior safety profile was surely a factor in the exacerbation of the opioid crisis in some countries [3], now made worse by the availability of synthetic compounds of astonishing potency such as fentanyl and the even stronger nitazines.



**Figure 1.** Chemical structures of selected poppy alkaloids, with scientist's name and year of first isolation.

The *Alkaloida Chemical Company* (Alkaloida Vegyészeti Gyár) was founded by the Kabay brothers János, Péter and József in Bűdszentmihály (former Tiszabűd and Szentmihály; Tiszavasvári since 1952) in Hungary [4–7], with the signing of the foundation agreement taking place on 10 September 1926 [8,9]. The principal founder, pharmacist János Kabay (1896–1936), is notable for his 1925 patent [10,11] on the innovative «green method» for directly extracting opiate alkaloids from parts of the poppy plant, thus circumventing the inefficient and labor-intensive process of opium harvesting by the collection of the resin [10,11]. Further improvements in 1931 enabled the commercially viable extraction of the key alkaloids, morphine (**1a**) and an alkaloid mixture of mainly codeine (**2a**), and the phthalideisoquinoline derivative narcotine (**8**) from the previously worthless straw and dried capsules of the poppy plant («dry method») [10,11]. As the foundation of the Hungarian morphine alkaloid industry, Kabay's process was adopted the world over [12–14].

*Kossuth Lajos University* (Kossuth Lajos Tudományegyetem, KLTE; today the University of Debrecen, Hungary) established its Institute of Organic Chemistry in 1947. The early 1950s saw a strong initiative by the Hungarian Heavy Industries and Education Ministries to form regionally important connections between new industrial centers and nearby universities. The long-standing collaboration between the Institute of Organic Chemistry of KLTE and Alkaloida arose as a direct result of these efforts. Rezső Bognár (1913–1990) [15], a former student of Emil Fischer's (1852–1919) associate Géza Zemplén (1883–1956), received in 1950 the appointment as head of the Institute of Organic Chemistry. Early in his tenure, Bognár placed special emphasis on joint efforts with Alkaloida specialists to optimize the Kabay technology, aiming to obtain higher yields of the valuable opiate alkaloids codeine, thebaine, narceine, neopine, and narcotoline [16–20]. During the period of 1979–1995, Sándor Makleit (1930–2012) became head of the Department of Organic Chemistry and its morphine alkaloid research group, in which capacity he coordinated interactions between KLTE and Alkaloida. Upon Makleit's retirement, Sándor Berényi (1947–2019) redirected

research toward an emphasis on aporphine chemistry via the rearrangement of morphinans. The contributions of László Szilágyi (NMR), Gyula Batta (NMR) and Zoltán Dinya (IR, MS) were essential in the field of structural analysis of the new synthetic morphinan derivatives. Sándor Hosztafi (1952–), formerly of the Alkaloida Chemical Company, has contributed enormously to the field of semisynthetic morphinans, aporphine derivatives and other poppy alkaloids, and remains active at the Department of Pharmaceutical Chemistry of Semmelweis University, Budapest.

In this account, we cannot omit mentioning the long-standing cooperation between the Debrecen morphine alkaloid research group and the Department of Pharmacology of Semmelweis University (Budapest) for the pharmacological analysis of newly synthesized opioid receptor (OR) ligands. József Knoll (1925–2018) and Zsuzsanna Fürst (1939–) first directed these investigations. The biochemical characterization of new semisynthetic alkaloids was performed under the guidance of Anna Borsodi, Sándor Benyhe and Géza Tóth at the Biological Research Center of the Hungarian Academy of Sciences (MTA Szegedi Biológiai Központ, Biokémiai Intézet, Szeged), and at Gedeon Richter Pharmaceuticals (Richter Gedeon Vegyészeti Gyár, Budapest).

Given this historical and personal background, we now present a comprehensive account of opiate alkaloid chemistry, placing our focus on the extensive contributions in recent decades of the Hungarian research group in morphine alkaloids in Debrecen and of the Alkaloida Chemical Company in the field of morphinan syntheses, as part of a concerted search for novel structures and synthetic approaches. We begin with a brief presentation of opiate nomenclature, stereochemistry and the biosynthesis of morphinan alkaloids.

## 2. Chemistry

### 2.1. Poppy Alkaloids

The diverse alkaloids of *Papaver somniferum* are categorized based on their chemical structures [21–25]. The most well known of these are benzylisoquinoline-(I), morphinan-(II), aporphine-(III), benzo[c]phenantridine-(IV), papaverrubine-(V), narceine-typ-(VI), protoberberine-(VII), protopine-(VIII) and phthalideisoquinoline (IX), with ground scaffolds presented in Figure 2.



**Figure 2.** Ground scaffolds of poppy alkaloids.

### 2.2. The Stereochemistry of Morphinans

The morphinan scaffold contains three asymmetric centers (9,13,14). The stereochemistry of morphinan derivatives and other types of OR ligands is of fundamental importance in determining their pharmacological selectivity between the OR sub-types (μ, δ, κ, NOP) or off-target binding to other receptor types, e.g., NMDA receptors. For example, levorphan ($N^{17}$-methyl-3-hydroxy-morphinan), which has an *R* absolute configuration at all three asymmetric carbons (9R,13R,14R, Figure 3, structure IIa), is an OR agonist with seven-fold higher affinity than morphine (**1a**). Dextrorphan ($N^{17}$-methyl-3-hydroxy-morphinan) with a 9S,13S,14S absolute configuration has a different pharmacological profile. It has selectivity for the binding site of NMDA glutamate receptors. Dextromethorphan ((9S,13S,14S)-$N^{17}$-methyl-3-methoxy-morphinan) has little analgesic activity at μORs, but is a commonly used cough suppressant [23]. There are also semisynthetic 6,14-ethenomorphinans with up to seven asymmetric carbons (5,6,7,9,13,14,20), with the absolute configuration of the C-20 chiral carbon being of particular importance for OR affinity and selectivity. While the 20S version of etorphine has about 40 times higher potency than morphine (**1a**), 20R-etorphine surpasses its diastereomer by far, with its potency being 3200-fold that of morphine (**1a**).



**Figure 3.** Structures of B/C-*cis* and B/C-*trans* morphinans.

There are two theoretical sterical arrangements in the case of decalin and morphinans (Figure 3), depending on the ring-junction of the A/B-ring and B/C-ring, respectively [23]. For *cis*-decalins, the H-1 and H-6 hydrogens, and for cis-morphinans, H-14 and the $C^{13}$–$C^{15}$ bond, are on the same face. In *trans*-decalins, the H-1 and H-6 hydrogens, and in B/C-*trans*-morphinans, H-14 and the $C^{13}$-$C^{15}$ bond, are on the opposite face. In naturally occurring morphinan alkaloids, the junction of the B- and C-rings is a B/C-*cis* fusion analogous to *cis*-decalin, as shown in structure **IIa** of Figure 3, where **IIb** presents the structure of a B/C-*trans*-morphinan. It is not possible to convert a morphinan (B/C-*cis*-morphinan) into an isomorphinan (B/C-*trans*-morphinan) by the rotation of molecular parts without breaking chemical bonds. The absolute configurations of the C-14 chiral carbon differ for the isomers: 14R (morphinan) and 14S (isomorphinan).

Morphine (**1a**, Figure 4) and a significant number of its derivatives have a T-shaped three-dimensional molecular geometry. The isomers of morphine (**1a**, Figure 4, Table 1) and codeine (**2a**) have five chiral carbons: positions 5, 6, 9, 13 and 14. In **1a** and **2a**, the

carbon–carbon double bond is situated in position C7–C8 ($\Delta^{7,8}$), the ring-C has a flattened boat conformation, and the allylic hydroxyl group in position C-6 is pseudo-equatorial. The C-6 in **1a** and **2a** has absolute configuration *S*. In the C-6 epimer molecules isomorphine (**1b**, α-isomorphine, Figure 4) and isocodeine (**2b**), the 6-hydroxyl group is located above the plane of the ring-C in a pseudo-axial position. The C-6 in **1b** and **2b** has absolute configuration *R*.



**Figure 4.** Chemical structures of selected morphinan alkaloids and their synthetic derivatives. * Makleit–Bognár nomenclature.

**Table 1.** Absolute configuration of the selected morphinan alkaloids and their semisynthetic derivatives depicted in Figure 4.

| Comp. | Name | Position of the C=C Double Bond | Position | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | | 5 | 6 | 8 | 9 | 13 | 14 |
| **1a** | morphine | $\Delta^{7,8}$ | 5R | 6S | - | 9R | 13S | 14R |
| **1b** | isomorphine * | $\Delta^{7,8}$ | 5R | 6R | - | 9R | 13S | 14R |
| **1c** | allopseudomorphine ** | $\Delta^{6,7}$ | 5S | - | 8R | 9R | 13S | 14R |
| **1d** | γ-isomorphine | $\Delta^{6,7}$ | 5S | - | 8S | 9R | 13S | 14R |
| **2a** | codeine | $\Delta^{7,8}$ | 5R | 6S | - | 9R | 13S | 14R |
| **2b** | isocodeine | $\Delta^{7,8}$ | 5R | 6R | - | 9R | 13S | 14R |
| **2c** | allopseudocodeine | $\Delta^{6,7}$ | 5S | - | 8R | 9R | 13S | 14R |
| **2d** | pseudocodeine | $\Delta^{6,7}$ | 5S | - | 8S | 9R | 13S | 14R |
| **3a** | neopine | $\Delta^{8,14}$ | 5R | 6S | - | 9R | 13S | - |
| **3b** | isoneopine | $\Delta^{8,14}$ | 5R | 6R | - | 9R | 13S | - |
| **3c** | neomorphine | $\Delta^{8,14}$ | 5R | 6S | - | 9R | 13S | - |
| **3d** | isoneomorphine | $\Delta^{8,14}$ | 5R | 6R | - | 9R | 13S | - |
| **4** | thebaine | $\Delta^{6,7}$ and $\Delta^{8,14}$ | 5R | - | - | 9R | 13S | - |
| **5** | oripavine | $\Delta^{6,7}$ and $\Delta^{8,14}$ | 5R | - | - | 9R | 13S | - |

\* Isomorphine: known also as α-isomorphine; \*\* allopseudomorphine: known also as β-isomorphine.

Further $\Delta^{6,7}$ isomers for morphine (**1a**) and codeine (**2a**) are known as allopseudomorphine (**1c**, also known as β-isomorphine), γ-isomorphine (**1d**), allopseudocodeine (**2c**) and pseudocodeine (**2d**). In these compounds, the alcoholic hydroxyl group connects to position-8 of the ring-C. Of the ring-C carbons, C-5, C-6, C-7, C-8 and C-13 are in the same plane, while C-14 is located above them. The ring-C of the compounds has an envelope conformation. In allopseudomorphine (**1c**) and allopseudocodeine (**2c**), the 8-OH is pseudo-axial and the configuration of C-8 is *R*. The two isomers with a $\Delta^{6,7}$ double bond and pseudo-equatorial 8-hydroxyl group, γ-isomorphine (**1d**) and pseudocodeine (**2d**), have an 8S absolute configuration. Figure 4 and Table 1 provide an overview of the structure and absolute configuration of the parent compounds.

The neopine (**3a**), isoneopine (**3b**), neomorphine (**3c**) and neoisomorphine (**3d**) derivatives also have a $\Delta^{8,14}$-unsaturated bond in ring-C. These compounds have only four asymmetric carbon atoms (5, 6, 9 and 13), since the $\Delta^{8,14}$ double bond C-14 is no longer asymmetric. The C-ring is rigid and of a half-chair conformation. In the cases of neopine (**3a**) and neomorphine (**3c**), the 6-hydroxy group is in a pseudo-axial position and the carbon-6 has absolute configuration *S*. In compounds of the 6-beta series, like isoneopine (**3b**) and isoneomorphine (**3d**), the 6-OH is pseudo-equatorial and the carbon-6 has configuration *R*. The poppy alkaloids with a conjugated 6,8-dien system in ring-C—thebaine (**4**) and oripavine (**5**)—have only three asymmetric carbons, with the absolute configurations 5*R*, 9*R* and 13*S*.

### 2.3. Biosynthesis of Morphinan Alkaloids

A suite of five *O*-methyltransferases and two *N*-methyltransferase enzymes contribute to benzyisoquioline alkaloid (BIA) biosynthesis [26] in five genera of flowering plants, including *Papaveraceae* (poppy) and *Ranunculaceae* (buttercup). The phytochemical synthesis of morphine alkaloids begins with *L*-tyrosine (**10**) via a branching pathway that yields, on one side, tyramine (**11**) through the action of *L*-tyrosine decarboxylase, which is a dimeric pyridoxal-phosphate-dependent enzyme [27]. A phenolase enzyme then transforms the tyramine product (**11**) to dopamine (**13**). In the right-hand branch, *L*-tyrosine (**10**) gives rise to the keto acid 4-hydroxyphenylpyruvate (**12**) via *L*-tyrosine deaminase [28] and then to the corresponding acetaldehyde (**14**) via a specific decarboxylase. The condensation of the two products (dopamine (**13**) and 4-hydroxyphenylacetaldehyde (**14**)) to form (*S*)-norclaurine (**15**) proceeds via an asymmetric Pictet–Spengler condensation, which is catalyzed by the

enzyme norclaurine synthase [29]. Mechanistic studies of the norcoclaurine synthase enzyme derived from *Thalictum flavium* (yellow meadow-rue) indicated a two-step cyclization of the putative iminium ion intermediate, which constitutes the first committed step in the formation of poppy BIAs.

Once formed, (*S*)-norclaurine (**15**, Figure 5) undergoes a series of enzymatic methylations, first by norcoclaurin-6-*O*-methyltransferase in the presence of the co-substrate *S*-adenosylmethionine (SAM), which represents a key rate-limiting step in benzyisoquioline synthesis [30], followed by tetrahydrobenzylizochinoline-*N*-methyltransferase. The product (*S*)-*N*-methyl-coclaurine (**17**) undergoes ring hydroxylation by a phenolase enzyme or a higher affinity P450-dependent monooxygenase (CYP80B1) in poppy [31] and then a further SAM-dependent *O*-methyltransferase reaction to give (*S*)-reticulin ((*S*)-**19**). Interestingly, reticulin in the traditional food *Annona muricata* (soursop) may be responsible for dopamine neuron degeneration resulting in a form of Parkinsonism that is endemic to the island of Guadeloupe [32].



**Figure 5.** Biosynthesis of (*S*)-norcoclaurine. *Reactions catalyzed by enzymes*: (i): *L*-tyrosine decarboxylase (TyrDC); (ii): *L*-tyrosine transaminase (TyrAT); (iii): phenolase; (iv): 4-hydroxy-phenylpyruvate decarboxylase (4HPPDC).

A specific NADPH-dependent reductase isomerizes (*S*)-reticuline ((*S*)-**19**) to (*R*)-reticuline ((*R*)-**19**). After ring closure of (*R*)-reticuline ((*R*)-**19**, Figure 6) via an NADPH/O$_2$-dependent enzyme yielding salutidarine (**7**), an NADPH/NADP$^\oplus$-dependent oxidoreductase yields (7*S*)-salutaridinol (**21**), which is then ring-acetylated by an acetyl coenzyme A-dependent enzyme; spontaneous deacetylation gives thebaine (**4**, paramorphine), which gains its common name from the ancient Greco-Egyptian city of Thebes. In rat brain prepa-

rations, thebaine (**4**) has only weak binding affinity for ORs [33] and, unlike the synthetic enantiomer (+)-thebaine [34], has little analgesic potency. Having been long regarded as a useless side product of poppy extraction, thebaine (**4**) now has an annual global market value of USD 1 billion, serving as starting material in the industrial production of opiate agonists (e.g., oxycodone, oxymorphone), antagonists (Nal compounds: naloxone, naltrexone, nalbuphine) and Diels–Alder type Bentley compounds (buprenorphine, etorphine, diprenorphine). ORs in the brain present important targets for molecular imaging by positron emission tomography (PET), as presented in an extensive review [35]. In particular, thebaine (**4**) is a precursor for the radiosynthesis of various PET tracers for OR imaging (see Section 2.12). It has been known since the 1970s that thebaine (**4**) predominates in *Papaver bracteatum* (the Armenian poppy), which contains only a small amount of other alkaloids [36,37]. Alternatively, Zenk and researchers at Tasmanian Alkaloids obtained the morphine (**1a**)-free *Papaver somniferum* plant designated as top1 (top: **t**hebaine–**o**ripavine–**p**oppy) through genetic modification [38]. The genetic cultivar contains predominantly thebaine (**4**, 1.65%) and oripavine (**5**, 0.43%) but no morphine (**1a**, 0%) or codeine (**2a**, 0%).



**Figure 6.** Biosynthesis of (*R*)-reticuline. *Reagents and conditions*: (i): norcoclaurine-6-*O*-methyltransferase; (ii): tetrahydrobenzylisoquinoline-*N*-methyltransferase; (iii): phenolase; (iv): (*S*)-3′-hydroxy-*N*-methylcoclaurine-4′-*O*-methyltransferase; (v): 1,2-dehydroreticuline synthase, NADPH-dependent reductase.

Thebaine (**4**, Figure 7) yields morphine (**1a**) by two parallel pathways in the opium poppy. In one pathway, an enol ether hydrolase enzyme forms neopinone (**23**), which equilibrates to codeinone (**24**), an alkaloid with about one-third the analgesic potency of codeine (**2a**). An NADPH-dependent reductase converts codeinone (**24**) to codeine (**2a**), which is demethylated to yield the still more potently analgesic morphine (**1a**). In the other pathway, 3-*O*-demethylation of thebaine (**4**) yields oripavine (**5**), which is also a potent analgesic, albeit with high toxicity. Oripavine (**5**) is important industrially as a precursor for synthetic opiates (i.e., etorphine and buprenorphine); in the poppy plant, oripavine (**5**) undergoes enol ether hydrolysis to yield morphinone (**25**), which has similar

analgesic potency to codeine (**2a**). The conversion of morphinone (**25**) to morphine (**1a**) entails an NADPH-dependent codeinone reductase, various isoforms of which also catalyze the reduction of certain other intermediates of morphine (**1a**) biosynthesis [39]. Interestingly, morphine biosynthesis in the poppy plant entails compartmentation in several cell types [40,41]; the initial steps occur in sieve elements of the phloem, whereas the conversion of salutaridine (**7**) to thebaine (**4**) predominantly takes place in adjacent laticifers, where the main morphine accumulation occurs.



**Figure 7.** Biosynthesis of thebaine from (*R*)-reticuline. *Reagents and conditions*: (i): salutaridine synthase (NADPH, O$_2$); (ii): NADPH-dependent salutaridine oxydoreductase (NADPH, NADP$^\oplus$); (iii): salutaridinol-7-*O*-acetyltransferase (AcCoA, CoA); (iv): spontaneous (pH 8–9, -AcOH).

Raw opium is the dried latex from seedpods of the opium poppy, which naturally contains a mixture of thebaine alkaloids and intermediates, the composite of which contributes to its somnorific/analgesic effects and toxicity. The principle alkaloid in opium samples from South East Asia was morphine (11–23%), with lesser amounts of codeine (2–4%) and thebaine (1–3%) [42]. Poppy straw from various *Papaver somniferum* cultivars used in oil seed production in the Czech Republic had relatively invariant alkaloid concentrations across three consecutive harvests [43]. Cluster analysis distinguished cultivars with high morphine concentration (1.6%) and relatively low levels of other alkaloids from cultivars with the opposite relationships. Comestible poppy seeds also contain various alkaloids, extending over a >100-fold concentration range, depending on the source [44]. Baking substantially reduces the alkaloid content of poppy seeds, such that it would be practically impossible to experience intoxication from Bejgli, a traditional Hungarian Christmas cake, although there are case reports of individuals with opioid dependence consuming poppy seeds by the kilogram [45]. On the other hand, there are reports of lethal codeine (**2a**)/morphine (**1a**) overdose among poppy seed tea drinkers [46], and in drinkers of tea

made with «home-grown» dried seedpods [47]. Thebaine (**4**) is a pro-convulsant at high doses, and poppy seeds with a particularly high content of thebaine (**4**, Figure 8) caused serious neuromuscular toxicity in tea drinkers in Australia [48]. Thus, the toxicity of poppy products depends upon factors such as the particular cultivar, growing conditions and mode of preparation.



**Figure 8.** Biosynthesis of morphine from thebaine. *Reagents and conditions*: (i): enolether hydrolysis; (ii): chemical equilibrium; (iii): codeinone reductase; (iv): 3-*O*-demethylation.

ORs [49] regulate numerous (patho)physiological processes, being involved in pain modulation, euphoria, reward behaviors and substance abuse, with involvement in the pathophysiology of various psychiatric disorders, epilepsy and neurodegenerative conditions such Alzheimer's disease (AD) [50]. Endogenous opioid peptide ligands and exogenous opioids activate several types of G protein-coupled (GPCR) receptors (μ-OR, δ-OR κ-OR, NOP). The concept of «biased agonism» underlies the search for OR ligands eliciting therapeutic effects but with a lesser risk of toxicity and dependence [51,52]. In general, OR agonists inhibit the enzyme adenyl cyclase (AC), thus decreasing the intracellular cAMP level and thereby inhibiting the voltage-gated $Ca^{2\oplus}$ ion channels while activating $K^{\oplus}$ efflux. The resulting hyperpolarization inhibits the presynaptic release of neurotransmitters (e.g., dopamine (DA), norepinephrine (NE), acetylcholine (ACh), γ-aminobutyric acid (GABA)), which produce a variety of effects including sedation, central analgesia and euphoria.

Morphine (**1a**) yields a number of metabolites in humans by various metabolic pathways [53]. The most important morphine metabolites are M3G (**26**, Figure 9) and M6G (**27**), which form by glucuronidation catalyzed by hepatic uridine 5′-diphosphoglucuronyltransferase (UGT).The sulfation of **1a** by hepatic sulfotransferase (SULT1A3) results in morphine-3-sulfate (**30**, M3S) and morphine-6-sulfate (**28**, M6S). The $N^{17}$-demethylation of **1a** by cytochrome P450 (CYP450) gives normorphine (**29**), and oxidative dimerization leads to pseudomorphine (**6**, 2,2′-bimorphine). The SAM-dependent 3-*O*-methylation of morphine (**1a**) to codeine (**2a**) can occur in the liver, lung or kidney.

**Figure 9.** Structures of selected morphine metabolites.

The chemical structures of some phase I and phase II metabolites of morphine are depicted in Figure 9.

### 2.4. The Makleit–Bognár Nomenclature

In 1968, Makleit and Bognár [54,55] proposed the introduction of a new nomenclature for morphine derivatives. According to this nomenclature, the naming of all ring-C-substituted semisynthetic compounds derives from the isomers of codeine (**2a–d**, Figures 4 and 10). The Makleit–Bognár nomenclature requires only prior knowledge of the names and stereochemistry of the basic four codeine isomers: codeine (**2a**), isocodeine (**2b**), allopseudocodeine (**2c**) and pseudocodeine (**2d**).



**Figure 10.** Three-dimensional structures of codeine isomers.

Makleit and Bognár suggested abandoning the previously used names for morphine isomers, α-(**1b**), β-(**1c**) and γ-isomorphine (**1d**), in favor of isomorphine (**1b**), allopseudo-morphine (**1c**) and pseudomorphine (**1d**), all in analogy to the codeine isomer nomenclature. They also proposed the adoption of the rational name "2,2′-bimorphine" to replace the old name of the poppy alkaloid bis-derivative pseudomorphine (**6**, Figure 1). This simplified nomenclature is generalizable to all ring-C-substituted derivatives and faithfully reflects their structure and stereochemistry. Ergo, chemists can ascertain quickly and precisely the name and exact structure of any new derivatives, knowing the names and structures of the four codeine isomers (**2a–d**, Figures 4 and 10). We note that the position of a substituent below and above the plane ring-C differs for C-6 and C-8; if a C-6 substituent is pseudo-axial, it lies above the plane of the ring-C, while a C-8 pseudo-axial substituent is below the ring-C.

The term "deoxy-X" is a proposed term for all ring-C-modified derivatives, rendering redundant the descriptions (6α, 6β, 8α, 8β), as the name already specifies the exact structure of the compound. For the interpretation of this nomenclature, we present numerous examples in Figure 11. Like the Maat nomenclature system [56] in the field of the Diels–Alder adducts of morphinan-6,8 dienes [57], chemists have not universally adopted the rational Makleit–Bognár nomenclature [54,55], despite its considerable advantages.



**31a**

**6-deoxy-6-X-morphine**
**6-deoxy-6-X-codeine**

**31b**

**6-deoxy-6-X-isomorphine**
**6-deoxy-6-X-isocodeine**

morphine series R = H
codeine series R = CH$_3$

**31c**

**8-deoxy-8-X-allopseudomorphine**
**8-deoxy-8-X-allopseudocodeine**

**31d**

**8-deoxy-8-X-pseudomorphine**
**8-deoxy-8-X-pseudocodeine**

**Figure 11.** Examples for the application of the Makleit–Bognár nomenclature.

### 2.5. Early Syntheses of Morphine Derivatives with Pharmaceutical Importance

Opiates are plant products formed by a series of enzymatic reactions as outlined above, whereas chemistry has built upon the rather sparse selection of poppy alkaloid scaffolds to generate countless derivatives. After the elaboration of the Kabay–Bognár technology for the isolation of morphine (**1a**) and its accompanying alkaloids from dry poppy straw and heads [16], the transformation of morphine (**1a**) to other active pharmaceutical ingredients came into focus at Alkaloida and the University of Debrecen.

Morphine (**1a**) was converted to codeine (**2a**) by methylation of the phenolic 3-hydroxyl group by aryl trimethylammonium hydroxides (Rodionov's method [58,59]). Methods were elaborated for the synthesis of benzylmorphine (**32**, 7,8-didehydro-4,5α-epoxy-6α-hydroxy-17-methyl-3-phenylmethoxy-morphinan), ethylmorphine (**33**, 7,8-didehydro-4,5α-epoxy-

6α-hydroxy-17-methyl-3-ethoxy-morphinan) and pholcodine (**34**, 7,8-didehydro-4,5-epoxy-6α-hydroxy-17-methyl-3-(2-(4-morpholinyl)ethoxy)-morphinan) [60] on an industrial scale starting from morphine (**1a**, Figure 12). The latter compound (**34**) became clinically significant because of its lesser toxicity and proclivity to induce respiratory depression in comparison to morphine (**1a**), and due to its more favorable sedative effect as compared to codeine (**2a**) or other morphine derivatives. The application of pholcodine (**34**) as an antitussive agent in the treatment of dry non-productive cough for young patients and adults has been widespread, and **34** was for a long time the second-most important active pharmaceutical ingredient (API) manufactured from morphine (**1a**) [14]. Neuromuscular blocking agents (NMBAs) are among the leading causes of life-threatening drug-induced perioperative anaphylaxis. Novel studies performed by Mertes et al. [61] confirmed a remarkable relationship between the application of pholcodine (**34**) and other quaternary ammonium derivatives and the risk for NMBA-related perioperative anaphylaxis mediated by immunoglobulin E (IgE). This association led to the withdrawal of pholcodine-containing antitussive syrups and cold medicines from the EU and UK markets [62].



**Figure 12.** Industrial-scale syntheses of some morphine derivatives. *Reagents and conditions*: (i): benzyl bromide, NaOEt, EtOH, heating; (ii): ethyl bromide, NaOEt, EtOH, 100 °C, 2 h; (iii): morpholinylethylchloride hydrochloride, NaOEt, ethanol, reflux, 1 h, 72%; (iv): $H_2$, Pd-C, 1 N HCl or diluted AcOH; (v): catalytic rearrangement; (vi): (1) BrCN, CHCl$_3$, reflux; (2) A: KOH, $H_2O$, EtOH, 50 °C, B: diluted HCl, heating; (3) allyl bromide, NaHCO$_3$, EtOH, reflux, 10 h; (vii): cc. HCl, sealed tube; (viii) see details in Section 2.6.

Dihydromorphine (**35**, paramorphan) was synthesized by the heterogeneous catalytic hydrogenation of the $\Delta^{7,8}$ double bond of morphine (**1a**) in dilute acetic acid. Dihydromorphinone (**36**, dilaudid) was prepared either by the catalytic rearrangement of **1** or by the Oppenauer oxidation of dihydromorphine (**35**). Szabó and Bognár from KLTE developed a procedure for the preparation and purification [63] of the OR antagonist $N^{17}$-allyl-normorphine (**37**, nalorphine). Synthesis starts from morphine (**1a**, route [64]: **1** $\rightarrow$ diacetylmorphine $\rightarrow$ diacetyl-$N^{17}$-cyano-normorphine $\rightarrow$ normorphine $\rightarrow$ **37**) using (among other approaches) the von Braun method [65] for the *N*-demethylation step. Apomorphine (**39**), a dopamine receptor agonist that can relieve motor symptoms of Parkinson's disease, was synthesized from morphine (**1a**) by treatment with concentrated hydrochloric acid. Berényi et al. [66,67] later investigated in detail the mechanism of the morphine (**1a**) $\rightarrow$ apomorphine (**39**) rearrangement. For details of the desomorphine (**38**) synthesis [68–70], see Section 2.7.

### 2.6. Reduction of Thebaine

Thebaine (**4**) comprises a 6,8-diene and an enol ether function in ring-C, which together correspond to a 1-methoxy-1,3-cyclohexadiene sub-structural unit [22,23]. The B- and C-rings together form a *trans*-3,4,8,9-tetraline system, while the C- and D-rings constitute a *trans*-1,2,3,4,5,10-hexahydro-isoquinoline subunit. An easily attacked part of the molecule is the $C^5$-O bond of the dihydrofuran-ring-E, which is part of the $C^4$-O-$C^5$-$C^6$=$C^7$ allyl ether system. The characteristics of these sub-structures enable a large variety of reactions for thebaine (**4**) in a manner sensitive to reaction conditions. This is particularly apparent in its reduction with various reagents or during catalytic hydrogenation under different reaction conditions, which results in a diverse array of products (Figure 13).



**Figure 13.** Reduction of thebaine with chemical reducing agents. *Reagents and conditions*: (i): LiAlH₄, benzene, diethyl ether or THF, reflux, 8 h, 22–27%; (ii): Na, NH₃ (liq.), 90%; (iii): 5 equiv. SnCl₂, cc HCl, sealed tube, 100 °C, 20 min, 53% (**42**); (iv): NaOEt, EtOH.

Indeed, the targeted reduction of thebaine is a very challenging process [71,72]. Neither the application of chemical reducing agents nor heterogeneous catalytic hydrogenation results in a sole product. In the first case, reduction in basic or acidic media yields products containing a phenolic hydroxyl group due to the opening of the E-ring. The treatment of thebaine (**4**) with sodium in hot ethanol results in dihydrothebaine-Φ (**43**, $\Delta^{5,8}$-phenolic dihydrothebaine) as the main product [73,74]. Bentley et al. [75,76] found that the application of

sodium–liquid ammonia gave dihydrothebaine-Φ (**43**) in 90% yield and a small amount of β-dihydrothebaine (**40**) [77], along with approximately 10% $\Delta^{6,8}$-phenolic-dihydrothebaine (**40**). Razdan et al. [77] reported that the treatment of thebaine (**4**) with an excess of potassium in liquid ammonia gave a 1:1 mixture of **40** and **43** in 95% yield, from which **40** could be isolated in 34% overall crystalline yield. The treatment of **43** with K/liquid ammonia in the presence of Fe(NO$_3$)$_3$ produced a 1:1 mixture of **40** and **43** in 79% yield. When performing reduction with LiAlH$_4$, in benzene–diethyl ether (or THF) [78,79], β-dihydrothebanie (**40**) was obtained in low (22–27%) yield. The third isomer $\Delta^{5,7}$-phenolic dihydrothebaine (**45**) can be prepared from codeinemethylether (**44**) by treatment with sodium ethylate [71]. The reduction of thebaine (**4**) with stannous chloride (SnCl$_2$) gave thebainone-A (**41**), or metathebainone (**42**) via the rearrangement of the carbon scaffold. The yield of the reduction of thebaine (**4**) to **40** with the intact conjugated 6,8-diene system was greatly improved by the findings of Linders et al. [80], whereby reduction with zinc under alkaline conditions resulted in almost quantitative conversion to dihydrothebaine (**40**).

For the formation of metathebainone (**42**) and thebainone-A (**41**), Robinson [81,82] suggested the following reaction mechanism (Figure 14): (i) the enol ether group of the hydrochloric salt of thebaine undergoes hydrolysis and an unstable addition product (**X**) is formed via proton attack on the oxygen of the E-ring; (ii) rearrangement—heterolysis of the C$^5$-O bond, electron shift and the anionotropic rearrangement of the ethanamine side-chain from C$^{13}$ to C$^{14}$ (**XI**); (iii) intermediate (**XI**) stabilizes via proton losing/transmission to (**XII**); and (iv) the formation of metathebainone (**42**) via the saturation of the easily accessible $\Delta^{7,8}$ double bond. The experimental conditions leading to the formation of thebainone-A (**41**) were as follows: (v) the unstable intermediate (**X**) transforms to (**XIII**) via the heterolysis of the C$^5$-O bond; (vi) the formation of (**XIV**) through the uptake of H$^\oplus$ and 2e$^\ominus$; and (vii) the ketonization of (**XIV**) through a 1,4-mechanism to thebainone-A (**41**).



**Figure 14.** Mechanism of the formation of metathebainone and thebainone-A. *Reagent and elementary step of the reaction*: (i): **A**: + HOH, **B**:−CH$_3$OH, **C**: + H$^\oplus$; (ii): rearrangement; (iii): −H$^\oplus$; (iv): H$_2$/catalyst; (v): heterolysis of C$^5$-O bond; (vi): + 2e$^\ominus$, + H$^\oplus$; (vii): ketonization with 1,4-mechanism.

As noted above, thebaine (**4**) is a non-analgesic neuromuscular toxin, long regarded as a nuisance side-product of poppy extraction. However, its conversion to pharmacologically useful semisynthetic opiates has since become the objective of concerted efforts. The catalytic hydrogenation of thebaine (**4**) results in a complex mixture of products depending on the reaction conditions (e.g., pH of the solution, type of catalyst) [83]. When the hydrogenation was interrupted after the disapperance of the starting material thebaine (**4**) (from the reaction mixture) but before cessation of hydrogen uptake neopine-6-methylether (**46**) was isolated as its quaternary methiodide salt in addition to dihydothebaine (**48**), dihydrothebainone (**52**) and tetrahydrothebaine (**50**) [72]. Interestingly, the hydrolysis of dihydrothebaine-Φ (**43**) with KHSO$_4$ resulted in thebainone-A (**41**, B/C-*cis*-series) and β-thebainone-A (**47**, B/C-*trans*-series).

The main driving force of these investigations in mid-20th century Hungary was to study the possibilities for the transformation of thebaine (**4**) via dihydrothebaine (**48**) to dihydrocodeinone (**49**, hydrocodone), an API (active pharmaceutical ingredient) used for the treatment of moderate-to-severe pain and as a cough suppressant. Szabó and Bognár [84,85] performed detailed research into the catalytic reduction of thebaine (**4**) as a function of reaction conditions (e.g., type of catalyst, pressure, concentration, temperature, pH, rate of hydrogen uptake). They isolated from the product mixtures a large number of morphinan derivatives, e.g., dihydrothebaine (**48**), dihydrocodeinone (**49**), dihydrothebainone (**52**), β-dihydrothebainone, etc. (see also Figure 15) [84,85]. For the characterization of the obtained products, Szabó and Bognár undertook a careful analysis of their infrared spectra and photometry combined with paper chromatography. This enabled them to detect more than twenty morphinans in the product mixture. They also performed their syntheses through independent reaction routes, and reported in detail the mechanisms of product formation [84,85].

The occurrence of parallel and consecutive side reactions during the heterogenous catalytic hydrogenation of thebaine (**4**) is explicable by the following processes (Figure 15):

(A)  1,2-Addition of hydrogen to the $\Delta^{7,8}$ double bond of thebaine (**4**). This results in dihydrothebaine (**48**), which is transformable to dihydrocodeinone (**49**) through hydrolysis;

(B)  1,4-Addition of hydrogen to the conjugated system of thebaine (**4**) in ring-C. This leads to codeine methyl ether (**44**), which is reducible to tetrahydrothebaine (**50**);

(C)  1,4-Addition of hydrogen to the oxygen atom of the E-ring and to C-7. This constitutes a hydrogenolysis of the allyl ether group, which results in the opening of the ether bridge. In the first step, $\Delta^{5,8}$-phenolic-dihydrothebaine (**43**, dihydrothebaine-Φ) is formed, which can be transformed to dihydrothebainone-$\Delta^5$-methylenolate (**51**). The enol ether hydrolysis of this compound results in dihydrothebainone (**52**). Subsequent hydrogenation leads to dihydrothebainol-6-methyl ether (**53**);

(D)  1,6-Addition of hydrogen to the oxygen atom of the E-ring and to C-14. This process results in $\Delta^{5,7}$-phenolic-dihydrothebaine (**45**). The following/further hydrogenation of the latter compound forms dihydrothebainone-$\Delta^5$-methyl enolate (**51**) and dihydrothebainol-6-methyl ether (**53**).

**Figure 15.** Products of the reduction of thebaine [84,85]. *Reagents and conditions*: (i): from **4** hydrochloride salt, H$_2$, atmospheric pressure, 0.08 M hydrochloric acid (2.8-fold), 10% Pd-C (0.1-fold), 62%; (ii): 5 equiv. 5 M hydrochloric acid, RT, 24 h, quant.; (iii): NaOEt, EtOH; (iv): H$_2$, 10% Pd-C (4 m/m %), 1 M hydrochloric acid, quant.; (v): Na, NH$_3$ (liq.), 90% [73,74,80–82]; (vi): H$_2$, PtO$_2$, NaHCO$_3$, EtOH, 45% or H$_2$, Pd-SrCO$_3$, EtOH, 50%; (vii): **A**: AcOH or 1 M HCl, RT, **B**: H$_2$, 10% Pd-C; (viii): 10% Pd-C, EtOH, or directly from **4** base by catalytic reduction in neutral solution (5% Pd-BaSO$_4$, EtOH), or alternatively by catalytic reduction (H$_2$, PtO$_2$) of β-dihydrothebaine (**40**) [79]; (ix): H$_2$, 5% Pd-BaSO$_4$, EtOH [67] or H$_2$, Pt black, NaHCO$_3$, EtOH; (x): H$_2$, 1,6-hydrogen addition [C$^5$-O; C$^{14}$] on the allyl ether group combined with the 6,8-diene system [86]; alternatively from codeine (**2a**), codeine → codeine-*N*-oxide → codeine-*N*-oxide-6-*O*-methylether → codeine-6-methylether → phenolic Δ$^{5,7}$-dihydrothebaine (**45**) [73,74,85]; (xi): H$_2$, 10% Pd-C, NaHCO$_3$, EtOH, RT, 7 h [85]; by application of H$_2$, 10% Pd-C, 1 M hydrochloric acid, thebainone-A and dihydrothebainone (**52**) formed [85]; (xii): warm aqueous KHSO$_4$ solution [74].

## 2.7. Synthesis of Desomorphine

Very recently, the chemistry, synthesis and pharmacology of desomorphine (**38**) were reviewed in considerable detail [87–89]. One can deduce the structure of 6-desoxymorphine derivatives from C-6 hydroxy compounds by the formal elimination of the hydroxy group or from 6-ketomorphinans by reduction. Due to their increased lipophilicity (and consequently greater brain penetration), these derivatives have higher analgesic potency compared to OR ligands with hydroxy and keto groups in position-6. This suggests that a substitution in position-6 is not essential for a high μOR affinity. Indeed, Rapoport and Bonner reported in 1951 [90] that Δ$^7$-desoxymorphine (**57**, 6-desoxymorphine, desomorphine-E; for binding affinity, see [91]: K$_i$ (μOR) = 2.9 nM, K$_i$ (δOR) = 11.8 nM, K$_i$ (κOR) = 44.5 nM, δ/μ = 4, κ/μ = 16) prepared from Δ$^7$-desoxycodeine (for binding affinity, see [91]: K$_i$ (μOR) = 305 nM, K$_i$ (δOR) = 4520 nM, K$_i$ (κOR) = 3090 nM, δ/μ = 15, κ/μ = 10) by 3-*O*-demethylation with pyridine hydrochloride at 220 °C (6 min, N$_2$ atmosphere) had ~8.5-fold higher analgesic potency than morphine (**1a**), consistent with the much higher μ-OR affinity. Comparing the analgesic properties of various morphine derivatives (mouse hot-plate test), Eddy et al. [92,93] found the following order of relative potencies (in brackets): desomorphine (11.7) > dihydromorphinone (7.0) > dihydromorphine (1.2) > morphine (1.0) > dihydrodesoxycodeine (0.72) > dihydrocodeinone (0.66) > dihydrocodeine (0.17).

6-Desoxydihydromorphine (**38**, $4,5\alpha$-epoxy-17-methylmorphinan-3-ol, also known as dihydrodesoxymorphine-D, and desomorphine) differs structurally from morphine (**1a**) with respect to the absence of the alcoholic hydroxyl group in position C-$6\alpha$ and the saturation of the $\Delta^{7,8}$ double bond in ring-C. Desomorphine (**38**) and morphine (**1a**) both have a T-shaped 3D structure, although in **38** the ring-C has a chair conformation, while that in **1a** has a boat conformation. Desomorphine (**38**) is about 8–10 times more potent than morphine (**1a**) in the mouse hot-plate test [94] ($ED_{50}$ (**38**) = 0.14 µmol/kg, $ED_{50}$ (**1a**) = 3.3 µmol/kg).

Furthermore, desomorphine (**38**) has a rapid onset and shorter duration of analgesic action and is accompanied with higher toxicity (rat $LD_{50}$ (**38**) = 27 mg/kg, $LD_{50}$ (**1a**) = 226–318 mg/kg [95]). Desomorphine (**38**) is apparently a high-affinity µ-OR agonist, as evident by its potent analgesic effects [96], but its sub-type selectivity is unknown. The synthesis of **38** was already described in the 1930s by Small and colleagues in the course of their search for new analgesics with a lesser addictive pharmacological profile compared to morphine (**1a**) [97,98]. In the 1950s, desomorphine (**38**) served as an API under the trade names Desomorphine®® and Permonid®® (Hoffmann-La Roche, Little Falls, NJ, USA) in the USA and in Switzerland. The early syntheses of **38** were performed from morphine (**1a**), codeine (**2a**), dihydromorphine (**35**) or desoxymorphine-C (a $\Delta^{6,7}$-didehydro compound: 17-methyl-$4,5\alpha$-epoxy-3-hydroxy-6,7-didehydro-morphinan). The 6β-chloro derivatives α-chlorocodide (**59b**, Figure 16), α-chloromorphide or α-chlorodihydromorphide were prepared with thionyl chloride ($SOCl_2$) from the corresponding starting morphinan (**1a**, **2a**, **35**) (note: α- and β-descripts are not sterical but positional: α: 6-substituted and β: 8-substituted). Thereafter, the respective halogenocodides (e.g., α-chlorocodide (**59b**) or β-chlorocodide (**65a**), Figure 17) or halogenomorphides were subjected to catalytic hydrogenation [98] for the reduction of the double bond in ring-C and dehalogenation. These reactions were performed in methanol or in diluted hydrochloric acid in the presence of Pd/BaSO$_4$. Depending upon the character of the substrate and the applied reaction and solvent conditions, these reactions gave desomorphine (**38**) in a yield of ~30–83%.

In 1956, Bognár and Makleit [68–70] developed four-step procedures for the preparation of dihydro-6-desoxymorphine (**38**) from morphine (**1a**, Figure 16, route A: **1a** → **35** → **54** → **58** → **38**; route B: **1a** → **55** → **54** → **58** → **38**). They first synthesized 3-*O*-acetyl-dihydromorphine (**54**) from morphine (**1a**) via dihydromorphine (**35**) or via 3-*O*-acetylmorphine (**55**). They performed partial acetylation by the method of Welsh [99] with acetic anhydride in the presence of an aqueous NaHCO$_3$ solution. The $\Delta^{7,8}$ double bond of 3-*O*-acetylmorphine (**55**) was saturated (H$_2$, Pd-C) in aqueous acidic media (HCl, pH 6–6.5). 3-*O*-Acetyl-dihydromorphine (**54**) was converted with *p*-toluene-sulfonyl chloride in pyridine to 3-*O*-acetyl-dihydromorphine tosylate (**58**), which was then treated with LiAlH$_4$ according to the method of Schmid and Karrer [100] in THF. This hydrogenolyzed (hydrogen-substituted) the tosyloxy group in position-6, in concert with 3-*O*-deacetylation, giving the desired 6-desoxydihydromorphine (**38**) in an overall yield of 7.7%.

In 1975, Makleit et al. [101] published a novel route for the preparation of desomorphine (**38**) starting from morphine (route: **1a** → 3-*O*-acetylmorphine (**55**) → 3-*O*-acetylmorphine tosylate (**56**) → desoxymorphine-E (**57**) → **38**). The authors concluded that with the lithium aluminum hydride reduction of 3-*O*-acetylmorphine tosylate (**56**), the presence of the allylic system in ring-C facilitates the elimination reaction [101], thus giving higher yield compared to the analogous reaction of 3-*O*-acetyldihydromorphine tosylate (**58**) [68–70]. Desoxymorphine-E (**57**, $\Delta^{7,8}$-didehydro) was converted with diazomethane to desoxycodeine-E (**61**, $\Delta^{7,8}$-didehydro) or by catalytic reduction (H$_2$, PtO$_2$, MeOH, 1 h) quantitatively to desoxydihydromorphine-D (**38**).

**Figure 16.** Synthesis of 6-desoxydihydromorphine. *Reagents and conditions*: (i): H$_2$, Pd-C, 1 N HCl or diluted AcOH; (ii): acetic anhydride, aqueous NaHCO$_3$ solution, 63%; (iii): H$_2$, 10% Pd-C, aqueous HCl (pH 6–6.5), 96%; (iv): acetic anhydride, aqueous NaHCO$_3$ solution, 92%; (v): TosCl, pyridine; **A**: 0 °C, 2 h, **B**: RT, 16 h, 51%; (vi): LiAlH$_4$, THF; **A**: reflux, 3 h, **B**: RT, 16 h, 25%; (vii): TosCl, pyridine; **A**: 0 °C, 2 h, **B**: RT, overnight; (viii): LiAlH$_4$, THF, reflux, 3 h, nitrogen stream; (ix): H$_2$, PtO$_2$, MeOH, 1 h; (x): SOCl$_2$; reflux, 1.5 h; (xi): H$_2$, Pd-BaSO$_4$, MeOH or 1 N HCl, 30–80%; (xii): MsCl, Et$_3$N, CH$_2$Cl$_2$, 0 °C, 1 h; (xiii); LiAlH$_4$, THF, RT, 1 h; (xiv): H$_2$, PtO$_2$, MeOH, 4 Bar, 1 h; (xv): BBr$_3$, CH$_2$Cl$_2$, RT, 30 min; (xvi): CH$_2$N$_2$, Et$_2$O, 48 h, 0–4 °C.

**Figure 17.** Reactions of codeine tosylate with nucleophiles. *Reagents and conditions*: (i): Bu$_4$NF, acetonitrile, reflux, 4 h, 48%; (ii): piperidine, benzene, reflux, 36 h, 87%; (iii): A. LiCl, acetone, reflux, 4 h, quant. or B. LiCl, DMF, 40 °C, 5 h, 76%; (iv): LiCl, DMF, 120 °C, 5 h, 33%; (v): LiBr, acetone, reflux, 2.5 h, 98%; (vi): NaI, acetone, reflux, 2.5 h, 43%; (vii): DMF, 120 °C, 10 h, 41%.

In 2012, the research group of Chen [102] described a novel protocol for the synthesis of desomorphine (**38**) from codeine (**2a**, route: **2a** → **60** → **61** → **62** → **38**). Codeine mesylate (**60**) was treated with 2 equiv. of LiAlH$_4$ in THF (0 °C, 30 min and RT for 1 h) to yield desoxycodeine-E (**61**) in 93% yield. The latter compound (**61**) was hydrogenated (H$_2$, PtO$_2$, MeOH, 4 Bar, 1 h) to dihydodesoxycodeine-D (**62**) in quantitative yield. The 3-*O*-demethylation of **62** was achieved by the application of boron tribromide in dichloromethane to yield **38** in 43% yield. The overall yield of the synthesis of **38** was 38% starting from codeine (**2a**). The authors also performed the synthesis of a deuterium-labeled version of desomorphine staring from dihydrodesoxycodeine-D in a three-step procedure.

Tragically, desomorphine (**38**) is the main active component [103] of the illicit designer drug krokodil (street name, from Russian word for crocodile: крокодил, also known as Russian magic, krok/crok, flesh-eating heroin, poor man's heroin), which has spread as a cheap substitute of heroin in former Soviet countries in the past two decades [95,102,104,105]. The illicit synthesis of desomorphine (**38**) utilizes codeine phosphate or codeine sulfate tablets sold at pharmacies as a cough suppressant. Operators reportedly use gasoline/petrol to extract the free base of **2a** liberated from the tablets by the addition of a strong alkali (KOH, NaOH). According to one street method (route: codeine (**2a**) → iodocodide (**59c**) → dihydrodesoxycodeine-D (**62**) → **38**), the extracted codeine (**2a**) is treated with iodine (iodine tincture), hydrochloric acid and red phosphorus

(from match heads) for dehalogenation. The heating of the mixture gives a very complex product mixture containing **38** as the main component, along with perhaps 50 different morphinan derivatives [106], with the carryover of residual phosphorus, heavy metals and highly toxic by-products. Naloxone serves as an antidote for acute krokodil toxicity, but it is naturally ineffective against somatic injury arising from subcutaneous or intravenous injection of such a terrible concoction. Indeed, the street name krokodil refers to the necrotic skin changes associated with its use. Habitual krokodil users also suffer from horrendous wounds including deep tissue destruction, limb amputation or the auto-amputation of fingers, and osteonecrosis of facial bones and teeth.

### 2.8. Nucleophilic Substitution Reactions in the Morphine Series

The nucleophilic substitution reaction of arylsulfonyl- or alkysulfonyl-esters (tosyl, mesyl, nosyl, brosyl, mesityl) leaving groups is a fundamental transformation [107,108] for the exchange of primary and secondary hydroxyl groups to other substituents in biology, organic chemistry and radiochemistry for the production of PET tracers [109]. In 1956, Stork and Clarke [110] studied the reactions of codeine tosylate (**63a**) with $Cl^\ominus$, $Br^\ominus$, $I^\ominus$ and piperidine nucleophiles. The reaction of **63a** with chloride anion (LiCl, acetone, reflux, 4 h) gave the kinetic product α-chlorocodide (**59b**, 6β-chloro-$\Delta^{7,8}$-deoxycodeine, 6-chloro-6-desoxyisocodeine) in quantitative yield according to the $S_N2$ mechanism (substitution with inversion). α-Chlorocodide (**59b**) is unstable and isomerizes readily to its thermodynamic isomer β-chlorocodide (**65a**, 8β-chloro-$\Delta^{6,7}$-deoxycodeine, 8-chloro-8-desoxypseudocodeine, $S_Ni'$). 6-Piperidocodide (**64**, 87%) was obtained by heating of codeine tosylate (**63a**) with piperidine in benzene for 36 h. In the reaction of codeine tosylate (**63a**) with bromide (LiBr, acetone, reflux, 2.5 h) or iodide (NaI, acetone, reflux, 2.5 h) anions, there was the formation of the corresponding β-halocodide derivatives (pseudocodeine series, $S_N2'$ ($S_N2 + S_Ni'$)) (**65b**, bromide, 98% and **65c**, iodide, 43%).

Bognár et al. [111,112] synthesized 6-deoxy-6-fluoroisocodeine (**59a**) from codeine tosylate (**63a**) with tetrabutylammonium fluoride in acetonitrile in 48% yield, and determined the configuration of its C-6 carbon by NMR spectroscopy. They found that the 6β-fluoro compound (**59a**) would not isomerize to the corresponding 8β-fluoro-derivative (β-fluorocodide, pseudocodeine series). In 1976, Makleit et al. [113,114] studied the substitution reaction of codeine tosylate (**63a**) with the $Cl^\ominus$ nucleophile (LiCl) in *N,N*-dimethylformamide. They found that the reaction temperature had a significant influence on the course of the reaction; at lower temperatures (40 °C, 5 h), there was the formation of the kinetic product α-chlorocodide (**59b**, $S_N2$, 76%), while at higher temperatures (e. g., 120 °C, 10 h), the thermodynamic isomer β-chlorocodide (**65a**, $S_N2 + S_Ni'$, 33%) was the predominant product. They also detected the high-temperature conversion of the 6β-chloro (**59b**) to the 8β-chloro (**65a**) isomer (120 °C, 10 h, 41%).

Makleit [115,116] thoroughly investigated the synthesis of tosyl and mesyl derivatives in the so-called morphine series ($\Delta^{7,8}$-unsaturated derivatives: morphine (**1a**), codeine (**2a**), 14-hydroxycodeine (**66**); and their 7,8-dihydro derivatives: dihydromorphine (**35**), dihydrocodeine (**67**), 14-hydroxydihydrocodeine (**68**); Figure 18). His objective was to study their nucleophilic substitution reactions, and to clarify the reaction mechanism, through the production of numerous semisynthetic morphinan derivatives [115,116]. The Makleit group further showed that the C-ring of the $\Delta^{7,8}$-unsaturated derivatives (**1a**, **2a**, **66**, Figure 18) has a flattened boat conformation, with the C-6 hydroxyl group having an allylic alcohol character in a pseudo-equatorial position. Conversely, the C-ring in the 7,8-dihydro series (**35**, **67**, **68**, Figure 18) has a chair conformation, with the C6-OH in an axial position. In both cases, the hydroxyl group connects to an asymmetric carbon in position-6. They prepared sulfonate esters of codeine (**2a**) and dihydrocodeine (**67**) by the application of previously

well-established methods, resulting in codeine tosylate (**63a**, 58%, Figure 19), codeine mesylate (**63b**, 16%), dihydrocodeine tosylate (**71a**, 75%) and dihydrocodeine mesylate (**71b**, 23%), respectively [116–118].

$\Delta^{7,8}$-unsaturated derivatives



**1a**

**morphine**

**2a**

**codeine**

**66**

**14-hydroxycodeine**

7,8-dihydro derivatives

**35**

**dihydromorphine**

**67**

**dihydrocodeine**

**68**

**14-hydroxydihydrocodeine**

**Figure 18.** Structures of derivatives belonging to the "*morphine series*" defined by Makleit and Bognár.

$\Delta^{7,8}$-unsaturated derivatives

63, 69–73
a: R = Tos
b: R = Ms



**63a–b**

**63a: codeine tosylate**
**63b: codeine mesylate**

**69a–b**

**69a: 3-*O*-acetylmorphine tosylate**
**69b: 3-*O*-acetylmorphine mesylate**

**70a–b**

**70a: 14-hydroxycodeine tosylate**
**70b: 14-hydroxycodeine mesylate**

7,8-dihydro derivatives

**71a–b**

**71a: dihydrocodeine tosylate**
**71b: dihydrocodeine mesylate**

**72a–b**

**72a: 3-*O*-acetyldihydromorphine tosylate**
**72b: 3-*O*-acetyldihydromorphine mesylate**

**73a–b**

**73a: 14-hydroxydihydrocodeine tosylate**
**73b: 14-hydroxydihydrocodeine mesylate**

**Figure 19.** Sulfonate esters of selected morphine derivatives.

## 2.8.1. Reactions of 7,8-Dihydro Compounds

The reactions of the 7,8-dihydro-6$\alpha$-sulfonate esters (**71–73**) with the nucleophile anions $H^{\ominus}$, $N_3^{\ominus}$, $CH_3COS^{\ominus}$ and $CH_3COO^{\ominus}$ in polar aprotic solvents occur according to the $S_N2$ mechanism via Walden inversion, yielding products of the *iso* series. Dihydrocodeine tosylate (**71a**) reacted with $N_3^{\ominus}$ nucleophile resulted in 6-desoxy-6-azido-dihydroisocodeine (**74a**, Figure 20) [54,55,117–120], while 14-hydroxydihydrocodeine tosylate (**73a**) under iden-

tical conditions (10 equiv., NaN$_3$, DMF, 100 °C, 24 h) with the same reagent gave 6-desoxy-6-azido-14-hydroxydihydroisocodeine (**74b**, 31%) [121,122]. The reduction of the 6-azido compounds (**74a–b**) with LiAlH$_4$ [117,118] or by catalytic hydrogenation [121,122] led to the corresponding 6-amino (6-beta-amino or 6-amino-dihydroisocodeine) derivatives (**75a–b**).



**Figure 20.** Reaction of the sulfonate esters of 7,8-dihydro derivatives with nucleophiles. *Reagents and conditions*: (i): NaN$_3$, DMF, H$_2$O, 100 °C, 24 h, R = H, 83%, R = OH, 67%; (ii): from **71b**, AcOH, Ac$_2$O, NaOAc, reflux, 31 h; (iii): KSCOCH$_3$, DMF, 100 °C, 24 h; under N$_2$ atmosphere; (iv): LiAlH$_4$, Et$_2$O, reflux, 3 h, 60% or H$_2$, 10% Pd-C, MeOH; (v): alkaline hydrolysis, (ii + iv) 21%; (vi): NaOMe, MeOH, room temperature, 24 h, 91%.

Makleit and Bognár [123,124] accomplished the epimerization of the C-6 chiral centers of codeine (**2a**) and dihydrocodeine (**67**). The acetolysis of codeine tosylate (**63a**) with 10% acetic acid (reflux, 4 h) gave isocodeine (**2b**) in 16% yield [123,124]. In the 1990s, the Makleit group developed protocols resulting in higher yields for the derivatives of the iso series via the application of the Mitsunobu reaction (see Section 2.11). 6-*O*-Acetyl-dihydroisocodeine (**76**) was prepared starting from dihydrocodeine mesylate (**71b**) with acetic acid, acetic anhydride and sodium acetate (reflux, 31 h). Subsequently, the 6-*O*-deacetylation of **76** was achieved by alkaline hydrolysis to yield dihydroisocodeine (**77**), with an overall 21% yield from dihydrocodeine mesylate (**71b**)). When dihydrocodeine tosylate (**71a**) was treated with the CH$_3$COS$^\ominus$ nucleophile (KSCOCH$_3$, DMF), 6-acetylthio-dihydroisocodeine (**78**) was obtained [125–128]. The latter compound was deacetylated with sodium methylate to 6-desoxy-6-thiol-dihydroisocodeine (**79**). Upon reacting 3-*O*-acetyl-dihydromorphine tosylate (**72a**) with hydride anion (LiAlH$_4$), there was the elimination of the tosyloxy group to yield 6-desoxydihydromorphine (**38**) [68–70].

2.8.2. Reactions of $\Delta^{7,8}$-Unsaturated Derivatives

Sulfonate esters (6α-O-tosyl and 6α-O-mesyl) of $\Delta^{7,8}$-unsaturated derivatives react with different nucleophiles either according to an $S_N2$ mechanism to give 6β-substituted derivatives, or via an $S_N2$ reaction accompanied by allylic rearrangement (an $S_N2 + S_Ni'$ mechanism) to result in 8-substituted-8-desoxypseudo compounds (see supposed mechanism in Section 2.9.1). Both the character of the nucleophile and the stereochemical properties of the substrates are of crucial importance in determining the reaction mechanism. For example, codeine tosylate (**63a**) with LiCl gave α-chlorocodide (**59b**) [110], whereas the reaction of isocodeine tosylate (**81**) under identical conditions with the same reagent resulted in β-chlorocodide (**65a**) [121,122].

Codeine tosylate (**63a**) with tetrabutylammonium fluoride in acetonitrile [111,112] led to the formation of 6-fluoro-6-desoxyisocodeine (**59a**, Figure 21). The isolated 6α-fluoro-type compound (**59a**, α-fluorocodide) cannot isomerize to the 8β-fluoro-type (β-fluorocodide) derivative. Compound **59a** was also prepared from pseudocodeine tosylate (see structure **97** in Section 2.8.3) with tetrabutylammonium fluoride (5.4 equiv., $CH_3CN$, reflux, reflux, 29 h) in poor yield (10%) [129,130]. 6-Fluoro-6-desoxy-14-hydroxyisocodeine (**80**) was prepared from 14-hydroxycodeine tosylate (**70a**) under identical conditions [121,122]. When codeine tosylate (**63a**) was treated with 10% acetic acid (reflux, 4 h), the main direction of the reaction was toward the formation of isocodeine (**2b**, 16% isolated yield) [123,124] without allylic rearrangement. This method was also applicable for the synthesis of isomorphine (**1b**, 16%) from 3-O-acetylmorphine tosylate (**69a**) with the subsequent preparation of dihydroisomorphine (**82**) through the catalytic reduction of isomorphine (**1b**) [131,132].

Codeine tosylate (**63a**) with azide anion ($NaN_3$) in N,N-dimethylformamide gave 8-azido-8-desoxypseudocodeine (**83**, 8-azidocodide, Figure 22), which was converted to 8-amino-8-desoxypseudocodeine (**84**, 8-aminocodide) with lithium aluminum hydride [54,55,117,118]. The azidolysis of 14-hydroxycodeine tosylate (**70a**) with 1.25 equiv. of sodium azide gave 6-azido-6-desoxy-14-hydroxyisocodeine (**87**, 38%) when the reaction mixture was heated at 100 °C for 4 h [121,122]. Meanwhile, the application of the same 0.25% $NaN_3$ excess and a longer reaction time (100 °C, 8h) led to 8-azido-8-desoxy-14-hydoxypseudocodeine (**85**, 46%). 6-Azido-6-desoxy-14-hydroxyisocodeine (**87**) was isomerized by heating in DMF (100 °C, 6 h) 83%) to **85** in 83% yield [121,122]. The reduction of 8-azido-8-desoxy-14-hydoxypseudocodeine (**85**) with $LiAlH_4$ gave 8-amino-8-desoxy-14-hydoxypseudocodeine (**86**), although the catalytic hydrogenation led to 8-amino-8-desoxy-14-hydoxydihydropseudocodeine (**88**) [121,122].

The treatment of codeine tosylate (**63a**) with the $CH_3COS^{\ominus}$ nucleophile ($KSCOCH_3$, DMF) [127,128] led to 8-acetylthio-8-desoxypseudocodeine (**89**, Figure 23), which was deacetylated with sodium methylate to give 8-thiol-8-desoxypseudocodeine (**90**). The oxidation of the latter compound gave an 8,8′-didesoxy-8,8′-pseudocodeinyl disulfide-type compound. Surprisingly, the reaction of codeine tosylate (**63a**) with thiocyanate anion ($^{\ominus}S=C=N$, KSCN, in acetone) gave (in a kinetically second-order reaction) the product 8-isothiocyanato-8-desoxypseudocodeine (**92**, -NCS) instead of the expected 8-thiocyanato-8-desoxyspseudocodeine (**91**, -SCN) [127,128].

The analogous reaction of 3-O-acetylmorphine tosylate (**69a**, Figure 24) with $CH_3COS^{\ominus}$ led to 3-O-acetyl-8-acetylthio-8-desoxypseudomorphine (**93**), which was deacetylated with sodium methylate to 8-thiol-8-desoxypseudomorphine (**94**) [127,128]. The treatment of **69a** with potassium thiocyanate resulted in 3-O-acetyl-8-isothiocyanato-8-desoxypseudomorphine (**95**) [133,134]. The reaction of **69a** with $N_3^{\ominus}$ anion gave 8-azido-8-desoxypseudomorphine (**96**, Makleit–Bognár nomenclature, 8-azido-8-desoxy-γ-isomorphine).

**Figure 21.** Reaction of selected 6-*O*-tosylates of $\Delta^{7,8}$-unsaturated morphinans. *Reagents and conditions*: (i): 1.6 equiv. Bu$_4$NF, CH$_3$CN, reflux, 4 h, 48% [111,112]; (ii): LiCl, acetone, reflux, 4 h; (iii): 10% AcOH (aq.), reflux, 4 h; (iv): H$_2$, BaSO$_4$/Pd-C, EtOH, 90%.

### 2.8.3. Reactions of Pseudocodeine Tosylate

In the early 1970s, Makleit et al. [117,118] extended their studies on the nucleophilic substitution reaction of sulfonate esters to the $\Delta^{6,7}$ double bond containing pseudocodeine tosylate (**97**, Figure 25). Pseudocodeine (**2d**) was prepared from α-chlorocodide (**59b**) by hydrolysis according to the method of Small and Lutz [135]. The tosyl ester (**97**) was prepared from **2d** in 76% yield. They investigated the substitution reactions by the application of a large variety of nucleophilic reagents. Using type-X reagents (F$^{\ominus}$, Cl$^{\ominus}$ or piperidine), *isocodeine* derivatives (**99**) were formed either by an S$_N$1′ or S$_N$2′ mechanism in a yield in the range of 10–65%. Using type-Y nucleophiles (Br$^{\ominus}$, I$^{\ominus}$, NCS$^{\ominus}$, N$_3{}^{\ominus}$, CH$_3$COS$^{\ominus}$), *pseudocodeine* derivatives (**98**) were isolated in poor yields (10–52%). In these latter cases, the mechanism of the reaction was either S$_N$1 accompanied by retention or a combination of S$_N$2′ and S$_N$i′.

**Figure 22.** Synthesis of 8-substituted-8-desoxypseudocodeine derivatives. *Reagents and conditions*: (i): 10 equiv. NaN$_3$, DMF, H$_2$O, 100 °C, 4 h, 65%; (ii): LiAlH$_4$, Et$_2$O, reflux, 3 h, 46%; (iii): 1.25 equiv. NaN$_3$, DMF, H$_2$O, 100 °C, 4 h, 38%; (iv): 1.25 equiv. NaN$_3$, DMF, H$_2$O, 100 °C, 8 h, 46%; (v): LiAlH$_4$, Et$_2$O, reflux, 3 h, 25%; (vi): H$_2$, Pd-C, MeOH, 75%; (vii): DMF, 100 °C, 6 h, 83%.



**Figure 23.** Reaction of codeine tosylate (**63a**) with CH$_3$COS$^{\ominus}$ and $^{\ominus}$SCN nucleophiles. *Reagents and conditions*: (i): 2 equiv. KSCOCH$_3$, DMF, 100 °C, 5 h, N$_2$ atmosphere, 57%; (ii): NaOMe, MeOH, room temperature, N$_2$ atmosphere, dark, 24 h, 38%; (iii): 2 equiv. KSCN, acetone, reflux, 2.5 h, 48%.

**Figure 24.** Reaction of 3-*O*-acetylmorphine tosylate with nucleophiles (following the Makleit–Bognár nomenclature [54,55]; γ-isomorphine derivatives). *Reagents and conditions*: (i): 2 equiv. KSCOCH₃, DMF, 100 °C, 5 h, N₂ atmosphere, 43%; (ii): NaOMe, MeOH, room temperature, N₂ atmosphere, dark, 24 h, 42%; (iii): 2 equiv. KSCN, reflux, 2.5 h, 90%; (iv): NaN₃, DMF, H₂O, 100 °C, 4 h (**96 → 128**).

The corresponding products were isolated in poorer yields despite more vigorous reaction conditions and longer reaction times in comparison to the analogous reactions of codeine tosylate (**63a**). The authors undertook comparative solvolysis of pseudocodeine tosylate (**97**) and codeine tosylate (**63a**) in an acetic acid–potassium acetate system, finding that the solvolysis of 8β-*O*-tosylate (**97**) occurred slower than that of 6α-*O*-Tos (**63a**) following, in both cases, a first-order reaction. They investigated more thoroughly the reaction of pseudocodeine tosylate (**97**) with piperidine, definitively showing the formation of the 6β-(1-piperidinyl) derivative (**64**, 6-piperidocodide) by an S$_N$1′ reaction mechanism.



**Figure 25.** Reactions of pseudocodeine tosylate with various nucleophiles. *Reagents and conditions*: (i): PCl₅, chloroform, room temperature, 2 h, 90–95%; (ii): water, acetic acid, reflux, 3 h, **2c**: 15%, **2d**: 38%; (iii): TosCl, pyridine, 0–5 °C, 2 h, and then room temperature, 24 h, 76%; (iv): **X** = **A**. Bu₄NF, acetonitrile reflux, 19 h, 10%; **B**. LiCl, acetone, reflux, 25 h, 16%; **C**. piperidine, benzene, reflux, 127 h, 65%; (v): **Y** = **A**: LiBr, acetone, reflux, 19 h, 52%; **B**. NaI, acetone, reflux, 19 h, 26%; **C**. KSCN, acetone, reflux, 16.6 h, 15%; **D**. NaN₃, DMF, 100 °C, 8 h, 30%; **E**. KSCOCH₃, DMF, 100 °C, 8 h, 10%.

### 2.8.4. Neopine Derivatives

Neopine derivatives (e.g., isoneopine (**3b**), Figure 26) are critical starting materials for the synthesis of B/C-*trans*-morphinans, which can be very difficult to produce [136,137]. In the 1970s, Berényi, Makleit and Bognár worked out numerous syntheses for the preparation of neopine (**3a**) [138,139] and isoneopine (**3b**) [140,141]. Furthermore, Berényi, Makleit and Dobány developed an improved method for the isolation of natural neopine (**3a**) from poppy straw [142], without interfering with the original Kabay process. In 1977, Makleit et al. [138,139] reported an efficient method for the preparation of neopine (**3a**) from thebaine (**4**) via 14-chlorocodeine. The reduction of the latter compound (**124a**) was achieved with sodium bis(2-methoxyethoxy)aluminum hydride. The overall yield for neopine (**3a**) from thebaine (**4**) was 72%. In 1980, Berényi and Makleit [140,141] published a novel method for the preparation of isoneopine (**3b**), wherein the azidolysis of neopine mesylate (**100**) resulted in 6-deoxy-6-azido-isoneopine (**101**) in 75% yield. The latter compound was reduced with Zn/NaI/DMF to 6-deoxy-6-amino-isoneopine (**102**, 65%). The treatment of the amino compound (**102**) with NaNO$_2$ in acetic acid gave 6-*O*-acetylisoneopine (**103**, 90%), and finally, the alkaline hydrolysis of the 6-*O*-acetyl group resulted quantitatively in isoneopine (**3b**). The overall yield from neopine (**3a**) was 44%.

Taking advantage of the availability of neopine (**3a**) in large quantities, Berényi et al. [143,144] prepared 6-*O*-mesylneopine (**100**, Figure 27) for the investigation of its substitution reactions with nucleophile partners (F$^{\ominus}$, Cl$^{\ominus}$, Br$^{\ominus}$, I$^{\ominus}$, N$_3{}^{\ominus}$). When 6-*O*-mesylneopine (**100**) was reacted with tetrabutylammonium fluoride in acetonitrile (reflux, 2 h), 6-demethoxythebaine (**105**, 77%) was obtained. In the reaction of neopine mesylate (**100**) with iodide anions (10 equiv. NaI, DMF, 120 °C, 30 h), 6-demethoxythebaine (**105**, 21%) was isolated, with 36% recovery of the starting material (**100**).



**Figure 26.** Synthesis of isoneopine. *Reagents and conditions*: (i): MsCl, pyridine, room temperature, 24 h; (ii): NaN$_3$, DMF, H$_2$O, 75%; (iii): Zn, NaI, DMF, reflux, 6 h, 65%; (iv): NaNO$_2$, AcOH, 20 °C, 24 h, 90%; (v): KOH, EtOH, reflux, 10 min, quant.

**Figure 27.** Reactions of 6-*O*-mesylneopine with nucleophiles. *Reagents and conditions*: (i): 5 equiv. Bu$_4$NF, CH$_3$CN, reflux, 2.5 h, 77%; (ii): 10 equiv. LiCl, DMF, 120 °C, 6 h, 38%; (iii): 10 equiv. LiBr, DMF, 120 °C, 11 h, 32%; (iv): 10 equiv. NaN$_3$, DMF, 100 °C, 24 h, 55%; (v): LiAlH$_4$, Et$_2$O, reflux, 1 h, 32%; (vi): 10 equiv. NaI, DMF, 120 °C, 30 h, 21% (**105**), and 36% recovered neopine mesylate (**100**); (vii): 85% formic acid, 30% H$_2$O$_2$, 40 °C, 2 h, 71%.

Through the application of chloride anions (10 equiv. LiCl, DMF, 120 °C, 6 h), 6-deoxy-6-chloro-isoneopine (**104a**) and 6-demethoxythebaine (**105**) were formed in a ratio of 6:4 [143,144]. Through the use of bromide anions as a nucleophile (10 equiv. LiBr, DMF, 120 °C, 11h), 6-deoxy-6-bromo-isoneopine (**104b**, 32%) and 6-demethoxythebaine (**105**, 31%) were isolated, with 10% recovery of the starting material (**100**). The 6-β position of the halogen substituent in compounds **104a** and **104b** (Cl, Br) was substantiated by NMR spectroscopy, in which the value of the geminal coupling of the H-5 and H-6 protons ($^3J_{5,6}$ = 9.5–10 Hz) was characteristic of both compounds. The azidolysis of neopine mesylate (**100**) with 10 equivalents of NaN$_3$ in DMF (120 °C, 24 h) resulted in 6-deoxy-6-azido-isoneopine (**101**, 55%). The latter compound (**101**) was converted to 6-deoxy-6-amino-isoneopine (**102**) by heterogenous catalytic reduction (H$_2$, 50% acetic acid, platinum oxide). The authors concluded that the first step of these reactions is an S$_N$2 nucleophile substitution resulting in the corresponding 6-desoxy-6-haloisoneopines (**104a–b**), followed by a second elimination step resulting in 6-demethoxythebaine (**105**). 6-Desoxy-6-bromo-isoneopine (**104b**) was converted to 6-demethoxythebaine (**105**, reflux, 4 h, 72%) with tetrabutylammonium fluoride, while 6-deoxy-6-chloro-isoneopine (**104a**) gave, according to 50% conversion, a 1:1 mixture of 6-demethoxythebaine (**105**) and the starting material (**104a**). Based on these observations, Hutchins et al. and Beyerman, Maat and Crabbendam reported improved preparations of 6-demethoxythebaine (**105**) in high yields either from neopine (**3a**) or from codeine (**2a**) via isocodeine (**2b**) or β-bromocodide (**65b**) [145–147]. The reaction of thebaine (**4**) with peracids, peracetic acid (CH$_3$CO-OOH) or performic acid (HCO-OOH) [148,149] resulted in 14-hydroxycodeinone by the 1,4-addition of hydroxyl groups to the 6,8-conjugated system followed by methanol elimination from the 6-hemiacetal intermediate.

The analogous treatment of 6-demethoxythebaine (**105**, Figure 27) with formic acid and hydrogen peroxide [143,144] gave 14-hydroxy-allopseudocodeine (**106**, 71%). Th latter compound was also prepared previously by Currie et al. [150] from 6-*O*-tosyl-14-hydroxycodeine (**70a**, Figure 28) in an S$_N$2′ reaction (70% AcOH) through 8-*O*-acetyl-14-hydroxy-allopseudocodeine

(**107**) and subsequent alkaline hydrolysis. Seki [151] prepared **106** from 14-hydroxy-α-chlorocodide (**108**) via acetolysis with 10% AcOH and subsequent hydrolysis.



**Figure 28.** Synthesis of 14-hydroxy-allopseudocodeine. *Reagents and conditions*: (i): AcOH-H₂O 7:1 (*v/v*), reflux, 4 h, 39% [150]; (ii): KOH, MeOH-H₂O 3:1 (*v/v*), reflux, 1 h; (iii): **A**. 10% AcOH, reflux, 4 h, 45% [151], **B**. KOH, MeOH-H₂O 4:1 (*v/v*), 40–50 °C, 1 h.

2.8.5. Alkyl Mesylate and Allyl Halide Structural Units in the Same Molecule

Studying the relative reactivity of alkyl mesylates (C$^8$-C$^7$-C$^6$-OMs) and allyl halides (C$^{14}$=C$^8$-C$^7$-X), Simon et al. [152,153] investigated the nucleophilic substitution reactions of 6-*O*-mesyl-7α-haloneopine derivatives (**112a–b**) containing both structural units in the same molecule. The starting materials 7α-chloroneopine (**111a**) and 7α-bromoneopine (**111b**) were prepared in three steps from thebaine (**4**) by the method of Abe et al. [154] (Figure 29). In brief, thebaine (**4**) was reacted with *N*-bromosuccinimide to give 14-bromocodeinone (**109**) [155]. The latter compound was stereoselectively reduced with NaBH₄ to 14-bromocodeine (**110**). The treatment of **110** with concentrated hydrochloric acid or 48% hydrobromic acid resulted in the corresponding 7α-haloneopines (**111a–b**).



**Figure 29.** Synthesis of 7α-haloneopines from thebaine. *Reagents and conditions*: (i): *N*-bromosuccinimide, acetone–water 2:1 (*v/v*), 71%; (ii): NaBH₄, benzene, MeOH, 5–10 °C, 1 h, 94%; (iii): cc. HCl, 5–10 °C, overnight, 90%, or 48% HBr, 0–5 °C, overnight.

Nucleophilic substitution reactions of 6-*O*-mesyl-7α-chloro-neopine (**112a**) and 6-*O*-mesyl-7α-bromoneopine (**112b**) were studied with the following nucleophiles: Cl$^\ominus$, Br$^\ominus$, I$^\ominus$ and N₃$^\ominus$ [152,153] (Figure 30). When 6-*O*-mesyl-7α-chloroneopine (**112a**, Figure 30) was reacted with azido anions (5 equiv. NaN₃), there was the formation of

a complex product mixture. Column chromatography isolated the main product 7-chloro-6-demethoxythebaine (**113a**, 31%) and the side products 6-*O*-mesyl-7β-azidoneopine (**114**, 10%) and 6-*O*-mesyl-6-demethoxythebaine (**115**, 5%).



**Figure 30.** Azidolysis of 6-*O*-mesyl-7α-haloneopines. *Reagents and conditions*: (i): 5 equiv. NaN₃, DMF, H₂O, 100 °C, 8 h; (ii) 5 equiv. NaN₃, DMF, H₂O, 100 °C, 20 min.

When 6-*O*-mesyl-7α-bromoneopine (**112b**, Figure 30) was reacted with 5 equiv. of sodium azide in *N,N*-dimethylformamide (addition of water was necessary to dissolve NaN₃), the main product was 6-*O*-mesyl-7β-azidoneopine (**114**, 48%). The isolated side products were 6-*O*-mesyl-6-demethoxythebaine (**115**, 14%) and 9α-azido-6-*O*-mesyl-indolinocodeine (**116**, 3%).

In studies of the reactions of 6-*O*-mesyl-7α-chloroneopine (**112a**, Figure 31) with 5 equivalents of reagent (LiCl, LiBr, KI) [152,153], the main product with chloride anions (5 equiv. LiCl, DMF, 100 °C, 24 h) was 7-chloro-6-demethoxythebaine (**113a**, 39%), with the isolation of 6-chloro-6-demethoxythebaine (**118a**, 18%) and 6-*O*-mesyl-7β-chloroneopine (**117a**, 3%) side products. When LiBr was used as the source of nucleophile under otherwise identical conditions, the main reaction was methanesulfonic acid elimination, which resulted in 7-chloro-6-demethoxythebaine (**113a**, 31%) and 6-bromo-6-demethoxythebaine (**118b**, 18%), as well as 6-*O*-mesyl-7β-bromoneopine (**117b**, 13%). In the presence of iodine anions (5 equiv. KI, DMF, 100 °C, 48 h), the main product was 6-demethoxythebaine (**105**, 34%).



**Figure 31.** Reaction of 6-*O*-mesyl-7α-chloroneopine with Cl⁻ and Br⁻ nucleophiles. *Reagents and conditions*: (i): 5 equiv. LiCl, DMF, 100 °C, 24 h; (ii): 5 equiv. LiBr, DMF, 100 °C, 24 h.

Shorter reaction times (20–40 min) were applied in studying the reactions of 7α-bromoneopine mesylate (**112b**, Figure 32) with Cl⁻, Br⁻ and I⁻ nucleophiles. With LiCl, the main product was 6-*O*-mesyl-7β-chloroneopine (**117a**, 19%), with the additional isolation of 6-*O*-mesyl-6-demethoxythebaine (**115**, 7%). When **112b** was reacted with LiBr, the products were 6-*O*-mesyl-7β-bromoneopine (**117b**, 24%), 7-bromo-6-demethoxythebaine (**113b**, 3%) and 6-*O*-mesyl-6-demethoxythebaine (**115**, 6%). When potassium iodide

was applied, 6-demethoxythebaine (**105**, 72%) was the single isolated product. The study [152,153] also presented an elegant and efficient method for the preparation of 7-halo-6-demethoxythebaines (**113a–b**).



**Figure 32.** Reaction of 6-*O*-mesyl-7α-bromoneopine with nucleophiles. *Reagents and conditions*: (i): 5 equiv. LiCl, DMF, 100 °C, 30 min; (ii): 5 equiv. LiBr, DMF, 100 °C, 20 min.

When 6-*O*-mesyl-7α-chloroneopine (**112a**, Figure 33) or 6-*O*-mesyl-7α-bromoneopine (**112b**) was boiled in the presence of potassium *tert*-butylate in methanol, the main reaction was methanesulfonic acid elimination (E$_{1,2}$ (-CH$_3$SO$_2$OH)). 7-Chloro-6-demethoxythebaine (**113a**) was prepared as the sole product in 95% yield from **112a**, and 7-bromo-6-demethoxythebaine (**113b**) was the main product in 50% yield from **112b**.



**Figure 33.** Nucleophilic substitution reactions of 7α-haloneopine mesylates. *Reagents and conditions*: (i): MsCl, Et$_3$N, CH$_2$Cl$_2$, 15 min, from **111a**, X = Cl, 61%, from **111b**, X = Br, 51%; (ii): Nu$^{\ominus}$ = Cl$^{\ominus}$, Br$^{\ominus}$, N$_3$$^{\ominus}$, S$_N$2; (iii): S$_N$i + -H; (iv): Nu$^{\ominus}$ = I$^{\ominus}$, S$_N$2 + E$_{1,2}$; (v): Nu$^{\ominus}$ = N$_3$$^{\ominus}$, E$_{1,2}$ (-HCl) or Nu = Cl$^{\ominus}$, Br$^{\ominus}$, N$_3$$^{\ominus}$, E$_{1,2}$ (- HBr); (vi): Nu = Cl$^{\ominus}$, Br$^{\ominus}$, I$^{\ominus}$, N$_3$$^{\ominus}$, E$_{1,2}$ (- CH$_3$SO$_2$OH); (vii): Nu$^{\ominus}$ = N$_3$$^{\ominus}$.

### 2.8.6. Substrates Containing Double Allylic System
Substrates with Allyl Halide and Allyl Tosylate Subunits

Berényi et al. [156–158] were the first to study the nucleophilic substitution reactions of 6-*O*-tosyl-14-halocodeine substrates (**119a–b**), which possess a double allylic system: allyl halide ($C^7$=$C^8$-$X^{14}$) and allyl tosylate ($C^8$=$C^7$-$C^6$-OTos) in the same molecule. They investigated reactions of 14-chlorocodeine tosylate (**119a**, Figure 34) [156–158] and 14-bromocodeine tosylate (**119b**) [155] with $Cl^{\ominus}$, $Br^{\ominus}$ and $N_3^{\ominus}$ nucleophiles. Surprisingly, 6-chloro-6-demethoxythebaine (**118a**, 68%) as well as 6-bromo-6-demethoxythebaine (**180b**, 74%) was isolated when the more stable 14-chlorocodeine tosylate (**119a**) was reacted with $Cl^{\ominus}$ or $Br^{\ominus}$ anions (LiX, X = Cl. Br, DMF, 100 °C, 24 h).

Interestingly, 6-*O*-tosyl-14-bromocodeine (**119b**) gave 6-*O*-tosyl-6-demethoxythebaine (**120**) under similar conditions. Heating 6-*O*-tosyl-14-bromocodeine (**119b**) in DMF (100 °C, 2 h) without any nucleophilic reagent gave the latter compound (**120**, 26%). A further surprising result was that 6-*O*-tosyl-6-demethoxythebaine (**120**) did not react with $Cl^{\ominus}$ or $Br^{\ominus}$ anions.

The authors [156–158] explained the complicated formation of 6-halo-6-demethoxythebaine derivatives (**118a–b**) by the following elementary steps (Figure 35): (i): $S_N2'$ reaction: nucleophilic attack at position-7, resulting in 6-*O*-tosyl-7-substituted neopine (**A**); (ii): $S_N2$ reaction: further nucleophile attack on the 6-tosyloxy group, resulting in 6-deoxy-6β,7β-disubstituted neopine (**B**); and (iii): 1,4-elimination reaction.



**Figure 34.** Reaction of 6-*O*-tosyl-14-halocodeines with nucleophiles. *Reagents and conditions*: (i): 6 equiv. LiCl, or 5 equiv. LiBr, DMF, 100 °C, 24 h; (ii): without any nucleophilic partner, DMF, 100 °C, 2 h.

**Figure 35.** Supposed elementary steps of the formation of 6-halo-6-demethoxythebaines.

The azidolysis [156–158] of 14-chlorocodeine tosylate (**119a**, Figure 36) with 2.5 equiv. NaN$_3$ resulted in 6-deoxy-6β,7α-diazido-neopine (**121**, 27%) as the main product and 6-deoxy-6β,7β-diazido-neopine (**122**, 7%) as a minor by-product. Carrying out the azidolysis of **119a** with 2.5 equiv. trimethylsilyl azide in DMF at 100 °C yielded 6-O-tosyl-6-demethoxythebaine (**120**) and 6-deoxy-6β,7β-diazido-neopine (**122**) in a ratio of approximately 1:1, with a significant amount of the starting material (**119a**) remaining in the product mixture after a 24 h reaction time. When 6-O-tosyl-14-bromocodeine (**119b**) was reacted with azido anions (2.5 equiv. NaN$_3$), the major product was 6-O-tosyl-7β-azidoneopine (**123**, 25%), with a lesser amount of 6-O-tosyl-6-demethoxythebaine (**120**, 16%) in 16% yield [156–158]. The reactivity sequence of the leaving groups was as follows: allyl bromide > allyl tosylate > allyl chloride.



**Figure 36.** Azidolysis of 14-chlorocodeine tosylate and 14-bromocodeine tosylate. *Reagents and conditions*: (i): NaN$_3$, DMF, H$_2$O, 100 °C, 24 h; (ii): NaN$_3$, DMF, 100 °C, 2 h.

Substrates Containing Double Allyl Halide Sub-Structural Units

In 1988, Berényi et al. [159] reported the substitution reactions of 6β,14-dichlorodesoxycodeine (**125a**) and 6β-chloro-14-bromodesoxycodeine (**125b**, Figure 37), containing double allyl halide (C$^7$=C$^8$-C$^{14}$-X and C$^8$=C$^7$-C$^6$-Cl) sub-structural units with the nucleophiles Cl$^\ominus$, Br$^\ominus$ and N$_3^\ominus$ applied as LiCl, LiBr and NaN$_3$, respectively. They also studied reactions in hot DMF in the absence of a nucleophilic partner. The authors claimed that only leaving groups (Cl$^\ominus$, Br$^\ominus$) linked to the tertiary C$^{14}$ carbon (C$^7$=C$^8$-C$^{14}$-X) took part in nucleophilic substitution reactions among the investigated 6β-chloro-14-halodesoxycodeines (**125a–b**).

**Figure 37.** Nucleophilic substitution reactions of derivatives containing double allyl halide system. *Reagents and conditions*: (i): 2 equiv. $PCl_5$, $CHCl_3$, 0 °C, 2 h, **125a** (66%), **125b** (53%); (ii): 6 equiv. LiCl, DMF, 100 °C, 8 h; (iii): **A**: 10 equiv. LiCl, DMF, 100 °C, 30 min, **126a** (42%) and **126b** (4%); **B**: 5 equiv. LiBr, DMF, reflux, 4 h, **126c** (16%); **C**: 5 equiv. $NaN_3$, DMF, $H_2O$, 100 °C, 1 h, **126d** (44%) and **127** (8%); (iv): 5 equiv. $NaN_3$, DMF, $H_2O$, 100 °C, 1 h, **126d** (48%) and **127** (7%); (v): from **126c**, standing at RT for a few days.

The starting materials **125a** and **125b** for these investigations were prepared from 14-chlorocodeine (**124a**) [155] and 14-bromocodeine (**124b**, thebaine (**4**) → 14-bromocodeinone (**109**) → **1b**), respectively [160]. The reaction of **124a** with 2 equiv. phosphorus pentachloride in chloroform gave **125a** in 66% yield, and the analogous reaction of 14-bromocodeine (**124b**) gave **125b** in 53% yield. The researchers also prepared **125a** from 14-chlorocodeine tosylate (**119a**) with LiCl.

6β-Chloro-14-bromodeoxycodeine (**125b**, $C^7=C^8$-$C^{14}$-Br and $C^8=C^7$-$C^6$-Cl) reacted readily with $Cl^\ominus$ anion (10 equiv. LiCl) in DMF, giving 6β-chloro-7β-bromodesoxyneopine (**126a**) as the main product in 42% yield, with the further isolation of 6α-chloro-7β-bromodesoxyneopine (**126b**) in 4% yield by the column chromatographic separation of the mother liquor. The application of a $Br^\ominus$ nucleophile (5 equiv. LiBr, DMF) for **125b** gave 6-β-chloro-7β-bromodesoxyneopine (**126c**) in 16% yield. Using $N_3^\ominus$ anions (5 equiv. $NaN_3$, DMF, 100 °C, 1 h) gave 6β-chloro-7α-azidodesoxyneopine (**126d**, 44%) and 6β-chloro-9α-azidodesoxyindolinocodeine (**127**, 8%). After the heating of **125b** in DMF at 100 °C for 30 min in the absence of $Nu^\ominus$ unreacted starting material (**125b**), 6β-chloro-7β-bromodesoxyneopine (**126c**) and 6-chloro-6-demethoxythebaine (**118a**) were separated from the product mixture by column chromatography. Extending the reaction time (1 h) gave 6-chloro-6-demethoxythebaine (**118a**) in 62% yield.

The reaction of 6β,14-dichlorodesoxycodeine (**125a**, $C^7=C^8$-$C^{14}$-Cl and $C^8=C^7$-$C^6$-Cl) with $Br^\ominus$ anions (5 equiv. LiBr, DMF, 100 °C, 8 h) led to 6-chloro-6-demethoxythebaine (**118a**) in 72% yield. The azidolysis of **125a** under identical conditions to those described above for **125b** resulted similarly in 6β-chloro-7β-bromodesoxyneopine (**126c**, 48%) and 6-chloro-6-demethoxythebaine (**118a**, 7%). After the heating of **125a** in DMF at 110 °C without $Nu^\ominus$ reagent for 30 min, 6-chloro-6-demethoxythebaine (**118a**, 60%), 6β-chloro-7β-chlorodesoxyneopine (**126a**, 4%) and 6β-chloro-7α-chlorodesoxyneopine (**126b**, 1%) were

isolated. Upon continuing the heating for 24 h, 6-chloro-6-demethoxythebaine (**118a**) was obtained in 72% yield. The differences in reactivity between the allyl chloride ($C^7=C^8-C^{14}$-Cl and $C^8=C^7-C^6$-Cl) and allyl bromide ($C^7=C^8-C^{14}$-Br) subunits of the molecules manifested in the differing times required for whole conversion via an elimination reaction ($E_{1,2}$ type) in the absence of $Nu^\ominus$ reagents. Thus, the conversion of 6β-chloro-14-bromodesoxycodeine (**125b**) to 6-chloro-6-demethoxythebaine (**118a**) took one hour, whereas the conversion of 6β,14-dichlorodesoxycodeine (**125a**) required 24 h.

*2.9. Azidomorphinans*

Organic azides [161–163] are suitable building blocks for the synthesis of a broad range of nitrogen-containing scaffolds. Due to the high electrophilicity of the azido group (mesomeric structures: $-N=N=N: \leftrightarrow -N=N^\oplus=N^\ominus \leftrightarrow -N^\ominus-N^\oplus\equiv N \leftrightarrow -N^\ominus-N=N^\oplus$), organic azides are prone to react with various nucleophiles [164,165] and, furthermore, serve as starting materials for a large variety of transformations (e.g., reactions with electrophiles, cycloaddition, 1,3-cycloaddition with alkynes = click reaction, reduction to amines, etc.). The incorporation of the azido pharmacophore into a bioactive scaffold can be advantageous in providing new molecules with desirable pharmacological profiles, including increased potency, and other biochemical and pharmacological characteristics [166].

Cocker et al. [167] and later Willner et al. [168] thoroughly investigated the displacement by $N_3^\ominus$ and other nucleophiles of *N*-acetylated 7-aminocephalosporanic acid (7-ACA) derivatives. The prepared 3-azidomethyl-3-cephem analogs were effective in inhibiting the growth of Gram-negative bacteria [167,168].

Azidomazenil (8-azido-5,6-dihydro-5-methyl-6-oxo-4*H*-imidazo-1,4-benzodiazepine-3-carboxylic acid ethyl ester, Ro-15,4513, Hoffmann-La-Roche), the azido analog of the 1,4-benzodiazepine derivative flumazenil (Ro-15,1788, Hoffmann-La-Roche), a partial inverse GABA$_A$ receptor (GABA$_A$R) agonist, blocks the electrophysiological and behavioral effects of low-to-moderate ethanol doses [169]. Indeed, GABA$_A$Rs may mediate the rewarding effects of ethanol, which require binding at the benzodiazepine-binding site (cBZR) of the α5-subunit of the GABA$_A$R [170]. In 1992, the ^{11}C-labeled version of Ro-15,4513 was developed by Halldin et al. [171] for PET imaging of benzodiazepine receptors in a living human brain [170].

The azido analog of levorphan and its tritiated version $N^{17}$-(4-azidophenyl-CH$_2$C($^3$H)$_2$)-norlevorphan were synthesized by Winter et al. [172] in 1972. $N^{17}$-Desmethyl-levorphan was reacted with β-(4-azidophenyl)ethyl bromide in methanol (K$_2$CO$_3$, 42 °C, 90 h) to yield the target compound, which was four-fold more effective (ED$_{50}$ = 0.78 mg/kg) than levorphan as an analgesic in the mouse hot-plate test, perhaps due to its greater lipophilicity and brain penetration.

2.9.1. Azidomorphine Analogs

6-Azido-substituted morphine derivatives have a conspicuous analgesic effect [173,174], having a 50–300-fold increase in analgesic potency relative to morphine (**1a**) in the case of a 6-azido substitution of dihydroisomorphine (**82**, Figure 21) [175–177]. Over several decades, the research group of Makleit paid particular attention to investigating the nucleophilic substitution reaction of the sulfonate esters of the morphine series (see Figures 18 and 19). They studied extensively the azidolysis of 6-*O*-tosyl and 6-*O*-mesyl esters of different morphinans and the subsequent transformations to the corresponding amino derivatives. In 1968, Bognár and Makleit investigated the syntheses of aminocodide and aminomorphide derivatives (Figure 38) [54,55], at a time when only a few ring-C amino-substituted morphinan derivatives were known. Furthermore, the absolute stereochemistry of these compounds, 6-aminocodide, 8-aminocodide (**84**) and 8-aminodihydrocodide (**75a**), was uncertain at the time. As starting

points in the $\Delta^{7,8}$-unsaturated series, they used the sulfonate esters of codeine (**2a**) and 3-*O*-acetylmorphine (**55**). These materials readily reacted with azide anion ($N_3^{\ominus}$), giving the 8β-azides azidocodide (**83**) as well as 8-azidomorphide (**128**), i.e., products belonging to the pseudocodeine or γ-isomorphine series (pseudomorphine derivatives, according to the Makleit–Bognár nomenclature).



**Figure 38.** Synthesis of aminocodide and aminomorphide derivatives [54,55]. *Reagents and conditions*: (i): TosCl or MsCl, pyridine, A. 0 °C, 2 h, B. room temperature 24 h; (ii): 1.25 equiv. $NaN_3$, DMF, $H_2O$, 100 °C, 4 h (**83**,**128**) 24 h (**74a**,**130**); (iii): 3–8 equiv. $LiAlH_4$, $Et_2O$, reflux, 3 h.

The nucleophile substitution of codeine tosylate (**63a**) with azide anion ($N_3^{\ominus}$) can occur according to an $S_N2'$ reaction mechanism (Figure 39), whereby the azide anion attacks the $\Delta^{7,8}$ double bond at the C-8 position to give the 8β-azide (**XV**, Nu = $N_3$, **83**) directly. Another possible mechanism is an $S_N2$ reaction followed by allylic rearrangement ([3,3]-suprafacial sigmatropic rearrangement, $S_Ni'$ mechanism), where the nucleophile ($N_3^{\ominus}$) attacks the C-6 position. The hypothesized 6β-azide (**XVI**, Nu = $N_3^{\ominus}$, allylic azide) intermediate undergoes an allylic rearrangement, which shifts the new substituent from C-6 into the C-8 position to give 8-azidocodide (**XV**, Nu = $N_3^{\ominus}$, **83**).

The analogous reaction of 6-*O*-sulfonate esters belonging to the 7,8-dihydro series (e.g., **71a**, **72a**) [117,118] with the $N_3^{\ominus}$ nucleophile gave the corresponding 6β-azides: 6-desoxy-6-azidodihydroisocodeine (**74a**, "azidocodeine") [119,120] and 6-desoxy-6-azidodihydroisomorpine (**130**, "azidomorphine") [119,120], with the inversion of the configuration in a stereospecific nucleophile substitution reaction ($S_N2$). The azides (**83**,**128** and **74a**,**130**) were reduced with $LiAlH_4$ in THF to their corresponding 8β-amino (**84**,**129**) or 6β-amino (**75a**,**131**) derivatives.

In a rat hot-plate test of analgesia, azidomorphine (**130**, 6-AM, 6-desoxy-6-azidodihydroisomorphine; 3-hydroxy-4,5-α-epoxy-6β-azido-7,8-dihydro-17-methyl- morphinan) [119,120] was 270–300 times more potent than morphine ($ED_{50}$ (**130**) = 0.016 mg/kg, versus $ED_{50}$ (**1a**) = 4.7 mg/kg), whereas azidocodeine (**74a**, 6-desoxy-6-azidodihydroisocodeine, $ED_{50}$ (**74a**) = 0.36 mg/kg;) was only 10 times more potent than morphine (**1a**) [178]. Nonetheless, mice showed lesser propensity for developing physical dependence on azidomorphine (**130**) compared to morphine (**1a**). Interestingly, there was a consistent dissociation between analgesic activity and physical dependence liability in monkeys, rats and mice [178]. Intensive investigations by Bulaev et al. of the pharmacological characteristics in vivo of azidomorphine (**130**) in different animal models (rats, rabbits and cats) consis-

tently showed 20–100 times greater analgesic activity compared to morphine (**1a**) [179,180]. Knoll et al. [181–183] demonstrated that azidomorphine (**130**) is metabolized in rats by *N*-demethylation to norazidomorphine and by conjugation with glucuronic acid. In human studies, azidomorphine (**130**) was 40–300 times more potent than morphine (**1a**) [184], relieving severe pain in 0.5–1 mg doses (sc. or. iv.), but with less constipation, vomiting and euphoria than with equianalgesic doses of morphine (**1a**). When a composition containing azidomorphine (**130**, 0.5 mg) was given, the non-narcotic analgesic rimazolium mesylate (1,6-dimethyl-3-carbethoxy-4-oxo-6,7,8,9-tetrahydro-homopyrimidazol, probon, MZ-144; 150 mg) potentiated the analgesic effects while antagonizing the respiratory depressant effects of **130** [175–177]. In a human subject, azidomorphine (**130**) was metabolized by conjugation (6-AM-3G) and by reduction to 6-desoxy-6-aminoisomorphine [185].



**Figure 39.** Supposed mechanism of the synthesis of 8-azidocodide. Nu = $N_3^{\ominus}$.

In 1974, Sasvári et al. [186] reported the X-ray structural analysis of azidomorphine (**130**). When exploring the crystal structure of 14-hydroxyazidomorphine (**138**), Kálmán et al. [187] found that the substitution of the H-14 of azidomorphine (**130**) with a hydroxy group did not alter the C- and D-ring chair conformation, but did alter the orientation of the 6β-azido group. Tamás et al., studied the mass spectroscopic fragmentation pathway of azidomorphine (**130**) and its derivatives [188]. Under electron impact (70 eV, source temperature 100–150 °C), azidomorphine analogs gave a remarkably different fragmentation pattern compared to that of the parent morphine alkaloids; the main decomposition route involved the loss of a nitrogen ($N_2$) molecule in the 6-desoxy-6-azidoisomorphine series (**74a**, **130**, **138**, **144**). Among 8-azido-substituted compounds containing a $\Delta^{6,7}$ double bond in ring-C (e.g., azidomorphide (**128**, 8-desoxy-8-azido-γ-isomorphine) or azidocodide (**83**)), there was a loss of the $N_3$ radical ($\cdot N=N^{\oplus}=N^{\ominus}$) due to the allylic effect. Dinya et al. [189–191] performed infrared spectroscopic investigations and quantum chemical analysis of azidomorphinans.

Aiming to improve upon the toxicity of azidomorphine (**130**, LD$_{50}$ (**130**) = 8.1 mg/kg; LD$_{50}$ (**1a**) = 320 mg/kg, i.v. in a rat) [178], Makleit et al. developed "14-hydroxyazidomorphine" (**138**, 6-desoxy-6-azido-14-hydroxydihydroisomorphine, 3,14β-dihydroxy-4,5α-epoxy-6β-azido-7,8-dihydro-17-methylmorphinan, Figure 40) in 1972 [121,122,192–194]. The synthesis of **138** from thebaine (**4**) followed seven consecutive steps. In brief, 14-hydroxycodeinone (**132**) was obtained from **4** with hydrogen peroxide and formic acid [151], and the $\Delta^{7,8}$ double bond of **132** was then saturated under heterogenous catalytic conditions (H$_2$, 10% Pd-C, AcOH)

to give oxycodone (**133**). Oxymorphone (**134**) was prepared from **133** by 3-*O*-demethylation with 48% hydrobromic acid. The C-6 keto group of **134** was reduced by sodium borohydride in a stereospecific reaction to 14-hydroxy-dihydromorphine (**135**). The phenolic 3-hydroxyl group of **135** was protected by partial acetylation using the method of Welsh [99] with acetic anhydride (NaHCO$_3$, H$_2$O). The 6$\alpha$-hydroxyl group of compound **136** was transformed to sulfonate esters (**137a–b**) with the corresponding reagent (MsCl or TosCl, pyridine, 24 h, RT). Finally, the tosyl ester (**137a**) was subjected to azidolysis (sodium azide, DMF, H$_2$O, 100 °C, 24 h) to give the desired azido derivative (**138**) [121,122,192,193]. 6-Desoxy-6-azido-14-hydroxydihydroisomorphine (**138**) had similar analgesic potency in the mouse hot-plate test to azidomorphine (**130**) (ED$_{50}$ (**130**) = 0.024 mg/kg, ED$_{50}$ (**138**) = 0.029 mg/kg) [184], although with lower toxicity. The introduction of the hydroxy group in position-14 of azido-morphine (**130**) conspicuously reduced toxicity; azidomorphine (**130**) was 6.5 times more toxic in rats and 11.6 times more toxic in mice than 14-hydroxyazidomorphine (**138**) [184]. Human studies indicated 40-fold greater analgesic activity for azidomorphine (**130**) and 14-hydroxyazidomorphine (**138**) compared to morphine (**1a**) [195,196].

　　　The antitussive activity of **138** was determined and compared with that of the reference antitussive codeine (**2a**) using the Gosswald citric acid aerosol-induced cough test in Wistar rats [194]. 14-Hydroxyazidomorphine (**138**) had 1000-fold higher antitussive activity compared to codeine (**2a**, AtD$_{50}$ (**2a**, s.c.) = 19.0 mg/kg, AtD$_{50}$ (**138**, s.c.) = 0.021 mg/kg, ratio **2a**/**138** = 904) [194].



**Figure 40.** Synthesis of 14-hydroxyazidomorphine. *Reagents and conditions*: (i): formic acid, H$_2$O$_2$, 40 °C, 2 h; (ii): H$_2$, 10% Pd-C, acetic acid; (iii): 48% hydrobromic acid, 120 °C, 20 min; (iv): NaBH$_4$, EtOH, 20 °C, 20 h; (v): Ac$_2$O, NaHCO$_3$, H$_2$O, 20 °C; (vi): MsCl or TosCl, pyridine, 20 °C, 24 h; (vii): NaN$_3$, DMF, 100 °C, 24 h, 73%.

　　　In a subsequent study, the same research group [197,198] performed structure optimiza-tion investigations, aiming to identify azidomorphine analogs with a more advantageous pharmacological profile. For the synthesis of 3-desoxyazidomorphine (**141**, Figure 41), they first produced the starting material 3-desoxydihydromorphine (**139**) by the removal of the 3-hydroxyl group of morphine via the hydrogenation of morphine-3-(1-phenyltetrazolyl)- or morphine-3-(pyrimidyl)-ether [199]. Under these conditions, the $\Delta^{7,8}$ double bond was also saturated. In the next steps, the tosyl ester (**140**) was prepared and subjected to azidol-ysis (sodium azide, DMF, H$_2$O, 100 °C, 24 h) and transformed to 3-desoxyazidomorphine (**141**) in 20% yield.

　　　Analogously, "azidoethylmorphine" (**144**, "3-*O*-ethylazidomorphine", azidodionine, 6-azido-6-desoxy-ethyldihydroisomorphine) [197,198] was prepared from ethylmorphine

(**33**) in three steps (Figure 41). Compound **33** was reduced to 3-*O*-ethyl-dihydromorphine (**142**) [200,201], which was converted to the esters ethyldihydromorphine tosylate (**143a**) or mesylate (**143b**) [200,201]. The subsequent azidolysis of the esters (**143a–b**) gave azidoethylmorphine (**144**). Antitussive activity measured by the Gosswald method in rats was 60-fold higher for azidodionine (**144**) than for codeine (**2a**) (AtD$_{50}$ (**2a**, oral) = 100.0 mg/kg, AtD$_{50}$ (**144,** oral) = 1.67 mg/kg, ratio **2a**/**144** = 59.88) [197,198,202,203].

3-*O*-Morpholinylethylazidomorphine (**145**, azidopholcodine, Figure 41) [197,198,202] has also been prepared from morphine (**1a**) in five steps (morphine (**1a**) → ethylmorphine (**33**) → ethyldihydromorphine → 3-*O*-morpholinylethyldihydromorphine → 3-*O*-morpholinylethyldihydromorphine mesylate → **145**), and directly from azidomorphine (**130**) by alkylation with morpholinylethylchloride thanks to the stability of the azido group of **130** against the strong base NaOEt. Azidopholcodine (**145**) had four-fold greater antitussive activity in rats (AtD$_{50}$ (**145,** s.c.) = 4.5 mg/kg) as compared to codeine (**2a**) (AtD$_{50}$ (**2a,** s.c.) = 19.0 mg/kg, ratio **2a**/**145** = 4.22) [203].



**Figure 41.** Synthesis of azidomorphine analogs. *Reagents and conditions*: (i): 1 equiv. TosCl, pyridine, room temperature, 24 h, 50%; (ii): 13 equiv. NaN$_3$, DMF, H$_2$O, 100 °C, 24 h, 50%; (iii): H$_2$, Raney-Ni, MeOH or EtOH, RT, atmospheric pressure [200,201]; (iv): **A**. 1.2 equiv. TosCl, pyridine, 0 °C, 2 h, than RT for 24 h, 78%, or **B**. 1.1 equiv. MsCl, pyridine, 0 °C, 2 h, then room temperature for 24 h, 64%; (v): 10 equiv. NaN$_3$, DMF, H$_2$O, 100 °C, 24 h, 65%; (vi): 1.4 equiv. morpholinylethylchloride HCl, 2.3 equiv. Na, EtOH, reflux, 1 h, 40%.

To study antagonistic properties in the azidomorphine series, Makleit et al. synthesized the $N^{17}$-substituted analogs (**149a–b**, cyclopropylmethyl, allyl, Figure 42) of azidomorphine (**130**), azidocodeine (**74a**), 14-hydroxyazidomorphine (**138**) and 14-hydroxyazidocodeine [204,205]. $N^{17}$-Cyclopropylmethyl-norazidomorphine (**149a**, CAM) and $N^{17}$-allyl-norazidomorphine (**149b**, AAM) were synthesized via two different routes. In the first approach, the acetylation of the phenolic hydroxy group in position-3 of azidomorphine (**130**) resulted in 3-*O*-acetylazidomorphine (**146**). The von Braun reaction with cyanogen bromide in the presence of the 6-azido group gave high yields (e.g., **146** → **147** in 90% yield). The alkaline hydrolysis of the cyanamide (**147**) and subsequent acid hydrolysis

gave azidonormorphine (**148**) in 47% yield. The $N^{17}$-alkylation of **148** with allyl bromide or cyclopropylmethyl bromide resulted in the corresponding $N^{17}$-substituted norazidomorphines (**149a–b**). On the other hand, the partial acetylation of $N^{17}$-cyclopropylmethyl-nordihydromorphine (**150a**) or $N^{17}$-allyl-nordihydromorphine (**150b**) resulted in the corresponding 3-*O*-acetyl-nordihydromorphines (**151a–b**). The latter compounds were converted into their sulfonate esters (tosyl, mesyl, **152a–d**) for subsequent azidolysis, resulting in the desired analogs (**149a–b**).



**Figure 42.** Synthesis of $N^{17}$-substituted azidomorphine analogs. *Reagents and conditions*: (i): based on Welsh's [99] method: Ac$_2$O, NaHCO$_3$, H$_2$O; (ii): 2 equiv. BrCN, 60 °C, 2.5–6 h, 90%; (iii): 5–10% aqueous HCl reflux, 5–10 h; (iv): 1.2 equiv. TosCl or MsCl, 20 °C, 24 h; (v): 10 equiv. NaN$_3$, DMF, 100 °C, 24 h.

In 1977, Knoll et al. [206] reported on their pharmacological investigations of numerous $N^{17}$-substituted-azidomorphine analogs. They compared the OR antagonistic properties of $N^{17}$-cyclopropylmethyl-norazidomorphine (**149a**, CAM, Figure 42), $N^{17}$-allyl-norazidomorphine (**149b**, NAM) and their 14-hydroxy analogs—$N^{17}$-cyclopropylmethyl-14-hydroxynorazidomorphine (COAM) and $N^{17}$-allyl-14-hydroxynorazidomorphine (NOAM)—relative to a reference antagonist (naltrexone) in different tissues. Surprisingly, $N^{17}$-substituted-azidomorphine analogs were potent antagonists in the isolated cat nictitating membrane (CNM) assay but were extremely potent pure agonists in the guinea pig ileum (GPI) and mouse vas deferens (MVD) tests. CAM (**149a**) [204,205] stimulated A-type receptors, which are involved in the behavioral effects of OR ligands (GPI and MVD tests; cholinergic neurotransmission). On the other hand, CAM (**149a**) had greater antagonist potency than naloxone in the CNM test (B-type receptor: responsible for the analgesic, antitussive and respiratory depressant effects of OR ligands; catechol adrenergic neurotransmission) [206]. Subsequently, Fürst et al. tested the antagonistic potencies of **149a–b** in the oxymorphone righting test [207]. The $N^{17}$-substituted azidomorphines (**149a–b**) were more potent antagonists than nalorphine or pentazocine but were equipotent with naloxone. $N^{17}$-Cyclopropylmethyl-norazidomorphine (**149a**, CAM) was suggested to be a κOR-sub-type agonist based on its agonistic activity in the rabbit vas deferens (RVD) assay and given the low potency of naloxone in reversing its agonistic effect in GPI and MVS

tests [207,208]. CAM (**149a**) has a different pharmacological profile from bremazocine or ethylketazocine (EK), which are agonists in the CNM assay.

Inspired by the novel pharmacological profile of $N^{17}$-substituted norazidomorphines (**149a–b**) [206], the Alkaloida research group prepared $N^{17}$-substituted-norazidoethylmorphine derivatives (**155a–c**, R = CPM, allyl, *n*-propyl, Figure 43) [209] through two independent routes, from azidoethylmorphine (**144**) as well as from ethyldihydromorphine (**142**).



**Figure 43.** Synthesis of *N*-substituted-norazidoethylmorphine analogs. *Reagents and conditions*: (i): 2.1 equiv. BrCN, CHCl$_3$, reflux, 4 h, 75%; (ii): 6% HCl, reflux, 6 h, 95%; (iii): **A**. cyclopropylmethyl bromide, NaHCO$_3$, EtOH, reflux, 15 h, 46%; **B**. allyl bromide, NaHCO$_3$, EtOH, reflux, 8 h, 54%; (iv): Ac$_2$O, 100 °C, 1 h, 94%; (v): BrCN, CHCl$_3$, reflux, 4 h, 95%; (vi): 10% HCl, reflux, 8 h, 94%; (vii): **A**. cyclopropylmethyl bromide, NaHCO$_3$, EtOH, reflux, 15 h, 75%; **B**. allyl bromide, NaHCO$_3$, EtOH, 80 °C, 20 h, 73%; **C**. *n*-propyl bromide, NaHCO$_3$, 80 °C, 20 h, 58%; (viii): 1.2 equiv. MsCl, pyridine, room temperature, 24 h, 83% (R = CPM); (ix): 10 equiv. NaN$_3$, DMF, H$_2$O, 100 °C, 24 h, 62%, R = CPM.

In brief, in the first reaction sequence [209], azidoethylmorphine (**144**, Figure 43) was *N*-demethylated using the von Braun method (BrCN) via *N*-cyano-azidoethylmorphine (**153**). The cyanamide (**153**) was hydrolyzed with 6% hydrochloric acid; the *N*-demethylation of azidoethylmorphine (**144**) was also achieved easily and in good yields with methyl- or phenyl-chloroformate. The formed $N^{17}$-phenyl- or $N^{17}$-methyl-oxycarbonyl-$N^{17}$-desmethyl-azidoethylmorphine was converted to norazido-ethylmorphine (**154**) with 25% KOH in ethanol. The subsequent alkylation of $N^{17}$-desmethyl-azidoethylmorphine (**154**) with cyclopropylmethyl bromide or allyl bromide resulted in $N^{17}$-cyclopropylmethyl-norazidoethylmorphine (**155a**, ECAM, Figure 43) and $N^{17}$-allyl-norazidoethylmorphine (**155b**) in yields of 46 and 54%, respectively.

In a second approach [209], the synthesis of $N^{17}$-substituted-norazido-ethylmorphines (**155a–c**, Figure 43) was performed in six consecutive transformations starting from ethyldihydromorphine (**142**). The alcoholic hydroxyl group in position-6 of **142** was protected with an acetyl group by treatment with acetic anhydride, resulting in 6-*O*-acetyl-ethyldihydromorphine (**156**, 94%). The von Braun *N*-demethylation of **156** with cyanogen bromide and subsequent hydrolysis of the cyanamide (**157**) gave ethyldihydronormorphine (**158**). Other routes to $N^{17}$-desmethyl-dihydromorphine (**158**) entailed the treatment of **156** with diethyl azodicarboxylate (DEAD) or with methyl- or phenyl-chloroformate. *N*-demethylation without the protection of the 6-OH function starting directly from ethyldihy-

dromorphine (**142**) was also feasible. Compound **158** was alkylated with the appropriate reagent (cyclopropylmethyl bromide, allyl bromide, *n*-propyl bromide) to $N^{17}$-substituted-ethyldihydronormorphines (**159a–c**). The compounds **159a–c** were converted into their mesyl esters (**160a–c**), and the subsequent azidolysis of these compounds gave target $N^{17}$-substituted-norazidoethylmorphines (**155a–c**).

The agonist–antagonist characteristics of the synthesized analogs were determined by the hot-plate method with rats. A ten-fold higher morphine (**1a**) dose was necessary to achieve the same analgesic effect in conjunction with 5 mg/kg s.c. ECAM (**155a**) compared to the controls without antagonist co-treatment [209]. With the oral application of **155a** (25–30 mg/kg), a 2–3-fold higher morphine (**1a**) dose was required for an equianalgesic effect. Similarly to ECAM (**155a**), the application of $N^{17}$-allyl-norazidoethylmorphine (**155b**) at 50 mg/kg (s.c.) raised tenfold the necessary morphine (**1a**) dose. Interestingly, ECAM (**155a**) showed an anorexic effect in food-deprived rats.

### 2.9.2. 14-Hydroxy-8-azido-8-desoxyallopseudocodeine Derivatives

In 1988, Gulyás et al. [210,211] synthesized a series of 6- and 7-halo-substituted 14-hydroxy-8-azido-8-desoxyallopseudocodeine derivatives (Figure 44). The starting materials for these investigations, 6-demethoxythebaine (**105**), 6-chloro- and 6-bromo-6-demethoxythebaine (**118a–b**) and 7-chloro- and 7-bromo-6-demethoxythebaine (**113a–b**), were prepared according to earlier protocols of the Makleit group [143,144,152,153,157,158] (see also Sections 2.8.4–2.8.6). 6-Demethoxythebaine (**105**) was obtained from neopine mesylate (**100**) with tetrabutylammonium fluoride [143,144], 6-chloro- and 6-bromo-6-demethoxythebaine (**118a–b**) from 14-chloro-codeine tosylate (**119a**) with LiCl or LiBr [157, 158] and, finally, 7-chloro- and 7-bromo-6-demethoxythebaine (**113a–b**) from 7α-halo-neopine mesylates (**112a–b**) by boiling with potassium *tert*-butylate in methanol [152,153]. 6-Demethoxythebaine derivatives (**105**, **113a–b**, **118a–b**) were converted to the corresponding 8β,14β-epoxides (**161a–e**, 8β,14β-epoxycodides) with formic acid–hydrogen peroxide (low yields: 22–42%) or, alternatively, with disuccinylperoxide or *m*-chloroperbenzoic acid in 10% formic acid. The epoxides (**161a–e**) were subjected to azidolysis (5 equiv. $NaN_3$, dioxane, $H_2O$, 100 °C, 10 h) to give 6- and 7-substituted 14-hydroxy-8-azido-8-desoxyallopseudocodeine derivatives (**162a–e**) [210,211] in 28–63% yields.

The latter compounds were transformed to the corresponding 8α-amines (**163a–e**) with a yield of 28–63%. The acetolysis of the epoxides (**161a–e**) was performed with 10% acetic acid at 70 °C (1.5 h), which gave 8α-acetoxy-14-hydroxy derivatives (**164a–e**, 36–83%). The hydrolysis of the acetates with 10% KOH in ethanol resulted in 6- and 7-substituted 14-hydroxyallopseudocodeine derivatives (**165a–e**) [210,211] in 36–90% yield.

In a subsequent study, Gulyás and Makleit [212,213] investigated the reactions of 8β,14β-epoxycodide [214,215] (**161a**, Figure 45) containing a vinyl-oxirane sub-structural unit. The starting material (**161a**) [210,211] was prepared from 6-demethoxytebaine (**105**). The reduction of **161a** with lithium aluminum hydride in diethyl ether gave 14-hydroxydesoxycodeine-C (**166**) in 50% yield. When the azidolysis of 8β,14β-epoxycodide (**161a**) with azidotrimethylsilane in the presence of zinc (II) iodide was performed, the sole isolated product was 14-trimethylsilyloxy-8-azido-8-desoxyallopseudocodeine (**167**, 60%). Removing the TMS protecting group with sodium fluoride in methanol yielded the same 14-hydroxy-8-azido-8-desoxyallopseudocodeine (**165a**, 67%), which was prepared earlier from **161a** with sodium azide (dioxane-$H_2O$, 100 °C, 10 h) [212,213]. When **161a** was treated with $Cl^\ominus$ anions in aqueous–acidic acetonitrile (LiCl, 10% HCl–$CH_3CN$) [212,213], there was the formation of 6-chloro-14-hydroxyisocodeine (**168**, 14-hydroxy-α-chlorocodide, 20%), 14-hydroxy-isocodeine (**169**) and 14-hydroxy-allopseudocodeine (**106**).

**Figure 44.** Synthesis of 14-hydroxy-8-azido-8-desoxyallopseudocodeine derivatives. *Reagents and conditions*: (i): 5 equiv. Bu$_4$NF, CH$_3$CN, reflux, 2.5 h, 77%; (ii): 6 equiv. LiCl or 5 equiv. LiBr, DMF, 100 °C, 24 h; (iii): 2.35 equiv. KO*t*-Bu, MeOH, EtOH, reflux, 10 min. from **112a** 95%, **112b**, 50%; (iv): A. from **105**, 85% formic acid, 30% H$_2$O$_2$, 40 °C, 25 min, 25%; B. from **105**, 10% formic acid, 90% *m*-chloroperbenzoic acid, EtOH, 0 °C, 105 min, 53%; C. from **105**, 2 equiv. disuccinyl peroxide, 10% formic acid, room temperature, 15 min., 32%; (v): 5 equiv. NaN$_3$, dioxane, H$_2$O, 100 °C, 10 h, 38–77%; (vi): 85% hydrazine hydrate, EtOH, reflux, 10 min, 28–63%; (vii): 10% AcOH, 70 °C, 1.5 h, 36–83%; (viii): 10% KOH solution (aq.), EtOH, reflux, 10 min, 36–90%.

Due to the difficulties encountered during the separation of the solvolysis products, the 6β,14β-dihydroxy (**169**, iso)/8α,14β-dihydroxy (**106**, allopseudo) product ratio was determined by a proton NMR spectrum analysis of the mixture, which gave a ratio of 5:6. The analogous reaction of 8β,14β-epoxycodide (**161a**) with Br$^{\ominus}$ ions in aqueous-hydrobromic acid–acetonitrile mixture (LiBr, 10% HBr–CH$_3$CN) resulted in 8-bromo-8-desoxy-14-hydroxy-pseudocodeine (**170**, 14-hydroxy-β-bromocodide, 31%) as the main product, and a mixture of by-products **169**/**106** (ratio: 3:4) [212,213]. The formation of the main products with different structures, i.e., 6β-chloro (**168**) and 8β-bromo (**170**), is explicable by steric, electronic and stability factors, and is in agreement with the earlier results of Bognár et al. [216,217] concerning the nucleophilic substitutions of 14-hydroxydihydrocodeine tosylate (**73a**). The reaction of **73a** with F$^{\ominus}$ or Cl$^{\ominus}$ nucleophiles gave the corresponding 6-substituted-6-desoxy-14-hydroxydihydroisocodeine derivatives, whereas using Br$^{\ominus}$ anions resulted in 8-bromo-8-desoxy-14-hydroxypseudocodeine (**170**) [216,217]. The treatment of 8β,14β-epoxycodide (**161a**) with the organocuprate reagent lithium dibutylcuprate (LiCu(C$_4$H$_9$)$_2$, prepared in situ from copper (I) iodide and butyllithium in diethyl ether–hexane at −78 °C) resulted in the 6β-butyl derivative (**171**) in 21% yield [212,213].

**Figure 45.** Investigations of the reactions of 8β,14β-epoxycodide. *Reagents and conditions*: (i): 1 equiv. LiAlH$_4$, Et$_2$O, reflux, 30 min, 50%; (ii): 3 equiv. trimethylsilyl azide, ZnI$_2$, CH$_2$Cl$_2$, reflux, 90 min, 60%; (iii): 3 equiv. NaF, MeOH, reflux, 2 h, 67%; (iv): LiCl, 10% HCl, acetonitrile, reflux, 2.5 h, **168** (20%), Σ (**169** + **106**) (12%), recovered **161a** (22%); (v): LiBr, 10% HBr, acetonitrile, 100 °C, 2 h, **170** (31%), Σ (**169** + **106**) (26%), recovered **161a** (15%); (vi): copper (I) iodide, BuLi, diethyl ether, hexane, N$_2$ atmosphere, −78 °C, 21%.

### 2.9.3. Azido Derivatives of 6,14-Ethenomorphinans

Berényi et al. investigated the azidolysis of tosyl esters (**174a–g**) derived from different in ring-C bridged morphinans (Bentley compounds, or 6,14-ethenomorphinans [218–221], **173a–g**, Figure 46) [222,223]. The morphinandienes **4**, **105** and **118a** were transformed with methyl vinyl ketone or acrolein in a diastereoselective Diels–Alder reaction to the corresponding ring-C bridged 7-acetyl (**172a,c,d**) or 7-formyl (**172b**) adducts. Next, the keto group (**172a–d**) was reduced with NaBH$_4$ in methanol to a mixture of diastereomeric secondary alcohols (**173a**, **b**, **d–g**) [222] or to the appropriate primary alcohol (**173c**) [223], which was tosylated (TosCl, pyridine, room temperature, 1–6 days) to yield **174a–g**. After separation by column chromatography of the diasteromerically pure tosylates (**174a–b**, **174d–g**), they were subjected to azidolysis (NaN$_3$, 100 °C, 1.5 h). A novel class of morphinans containing a 4-azatetracyclo-[4.4.0.0$^{2.4}$.0$^{3.8}$]decane ring system (**176a–g**) was prepared by heating the azides (**175a–g**) in *N,N*-dimethylformamide at 100 °C for 24 h.

**Figure 46.** Synthesis of morphinans with an azatetracyclodecane ring system. *Reagents and conditions*: (i): methyl vinyl ketone or acrolein, toluene, reflux, 24 h; (ii): 4.5 equiv. NaBH$_4$, MeOH, 0 °C, 30 min; (iii): 1.5 equiv. TosCl, pyridine room temperature, 1 day for **173d,e** and 6 days for **173f,g**; (iv): 5 equiv. NaN$_3$, *N,N*-dimethylformamide, H$_2$O, 100 °C, 1.5 h; (iv and v): 5 equiv. NaN$_3$, *N,N*-dimethylformamide, H$_2$O, 100 °C, 24 h.

When longer reaction times were used for the azidolysis of the tosylates (**174a–g**), substitution and subsequent cyclization by the intramolecular addition of the azide to the $\Delta^{18,19}$ double bond resulted directly in the aziridine derivatives **176a–g**. The authors found a significant difference in the course of the reactions for 20*S*- and 20*R*- tosyl esters. After azidolysis of the 20*S*-tosylates (**174**), 7-ethylidene derivatives were isolated as major products resulting from an elimination reaction. However, the azidolysis of the 20*R*-tosylates (**174**) under identical conditions led to the formation the 20*S*-azides (**175**), by the inversion of the configuration. Despite the detection of the products by TLC, their isolation and characterization were possible in only a few cases (e.g., 20*S*-**175g**, and **175c**) due to their generally low stability. When the tosyl ester (**174c**) of the primary alcohol (**173c**) was subjected to azidolysis (5 equiv., NaN$_3$, DMF, H$_2$O, 100 °C, 1.5 h), the 7-azidomethyl derivative (**175c**) and aziridine (**176c**) were formed. After separation by column chromatography, the product ratio **175c**/**176c** was 9:1. The azide **175c** was converted to aziridine (**176c**, 59%) by heating in *N,N*-dimethylformamide at 100 °C for 24 h. The structure of **175c** was also proven by chemical reaction; its reduction (hydrazine hydrate, Raney-nickel, EtOH, reflux, 30 min) resulted in the primary amine 7$\alpha$-aminomethyl derivative in 69% yield. In 1992, Batta et al. [224] reported the detailed NMR analysis of the 20*R*- and 20*S* diastereomeric alcohols (**173a–b**, **173d–g**), their tosylates (**174a–b**, **174d–g**), and also the 4-azatetracyclo [4.4.0$^{2.4}$.0$^{3.8}$] derivatives (**176a–f**). The authors [222–224] further discussed the differing behaviors of the 20*S* and 20*R* diastereoisomers, explaining the greater predisposition of the 20*S*-tosylates for elimination by the more advantageous, nearly antiperiplanar position of the 20-OTos group to the 7$\beta$-H.

The primary and secondary azides (**175a–g**, Figure 46) developed by Berényi et al. [222–224] proved to be unstable due to the intramolecular addition of the azido group into the $\Delta^{18,19}$ double bond. They degraded into azatetracyclodecane derivatives (**176a–g**, Figure 46) with nitrogen loss via heating or spontaneously at room temperature, and were thus unsuitable as ligands for pharmacological investigations. Therefore, the Makleit research group extended their investigations to the 20-tertiary azides of 18,19-dihydro-6,14-ethenomorphinans.

In 1993, Sepsi et al. [225] described the synthesis of a series of tertiary azides with a morphinan scaffold.

The first strategy, which was the synthesis of the target azides via nucleophilic substitution of aryl or alkylsulfonate esters, failed due to the conversion of the tertiary alcohols (e.g., 20-methylthevinol, **173a**, Figure 47) into the corresponding 20-*O*-tosylate or mesylate (e.g., **177**). However, the use of hydrazoic acid and BF$_3$-etherate [226] turned out to be practicable. 20-Methylthevinol (**173a**, Figure 47) thereby converted into the tertiary azide (**178**) in 62% yield, and its reduction to the corresponding tertiary amine (**179**) was successfully performed (83%) with hydrazine hydrate/Raney-Ni in ethanol (reflux, 30 min). As expected, the thermal treatment of **178** (DMF, 100 °C, 48 h) gave aziridine (**180**) as a result of the addition of the azido group into the 6,14-etheno bridge.



**Figure 47.** Synthesis of azides in the 6,14-ethenomorphinan series. *Reagents and conditions*: (i): methyl vinyl ketone, reflux, 1 h; (ii): MeMgI, toluene, THF, reflux, 1 h; (iii): 2 equiv. hydrazoic acid, 2 equiv. BF$_3$-etherate, room temperature, 4 h, 62%; (iv): 98% hydrazine hydrate, Raney-Ni, EtOH, reflux, 30 min, 83%; (v): Δ (-N$_2$), DMF, 100 °C, 40 h, 64%.

To avoid the aforementioned ring closure reactions, representatives of the 6,14-ethano series, tertiary alcohols (**182a–e**, Figure 48) prepared from dihydrothevinone (**181**) in Grignard reactions (RMgX, R = Me, Et, *n*Pr, Ph, *t*Bu), were chosen as starting materials for the synthesis of the target tertiary azides (**183a–e**). The replacement of the 20-OH tertiary hydroxyl group of **182b–d** (20*R*-**182b**, 20*R*-**182c**, 20*S*-**182d**, and 20*S*-**182e**) with an azido group using hydrazoic acid and boron trifluoride etherate resulted in a diastereomeric mixture of 20*R* and 20*S* of azides (**183b–d**, 35–44%) as major products, but also gave elimination products (**184b–d**, 5–13%). The diastereomeric azide ratios were determined from the $^1$H-NMR spectra based on the integrals of characteristic signals (20-CH$_3$, 6-OCH$_3$, 5β-H): **183b** (4:1), **183c** (3:1) and **183d** (1:1).

Efforts to split up the diastereomeric azides (**183b–d**) were unsuccessful, but there was the separation of the diastereomeric mixture of amines (**185a–b**), prepared from 20*R*-propyldihyrothevinol (**183c**) by reduction with hydrazine hydrate and Raney-Ni in boiling ethanol. The conversion of 20-*tert*-butyldihydrothevinol (**182e**) to the corresponding tertiary azide (**183e**) failed. Instead of **183e**, the furanocodide derivative (**190**) was isolated as the major product and the anhydro/olefin compound (**191**) as a minor by-product. Furanocodides are known acid-catalyzed rearrangement products of thevinols [227,228]. For the preparation of the tertiary azide with an orvinol structure (**189**), 20-methydihydrothevinol (**182a**) was 3-*O*-demethylated to 20-methyldihydroorvinol (**186**). The phenolic hydroxyl group of **186** was protected by the application of the Welsh method [99]. 3-*O*-Acetyl-

dihydroorvinol (**187**) was reacted with hydrazoic acid and BF$_3$ · Et$_2$O to give the azide **188** (60%), which was deprotected with hydroxylamine hydrochloride to yield **189** (79%). The *tert*-azido-orvinol derivative (**189**) [225] as a lead compound was tested for OR agonist properties in the GPI test in vitro and the mouse hot-plate test (HP) in vivo, proving it to be a μOR agonist. In the mouse HP tests, **189** and **186** showed 10–18 times higher potency relative to morphine (ED$_{50}$ (mg/kg) = 0.59 (**189**), 0.32 (**186**), 6.0 (**1a**). However, in comparison with the native 20-methyldihydroorvinol (**186**), the azido compound **189** did not show higher relative activity [225].



**182a–e**
**a**: R = Me
**b**: R = Et
**c**: R = *n*Pr
**d**: R = Ph
**e**: R = *t*Bu

**183a–d**
**a**: R = Me
**b**: R = Et
**c**: R = nPr
**d**: R = Ph
**e**: R = tBu

**184**
**a**: R$_1$ = Me, R$_2$ = Me
**b**: R$_1$ = Me, R$_2$ = Et
**c**: R$_1$ = Ph, R$_2$ = H
**d**: R$_1$ = *t*Bu, R$_2$ = H

20*R*-**185a**: R$_1$ = Me, R$_2$ = *n*Pr
20*S*-**185b**: R$_1$ = *n*Pr, R$_2$ = Me

**Figure 48.** Synthesis azides of 18,19-dihydro derivatives in the 6,14-ethenomorphinan series. *Reagents and conditions*: (i): Grignard reagents (RMgX: MeMgI, EtMgBr, *n*PrMgBr, PhMgBr, *t*BuMgCl), Et$_2$O–toluene or THF–toluene mixtures, reflux, 1–2 h; (ii): 2 equiv. HN$_3$, 2 equiv. BF$_3$-etherate, toluene, room temperature, 4 h, **183b–d**: 35–44% and **184b–d**: 5–13%; (iii): from **183c**, 8 equiv. hydrazine hydrate, Raney-Ni, ethanol, reflux, 30 min, 20*S*-**185a**: 58%, 20*R*-**185b**: 18%; (iv): KOH, diethylene glycol, 210 °C, 90 min; (v): based on Welsh's [99] method: Ac$_2$O, NaHCO$_3$, H$_2$O; (vi): 3 equiv. hydroxylamine hydrochloride, 50 °C, 30 min, 79%.

### 2.9.4. 6-Azido-6-demethoxythebaine

In 1997, Csutorás et al. [229] reported the synthesis of 6-azido-6-demethoxythebaine (**193**, Figure 49) in six consecutive transformations starting from thebaine (**4**). 6-Azido-6-desoxy-14-hydroxyisocodeine (**87**) was prepared from **4** as described earlier by Makleit et al. (**4** → **132** → **66** → **70a–b** → **87**, Figure 49) [121,122]. The sulfonate esters (**70a–b**) were converted to 6-azido-6-desoxy-14-hydroxyisocodeine (**87**) by treatment with NaN$_3$ in DMF/H$_2$O at 100 °C for 4 h. A more prolonged reaction time under the same conditions gave 8-azido-8-desoxy-14-hydroxypseudocodeine (**85**) through rearrangement. Otherwise, the reaction of **87** with two equivalents of PBr$_3$ resulted in 7β-bromo-6β-azidodesoxyneopine (**192**) in 77% yield. In this product (**192**), the trans-diaxial orientation of the 7β-bromo substituent relative to the 6α-hydrogen favors hydrogen bromide elim-

ination, which is readily obtained by treatment with potassium *tert*-butoxide in ethanol (room temperature, 30 min, 75%). The structure of 6-azido-6-demethoxythebaine (**193**) was confirmed by IR and NMR spectra and by chemical reaction. It was stable at −20 °C, but decomposed within a few days at room temperature due to its vinylazide structural element. In a search for derivatives showing higher stability, the reaction of the azidodiene (**193**) with carbon disulfide in the presence of triphenylphosphine (reflux, 2 h) gave 6-isothiocyanato-6-demethoxythebaine (**194**) in 51% yield. The hetero Diels–Alder reaction of 6-azido-6,8-morphinandiene (**193**) with 4-phenyl-4*H*-1,2,4-triazoline-3,5-dione (PTAD) at 0 °C readily gave a stable cycloadduct (**195**) in excellent yield.



**Figure 49.** Synthesis of 6-azido-6-demethoxythebaine. *Reagents and conditions*: (i): formic aid, $H_2O_2$, 40 °C, 2 h; (ii): $NaBH_4$, $H_2O$, dioxane; (iii): A. TosCl, pyridine, 0 °C, [152,153], or MsCl, pyridine, 66% [121,122]; (iv): 1.25 equiv. $NaN_3$, DMF, $H_2O$, 100 °C, 4 h, 38% [121,122]; (v): 1.25 equiv. $NaN_3$, DMF, $H_2O$, 100 °C, 8 h, 46% [121,122]; (vi): 2 equiv. phosphorus tribromide, $CHCl_3$, 50 °C, 2 h, 77%; (vii): 3.5 equiv. potassium *tert*-butoxide, EtOH, room temperature, 0.5 h, 75%; (viii): carbon disulfide, triphenylphosphine, reflux, 2 h, 51%; (ix): 1.2 equiv. 4-phenyl-4*H*-1,2,4-triazoline-3,5-dione (PTAD), acetone, room temperature, 20 min, 71%.

## 2.10. Fluorinated Morphinans

Halogenated derivatives of morphine alkaloids have been a subject of continuous interest in organic chemistry [22,24]. Brominated morphinans (e.g., 1-bromo and 1,7-dibromo derivatives of dihydrothebainone and β-dihydrothebainone, 1-bromo-nordihydrothebainone) were valuable intermediates for the first morphine total synthesis accomplished by Gates and Tschudi [230], and were later successfully used for the preparation of B/C-trans-fused 1-bromodihydrocodeinone [231] and for the synthesis of codeine from dihydrothebainone [232,233]. Iodinated and brominated morphinans are precursors for the synthesis of tritiated radioligands [234,235], which are valuable research tools for OR pharmacological investigations. The effects of fluorine incorporation in biologically active derivatives have been thoroughly investigated [236] and are the subject of a very recent comprehensive survey of fluorine-containing morphinans by Sandulenko et al. [237].

### 2.10.1. Ring-C Fluorinated Morphinans

The morphine alkaloid research group at the University of Debrecen has paid particular attention to the synthesis of ring-C halogenated morphinan derivatives [24,238]. 6-Fluoro-6-deoxyisocodeine (**59a**, Figure 50) was obtained via the $S_N2$ reaction of codeine tosylate (**63a**) with tetrabutylammonium fluoride (TBAF) [111,112] in 48% yield, and separately from pseudocodeine tosylate (**97**) [129,130] in an $S_N1'$ reaction with the same nucleophile in acetonitrile, albeit in poor yield (10%). In 1972, Bognár et al. [216,217] described the synthesis of 6-fluoro-6-deoxy-14-hydroxyisocodeine (**80**) from 14-hydroxycodeine tosylate (**70a**) with TBAF. In an extension of earlier studies of the group [117,118,121,122], Somogyi et al. [239,240] investigated the $S_N2$-type reactions of dihydrocodeine mesylate (**71b**) with halide anions ($F^\ominus$, $Cl^\ominus$, $Br^\ominus$, $I^\ominus$).



**Figure 50.** Synthesis of 6-halogene-substituted morphinans. *Reagents and conditions*: (i): 1.6 equiv. Bu$_4$NF, acetonitrile, reflux, 4 h, 48% [111,112]; 5.4 equiv. Bu$_4$NF, CH$_3$CN, reflux, 29 h, 10% [129,130]; (iii) [239,240]: **A** (Nu = $F^\ominus$): 13 equiv. Bu$_4$NF, acetonitrile, reflux, 12 h, **196a**, 8%; **B** (Nu = $Cl^\ominus$): 10 equiv. LiCl, DMF, reflux, 1 h, **196b**, 75%; **C** (Nu = $Br^\ominus$): 4 equiv. LiBr, 100 °C, 43 h, **196c**, 26%; (iv) [239,240]: **A** (Nu = $Br^\ominus$): 8 equiv. LiBr, DMF, reflux, 4 h, **197**, 63%; **B** (Nu = $I^\ominus$): 10 equiv. NaI, DMF, reflux, 7 h, **197**, 29%.

6-Fluoro-6-deoxydihydroisocodeine (**196a**, 6-fluorodihydrocodide, α-fluorodihydrocodide) was prepared from dihydrocodeine mesylate (**71b**) [239,240] with tetrabutylammonium fluoride in acetonitrile in low yield. 6-Chloro-6-deoxydihydroisocodeine (**196b**, 6-chlorodihydrocodide, α-chlorodihydrocodide) was also prepared by the heating of **71b** for 1 h with ten equiv. of lithium chloride in 75% yield. When **71b** was treated with LiBr in DMF at 100 °C for 43 h, 6-bromo-6-deoxydihydroisocodeine (**196c**, 6-bromodihydrocodide, α-bromodihydrocodide) was isolated in 26% yield. When the latter reaction was performed at higher temperatures (reflux for 4 h), desoxycodeine-C (**197**, $\Delta^7$-desoxycodeine) was formed in 63% yield. When **71b** was treated with 10 equiv. of sodium iodide, the corresponding 6-iodo derivative could not be isolated; instead, **197** was obtained in 29% yield.

In 1980, Boswell and Henderson [241] reported the fluorination of morphinan-6-ones (e.g., dihydrocodeinone (**49**), and 14-hydroxydihydrocodeinone) with diethylaminosulfur trifluoride (DAST). 6,6-Difluoro compounds were isolated as main products and 6-monofluoro-$\Delta^{6,7}$ unsaturated derivatives as by-products. In 1984, Ganti [242] synthesized numerous 14-fluoro-analogs of oxymorphone (**198a**, Figure 51), naltrexone (**198b**) and nalbuphine (**198c**) from 6-*O*-protected 14-hydroxy-dihydromorphinones with DAST.



**Figure 51.** Ring-C fluorinated morphinan derivatives.

In 1984, the research group of Kenner C. Rice [243–248] developed 6β-fluoro-oxymorphol (**204a**, foxy) and 6β-fluoro-naltrexol (**204c**, cyclofoxy) analogs (Figure 52). They performed the synthesis of 6-fluoro-6-desoxy-14-hydroxydihydroisomorphine derivatives (**204a–d**) in two steps from the corresponding 3-*O*-acetyl-6-trifluromethansulfonyloxy-14-hydroxydihydromorphines (**203a–d**).



**Figure 52.** Synthesis of foxy, cyclofoxy and their iodinated derivatives. *Reagents and conditions*: (i): 0.5 equiv. NaBH$_4$, THF, 0 °C, 1 h, 37%; (ii): Ac$_2$O, NaHCO$_3$, H$_2$O, quant.; (iii): 2 equiv. Tf$_2$O, CHCl$_3$, pyridine, 20 °C, 20 min, 72%; (iv): 7.2 equiv. KF, 18-crown-6 ether, acetonitrile, reflux, 2 min, 62%. (v): NH$_4$OH, MeOH, 80 °C, 30 min; (vi): Et$_4$NI, acetonitrile, 80 °C, 4 h, argon atmosphere; (vii) NH$_4$OH, acetonitrile, 25 °C, 20 min.

Specifically, the Rice group prepared cyclofoxy (**204c**, cyF) by introducing the fluorine substituent in the 6β-position via an $S_N2$ reaction by the displacement of the 6α-*O*Tf leaving group of **205c** with fluoride ions (potassium fluoride) in the presence of 18-crown-6 in acetonitrile. They then removed the acetyl protecting group by treating the fluorinated intermediate (**203c**) with $NH_4OH$ in methanol. For labeled foxy and cyclofoxy derivatives, see Section 2.12.

Woudenberg and Maat prepared chlorine-containing etorphine analogs from 7-chloro-morphinan-6,8-dienes (7-chloro-6-demethoxythebaine and 7-chloro-5β-methyl-6-demethoxythebaine) in multistep-syntheses [249], and subsequently evaluated their pharmacological characteristics, showing their generally high affinity for μOR and variable selectivity for κOR sub-types [250]. The Makleit group investigated Diels–Alder (DA) cycloaddition of the highly reactive dienophile 4-phenyl-4*H*-1,2,4-triazoline-3,5-dione (PTAD) to 7-halomorphinandienes (Cl, Br) [251]. In 1990, studying the DA reaction of thebaine with 2-fluoroacrolein, Jeong et al. observed the formation of a diastereomeric mixture of 7-fluoro-7-formyl-DA adducts (**207a–b**, 7α/7β, Figure 53) and a hetero-DA adduct [252]. The same research group reported the reactions of thebaine with trifluoromethyl-substituted acetylenic dienophiles (trifluoropropyne, hexafluoro-2-butyne) and with perfluoroaldehydes [253]. The hetero Diels–Alder (HDA) reaction of thebaine and 5-methyl-thebaine with trifluoroacetaldehyde resulted in 14-(trifluoro-2-hydroxy-ethyl)-5-methylcodeinone derivatives [254].



**207a–b**

**207a**: R₁ = F, R₂ = CHO
**207b**: R₁ = CHO, R₂ = F

**208a–c**

**208a**: R = CH₃, 6-fluoro-6-demethoxythebaine
**208b**: R = H, 6-fluoro-6-demethoxynorthebaine
**208c**: R = *n*Pr, *N*¹⁷-*n*Pr-6-fluoro-6-demethoxynorthebaine

**209**

6-fluoro-6-demethoxy-
20-methylorvinol

**210**

7β-fluoro-dihydrocodeine

**Figure 53.** Structures of fluorinated morphinans.

In 1992, Berényi and colleagues elaborated a new methodology for the synthesis of 6-fluoro-6-demethoxythebaine derivatives (**208a–c**, *N*¹⁷-substituent: CH₃, H, *n*-propyl) from 14-hydroxy-6-fluoro-6-deoxyisocodeine [255]. They used microwave-promoted synthesis for the acid-catalyzed rearrangement of morphinans and fluoromorphinans (**208a–c**) [256]

to yield the corresponding aporphine derivatives. Subsequently, they reported the cycloaddition reaction of 6-fluoro-6-demethoxythebaine with methyl-vinyl ketone and the synthesis and biological evaluation of 6-fluoro-6-demethoxy-20-methylorvinol (**209**) [257,258]. In 2013, Magnus performed the synthesis of 7β-fluorodihydrocodeine (**210**, Figure 53) [259]. The six-step transformation from codeine (**2a**) involved the fluorination of a 6,7-epoxyde intermediate with a hydrogen-fluoride–pyridine complex.

2-Haloaporphines are dopamine agonists that can be synthesized from halomorphinans by acid-catalyzed rearrangement. 2-Fluoro-*N*-*n*-propylnorapomorphine (2F-NPA) [255,260] is the most important member of this class, with extremely high affinity ($K_i$ = 12 pM) and $D_2$-sub-type selectivity ($D_2/D_1 > 50,000$) [261]. In 1994, Hosztafi and Makleit [262] reported the synthesis of numerous C-1 halogenated (1-chloro and 1-bromo) derivatives of codeine, morphine and their 7,8 dihydro analogs and, subsequently, the rearrangement of 1-halogenated-codeines to the corresponding ring-D-substituted 8-halogen-apomorphines [263]. The synthesis of [8,9-$^3$H]apomorphine was accomplished by the bromination of apomorphine hydrochloride in trifluoroacetic acid (TFA) with molecular bromine [264] to 8,9-dibromo-apomorphine and followed by tritium dehalogenation ($^3H_2$, 10% Pd/C, ethanol). Filer [265] presented the radiosynthesis of 8,9-di-[$^{18}$F]fluoroapomorphine by the fluorodestannylation of 8,9-di-(trimethylstannyl)-apomorphine. 8,9-Dibromoapomorphine and/or 8,9-diiodoapomorphine were applied as intermediates for the preparation of the labelling tin precursor.

### 2.10.2. 1-Fluoro-Substituted Morphinans

In 1974, Lousberg and Weiss [266] reported the first synthesis of 1-fluorocodeine (**216a**) in 1974. Subsequently, Makleit and Dubina [267] published an improved method for its preparation through the pyrolysis of diazonium fluoroborate (**215a**) (Balz–Schiemann reaction). 1-Fluorodihydrocodeine (**216b**) was prepared from 1-fluorocodeine (**216a**) by heterogenous catalytic reduction [267].

In 2016, Hosztafi and Marton [268] synthesized 1-fluoro-substituted codeine derivatives (**220a–b**, $N^{17}$-allyl, $N^{17}$-*n*-propyl, Figure 54) and their 7,8-dihydro derivatives (**220c–d**). They first prepared 1-fluoromorphine (**217a**) and 1-fluorodihydromorphine (**217b**) from their respective codeine precursors via 3-*O*-demethylation with boron tribromide in chloroform. 1-Fluorocodeine (**216a**) and $N^{17}$-*n*-propyl-1-fluorocodeine (**220a**) were subjected to acid-catalyzed rearrangement using methansulfonic acid (100 °C, 45 min) to give 8-fluoroapocodeine (**222a**) and $N^6$-propyl-8-fluoroapocodeine (**222b**), respectively, with low yields (20–24%). 3,6-di-*O*-Acetyl-1-fluorodihydromorphine (**221**) was synthesized by the acetylation of 1-fluorodihydromorphine (**218b**) with acetic anhydride (100 °C, 1 h, 55%). In 2018, Hosztafi et al. reported the synthesis of 1-iodo-substituted codeine and dihydrocodeine derivatives [269].

### 2.10.3. Fluorinated 6,14-Ethenomorphinans

In the past decade, the Moiseev research group expended considerable effort toward the synthesis of fluorinated 6,14-ethenomorphinan derivatives [237]. In 2016, they reported the synthesis of the key starting material for their investigations of the 7α-trifluoroacetyl analog of thevinone (**172a**)—21,21,21-trifluorothevinone (**224**, Figure 55)—starting with thebaine (**4**) [270]. Due to the low stability of the dienophile trifluoromethyl vinyl ketone, the direct conversion of **4** to **224** in a Diels–Alder reaction failed. This led them to adopt a three-step procedure in which thebaine was first converted in a [4 + 2] cycloaddition reaction with acrolein to the 7α-formyl cycloadduct (**172b**, thevinal, Figure 55). This was reacted with the nucleophilic trifluoromethylating Ruppert–Prakash reagent (TMSCF$_3$) to yield the diastereomeric mixture of the secondary alcohols 20*R*- and 20*S*-**223**, with the generation of

trifluoromethyl anion (CF$_3^{\ominus}$) in situ from TMSCF$_3$ in the presence of tetrabutylammonium fluoride (TBAF). The mixture of the epimeric alcohols (**223**) was transformed to the desired 21,21,21-trifluorothevinone (**224**) by Swern oxidation. Subsequently, Zelentsova et al. [271] prepared 21,21-difluorothevinone (**225**) and 21-fluorothevinone (**226**) via the defluorination of 21,21,21-trifluorothevinone (**224**) with magnesium and trimethylsilyl chloride, followed by the acidic hydrolysis of the TMS intermediate. The Grignard reaction of **224** with phenylmagnesium bromide gave a mixture of fluorinated 20*R*- and 20*S*-phenylthevinols (**227**) [270,272,273].



**Figure 54.** Synthesis of 1-fluoro-substituted codeine derivatives. *Reagents and conditions*: (i): Ac$_2$O, reflux; (ii): 65% nitric acid, glacial acetic acid, **A**. 5 °C, 1 h, **B**. room temperature, 1 h; (iii): 10% NaOH, EtOH, reflux, 1 h; (iv): SnCl$_2$, HCl, room temperature, 2 h; (v): 48% aqueous HBF$_4$, EtOH, 2 M NaNO$_2$, −15 °C 10 min; (vi): MgO, 170 °C, 1 h, in vacuo; (vii): BBr$_3$, CHCl$_3$, room temperature, 1 h; (viii): Ac$_2$O, reflux, 4 h; (ix): **A**. ACE-Cl, NaHCO$_3$, 1,2-dichloroethane, reflux, 8 h; **B**. MeOH, 50 °C, 1 h; (x): *n*-propyl bromide or allyl bromide, NaHCO$_3$, DMF, 95 °C, 18 h; (xi): Ac$_2$O, 100 °C, 1 h; (xii): methane sulfonic acid, 95 °C, 45 min.

In 2023, Sandulenko et al. [274] synthesized numerous 20-methyltrifluoro-6-*O*-desmethylorvinols (**229**, **232**, **235**, Figure 56) starting from thevinone (**172a**) and $N^{17}$-allyl-dihydronorthevinone (**233**). Notably, structure–activity relationships have only been reported so far for a few 6-*O*-desmethylorvinols [275]. The addition of Me$_3$SiCF$_3$ to thevinone (**172a**) resulted in 20*R*-**228**. Boiling the latter compound with 48% hydrobromic acid for 30 min led to 20-trifluoromethyl-6-*O*-desmethyl-orvinol (**229**, 60%) via an unusual simultaneous 3-*O*- and 6-*O*-demethylation. For the preparation of 20-trifluoromethyl-6-*O*-desmethyl-cyprenorphine (**232**), 20*R*-**228** was *N*-demethylated with ethyl azodicarboxylate to 20-trifluoromethyl-northevinol (**230**). Next, the secondary amine was acylated

with cyclopropanecarbonyl chloride, whereupon the resulting $N^{17}$-acyl compound reduced with lithium aluminum hydride to the $N^{17}$-cyclopropylmethyl derivative (**231**). The *O*-Demethylation of **231** with boron tribromide in dichloromethane at −78 °C gave **229** in 76% yield. Analogously, $N^{17}$-allyl-dihydronothevione (**233**) [276] with Me$_3$SiCF$_3$ gave 20*R*-**234**, which was *O*-demethylated to $N^{17}$-allyl-20-trifluormethyl-6-*O*-desmethyl-dihydronororvinol (**235**, 53%). In general, thevinols with tertiary hydroxyl groups in position-20 are acid-sensitive compounds and thus prone to undergo, by acid-catalyzed dehydration, enol ether hydrolysis and rearrangement to 14-alkenylcodeinones, anhydro-20-alkylthevinols or 5,14-bridged thebainones. The authors attributed the suitability of BBr$_3$ for the *O*-demethylation of fluorinated thevinols to the presence of the EWG CF$_3$ group in the molecule [272]. The 20-CF$_3$ group can prevent the formation of a carbocation from the C-20 tertiary alcohols and, accordingly, avoid the intramolecular rearrangements mentioned above. The target compounds (**229**, **232**, and **235**) administered s.c. were evaluated for analgesic activity in rodent tail-flick tests in comparison to morphine (**1a**). The results showed that the introduction of a fluorine substituent in position-20 of the orvinol scaffold did not eliminate the analgesic properties; 20-trifluoromethyl-6-*O*-desmethyl-orvinol (**229**) showed analgesic activity comparable to that of morphine (**1a**). 20-Trifluoromethyl-6-*O*-desmethyl-cyprenorophine (**232**) with $N^{17}$-cyclopropylmethyl substituent proved to be a partial agonist with weak analgesic activity, and $N^{17}$-allyl-20-trifluoromethyl-6-*O*-desmethyl-dihydronororvinol (**235**) displayed no analgesic activity.



**Figure 55.** Synthesis of fluorinated 6,14-ethenomorphinan derivatives. *Reagents and conditions*: (i): acrolein, benzene, reflux; (ii): **A**. Me$_3$SiCF$_3$, TBAF, THF, **B**. HCl, H$_2$O; (iii): **A**. oxalyl chloride, DMSO, CH$_2$Cl$_2$, −70 °C, 90 min, **B**. Et$_3$N, 20 °C, 10 min; (iv): **A**. Mg, Me$_3$SiCl, -5 °C, 4 h, B. 15% HCl, 1 h; (v): PhMgPr, THF, 20 °C, 24 h.

**Figure 56.** Synthesis of 21,21,21-trifluoro-6-*O*-desmethyl-orvinols. *Reagents and conditions*: (i): 2 equiv. MeSiCF$_3$, (ii): 48% HBr, reflux, 30 min, 60%; (iii): **A**. 1.5 equiv. DEAD, benzene, reflux, 24 h, **B**. 1.6 equiv. pyridinium hydrochloride, MeOH, 30 min, 31%; (iv): **A**. 2.5 equiv. cyclopropanecarbonyl chloride, K$_2$CO$_3$, CH$_2$Cl$_2$, 20 °C, 6 h, **B**. 4.9 equiv. LiAlH$_4$, THF, reflux, 1 h, 65%; (v): BBr$_3$, CH$_2$Cl$_2$, −78 °C, 76%;.

In a subsequent study, the same research group placed their attention on the stereochemistry of the C-20 chiral center of fluorine-containing thevinols [277]. They thoroughly investigated the reactions of 21,21,21-trifluorothevinone (**224**, 7α-trifluoroacetyl, Figure 57) with various alkylmagnesium halides (MeMgI, EtMgBr, *n*PrMgBr, *i*PrMgBr, *t*BuMgCl) and alkyllithium reagents (*t*BuLi, *i*PrLi) and also the addition of TMSCF$_3$ to thevinone (**172a**) and its analogs (7α-acetyl). These studies proved to be of fundamental importance in elucidating the structure–activity relationships of thevinols and orvinols with different C-20 configurations. The reaction of 7-acyl-type 6,14-ethenomorphinans with Grignard reagents results in complex product mixtures [57,278,279] due to various processes: Grignard addition, the reduction of the carbonyl function, and base-catalyzed rearrangement. Sandulenko et al. [277] found that the reaction of thevinone (**172a**) and its 7α-acyl analogs (7α-propionyl, 7α-butanoyl) with trimethyl-(trifluoromethyl)-silane in the presence of CsF in THF at room temperature gave a mixture of the tertiary alcohols 20*R*-**236** and 20*S*-**236**, with a predominance of the 20*R* isomer. The reaction of 21,21,21-trifluorothevinone (**224**) with two equivalents of methylmagnesium iodide in diethyl ether at room temperature resulted in a 100:67 mixture of the 20*R*-**236** and 20*S*-**236** epimeric tertiary alcohols. In the reaction of **224** with MeMgI, the researchers also studied the effects of the addition of metal salts (MgX$_2$, X = Cl, I; ZnCl$_2$, MeOMgI, *t*BuOK) on the product ratio, based on an earlier approach of Zelentsova et al. using one-dimensional $^{19}$F NMR spectra [273]. When **224** (Figure 57) was reacted with 1.2 equivalents of methyllithium in THF, a mixture of isomeric tertiary alcohols 20*R*-**236** and 20*S*-**236** (R = Me) was formed, with a predominance of the 20*S* epimer (e.g., at −78 °C, ratio 20*R*/20*S* = 25:100). Reacting 21,21,21-trifluorothevinone (**224**) with RMgX reagents other than MeMgI (R = Et, *n*Bu, *i*Pr, *t*Bu) gave a predominant formation of the secondary alcohols 20*R*-**237** and 20*S*-**237**.

**Figure 57.** Reaction of thevinones with organometallic reagents. *Reagents and conditions*: (i): Me₃SiCF₃, HCl, H₂O; (ii): **A**. Grignard reagents (MeMgI, EtMgBr, *n*BuMgBr, *i*PrMgBr, *t*BuMgCl), Et₂O or THF, 20 °C, 15 min–18 h; **B**. RLi (MeLi, *i*PrLi, *t*BuLi), Et₂O or THF, −78–20 °C, 15 min–60 h.

In 2023, Zelentsova et al. [271] reported the synthesis of 21,21-difluorothevinone (**225**) and 21-fluorothevinone (**226**) by the defluorination of 21,21,21-trifluorothevinone (**224**, Figures 55 and 57). Prominent members of the 6,14-ethenomorphinan series, buprenorphine, diprenorphine and dihydroetorphine, contain a saturated 6,14-ethano bridged C-ring [57,221,280]. Therefore, the next logical step was to try to synthesize the 18,19-dihydro analogs of **224**, **225** and **226**. The direct conversion of **224** to 18,19-dihydro-21,21,21-trifluorothevinone (**238**) by the catalytic hydrogenation of the $\Delta^{19,19}$ double bond failed. Even harsh reaction conditions at 60 Bar hydrogen pressure (AcOH, 10% Pd-C, 55–60 °C, 45 h) gave only a 15% conversion rate, with the isolation of the rearranged product **239** in 11% yield instead of the desired compound (**238**), which is the 7α-trifluoacetyl analog of dihydrothevinone (**181**). As an alternative route for the synthesis of $N^{17}$-substituted-20-difluoromethyl-tevinols (**242a–c**), dihydrothevinone (**181**) was refluxed with the pronucleophile (difluoromethyl)trimethylsilane (Me₃SiCHF₂) in HMPA/THF in the presence of CsF to give 20R-**240** in 35% yield. The secondary amine 20R-**241** was prepared from 20R-**240** by *N*-demethylation with diethyl azodicarboxylate (DEAD) in acetonitrile. Subsequently, the target tertiary amines (**242a–c**) were prepared by functionalization with the corresponding alky or acyl halides with yields in the range of 48–52%. 20R-**242c** was also prepared directly from $N^{17}$-allyl-dihydronorthevinone (**233**, Figure 58) with Me₃SiCHF₂ in 23% yield.

Aiming to synthesize the conjugates of 6,14-ethenomorphinans with bioactive molecules, the same research group prepared 7α- and 7β-carboxylic acid esters of thevinone, so-called thevinoic acid fluoroalkyl esters, from thebaine (**4**) with β-fluoroalkyl acrylates [281].

Very recently, Finke et al. [282] reported a procedure for the preparation of 6-trifluoromethyl-substituted morphinans from morphinan-6-ones. 6-Ketomorphinans (e.g., 14-hydroxycodeinone (**132**), 4-*O*-methylsinomenine, 1-iodo-4-*O*-methylsinomenine) were converted to the corresponding 6-trifluoromethyl compounds with (trifluoromethyl)trimethylsilane (Me₃SiCF₃, Ruppert–Prakash reagent) in the presence of Bu₄NF or *t*BuOK.

**Figure 58.** Synthesis of 21,21-difluorothevinol derivatives. *Reagents and conditions*: (i): H$_2$, 10% Pd-C, 60 Bar, 55–60 °C, 45 h, 11%; (ii): **A**. Me$_3$SiCHF$_2$, CsF, HMPA, DMPU, THF, reflux. 10 h, **B**. 15% HCl (aq.), room temperature, 1 h, 20*R*-**240**, (35%) and 20*R*-**242c** from **233** (23%); (iii) **A**. 2 equiv. DEAD, acetonitrile, reflux, 5 h, **B**. 3 equiv. pyridinium hydrochloride, 77%; (iv): **A**. allyl bromide, NaHCO$_3$, DMF, 90–95 °C, 20 h, 48%; **B**. (1) cyclopropanecarbonyl chloride, K$_2$CO$_3$, CH$_2$Cl$_2$, 20 °C, 2 h, (2) LiAlH$_4$, THF, reflux, 1 h, 52%, **C**. (1) cyclobutanecarbonyl chloride, K$_2$CO$_3$, CH$_2$Cl$_2$, 20 °C, 2 h, (2) LiAlH$_4$, THF reflux, 2 h, 50%.

## 2.11. Application of the Mitsunobu Reaction in the Morphine Series

The Mitsunobu reaction [283,284] continues to find wide use for the functionalization of alcoholic hydroxyl groups [285] and in the field of alkaloid synthesis [286]. During this reaction, a primary or secondary alcohol (R-OH, e.g., **2a**, Figure 59) substrate reacts with a pronucleophile (H-Nu (**243**), a compound containing a dissociable proton) in the presence of an azodicarboxylic acid ester (e.g., DEAD, DIAD, ADDP or DTBAD, **244**) and triaryl or trialkylphosphine (**245**, e.g., TPP or TBP, Figure 59). Following a complex reaction sequence, the alcohol (R-OH, **2a**) alkylates the conjugated base (Nu$^{\ominus}$) of the pronucleophile (H-Nu, **243**), forming R-Nu (**246**) as main product and the side products hydrazinecarboxylic acid alkyl ester and the corresponding phosphine oxide (e.g., Ph$_3$P=O, **248**).



**Figure 59.** Overall reaction equation of the Mitsunobu reaction of codeine with H-Nu.

The Mitsunobu reaction is an indispensable alternative to classical $S_N2$-type reactions. Taking place under mild (0–25 °C) and neutral conditions, the reaction operates in dipolar aprotic solvents (e.g., THF, benzene, DMF, acetonitrile). The reaction time ($\tau$) is commonly between 0.5 and 12 h, with rare instances of a more prolonged $\tau$-s. The Mitsunobu reaction is chemoselective: only the alcoholic hydroxyl groups react under such mild conditions. Typically, primary alcohols react more quickly than secondary alcohols, which enables the selective acylation of substrates when primary and secondary hydroxyl groups are present in the same molecule. The Mitsunobu reaction is usually stereoselective and yields products with opposite configurations (Walden inversion). Side reactions (elimination or allylic rearrangement) rarely occur. As pronucleophiles, molecules with dissociable protons ($pK_a < 11$) can be used, and examples of weak-acidity nucleophiles with higher $pK_a$ values (<15) are also known. The mechanism of the Mitsunobu reaction is depicted in Figure 60.

(1)  In the first elementary step of the process, a reactive betaine (**XVII**) is formed from the azodicarboxylic acid ester (**244**) and trialkyl or triarylphosphine (**245**) in an irreversible reaction;

(2)  In the second step, the reactive zwitterionic adduct (**XVII**) reacts with the acidic pronucleophile (H-Nu, **243**) to produce the nucleophile (Nu$^\ominus$);

(3)  The alcoholic hydroxyl group (**2a**) attacks the protonated betaine (**XVIII**) to form an alkoxyphosphonium intermediate (**XIX**). During this process, 1,2-hydrazinecarboxylic acid dialkyl ester (**247**) arises;

(4)  The conjugated base form (Nu$^\ominus$) of the pronucleophile (H-Nu, **243**) reacts with the alkylphosphonium intermediate (**XIX**), from which emerges the product (R-Nu, **246**) as well as triaryl or trialkylphosphine oxide (**248**). When a chiral secondary alcohol is applied as the starting substrate, a change in the configuration of the chiral center is to be expected (Walden inversion).

### 2.11.1. The First Application

Robson and Kosterlitz [287] postulated that the denaturation of the OR binding sites in guinea pig brain homogenates could be achieved by the alkylation of the protein with phenoxybenzamine (PBZ). Indeed, the incubation of brain preparations with PBZ reduced the specific binding of [$^3$H]dihydromorphine ($\mu$-ORs) and [$^3$H]*D*-Ala$^2$-*D*-Leu$^5$]enkephalin ($\delta$-ORs). Conversely, the presence of OR ligands (peptides or opiates) protected against inactivation due to alkylating agents. Smith and Simon [288] found that treatment with the thiol (SH) alkylating reagent *N*-ethylmaleimide (NEM) inhibited the stereospecific binding of tritiated OR ligands (e.g., [$^3$H]*D*-Ala$^2$-*D*-Leu$^5$]enkephalin). Bowen et al. [289] postulated that disulfide bonds in ORs are essential for ligand binding, proposing a three-state allosteric model ($\mu$-agonist-, $\mu$-antagonist- and $\delta$-agonist-preferring states) under regulation by an "SH"–"S-S" (thiol–disulfide) exchange mechanism.

Based on this hypothesis, in 1988, Fujii et al. [290] investigated the possibility of introducing an SH group into the C-6 position of the morphine (**1a**) skeleton. In a first attempt, morphine (**1a**) was reacted with thioacetic acid in the presence of 1,1-dineopentyloxytriethylamine (toluene, 80 °C) to yield the 3-*O*-acetyl-6β-thioester (**250**, Figure 61, 59%) and the 6β-thioester (**249**, 30%). In a second method, morphine (**1a**) was reacted with thioacetic acid under Mitsunobu conditions (diisopropyl azodicarboxylate (DIAD), triphenylphosphine (TPP)). This approach gave the predominant formation of 6-*S*-acetyl-6-desoxy-isomorphine (**249**, 73%) and its 3-*O*-acetyl derivative (**250**, 22%). The absolute stereochemistry of the C-6 stereo center was proven by NMR spectroscopic methods. In the $^1$H-NMR spectra of compounds **249** and **250**, the coupling constant $^3J_{5\beta,6\alpha}$ was 0.5 Hz, which implies a 6β-orientation of the thioacetyl group [291]. Fujii et al. [290] went on to hydrolyze *S*-acetyl-6-desoxy-isomorphine (**249**) by treatment with 0.2 M potassium hydroxide

in ethanol to give 6β-thiomorphine (**251**, 66%). Interestingly, the analogous reaction of dihydromorphine (**35**) with thioacetic acid (DIAD, TPP) resulted in 3-*O*-acetylmorphine (**254**) as the main product (93%) and the corresponding 3-*O*-acetyl-6β-thioacetyl derivative (**253**) as a minor product (7%). When dihydrocodeine (**67**) was subjected to the Mitsunobu reaction with thioacetic acid under identical conditions, there was the formation of the 6β-thioester (**255**) in almost quantitative yield. 3-*O*-Demethylation with boron tribromide in CHCl₃ gave **256** in 86% yield. The latter compound was hydrolyzed with 0.2 M KOH solution in ethanol to afford 6βthio-7,8-dihydro-morphine (**257**). The reaction of 6β-thiomorphine (**251**) and 6β-7,8-dihydro-thiomorphine (**257**) with 2-nitrobenzenesulfenyl chloride (acetonitrile, 0 °C) gave the corresponding disulfides (**252,258**).



**Figure 60.** Elementary steps of the Mitsunobu reaction as exemplified by the interaction of codeine R-OH, **2a**) with benzoic acid (H-Nu, **243**).

**Figure 61.** Reaction of morphine, dihydromorphine and dihydrocodeine with thioacetic acid under Mitsunobu conditions. *Reagents and conditions*: (i): thioacetic acid, *N,N*-dimethylformamide dineopentyl acetal, toluene, 80 °C; (ii): thioacetic acid, DIAD, TPP, THF, 0 °C; (iii): 0.2 M KOH, ethanol, N₂; (iv): 2-nitrobenzenesulfenyl chloride, acetonitrile or CHCl₃, 0 °C; (v): BBr₃, CHCl₃, 86% (vi): 5-nitro-2-pyridinesulfenyl chloride, CH₂Cl₂, 0 °C, 84%.

The analgesic activities of 6-*S*-acetyl-6-desoxy-isomorphine (**249**, Figure 61) and the disulfide (**252**) derivative were tested in guinea pig ileum (GPI) [290]. Compound **249** proved to be twice as potent as morphine (**1a**), whereas the disulfide (**252**) was quasi-equipotent with morphine (**1a**).

In 1990, Kanematsu et al. [292] synthesized *S*-activated 6-sulfhydryl-dihydoisomorphine (**253**) starting from dihydromorphine (**35**) using Mitsunobu conditions by a modification of the Fujii et al. [290,293] approach (5 eq. AcSH, 5 eq. DIAD and 5 eq. TPP). 6β-7,8-Dihydro-thiomorphine (**257**) was reacted with 5-nitro-2-pyridinesulfenyl chloride (CH₂Cl₂, 0 °C), giving the corresponding disulfide (**259**, 84%). The analgesic activity of the synthesized 6β-(5′-nitro-2′-pyridyldithio)deoxydihydromorphine (**259**) was tested in guinea pig ileum

(GPI) and mouse vas deferens (MVD) preparations, giving $IC_{50}$ values of 9.3 and 76 nM, respectively. In mice (MVD), compound **259** had approximately three times higher potency than morphine. The researchers also investigated the thiol–disulfide exchange reaction of the 5′-nitro-2′-pyridyldithio derivative (**259**) with *L*-cysteine methyl ester in DMF.

### 2.11.2. Preparation of Isomorphine and Isocodeine Derivatives

At the beginning of the 1990s, there were only a few known morphine derivatives with 6-beta configuration (iso series, 6β-OH). Their preparation in low-yield procedures was only possible by the application of complicated multistep syntheses, with the further disadvantage of numerous side products. In 1969, Makleit and Bognár [123,124] prepared isocodeine (**2b**) in low yield (16%) by the acetolysis of codeine tosylate (**63a**) with 10% acetic acid. Subsequently, there was a report of the synthesis of isomorphine (**1b**) from 3-*O*-acetylmorphine tosylate (**69a**), and the preparation of dihydroisomorphine (**82**) from isomorphine (**1b**) by catalytic reduction [131,132]. Fleischhacker [294] found higher yields when performing solvolysis with 70% acetic acid. In 1971, Kirby and Massey [295] reported the synthesis of isocodeine (**2b**) from codeine (**2a**) in a three-step procedure: codeine (**2a**) → codeine tosylate (**63a**) → isocodeine acetate → isocodeine (**2b**). Codeine tosylate (**63a**) was converted into isocodeine acetate with hexadecyltrimethylammonium acetate, and the alkaline hydrolysis of the resulting 6β-acetate led to isocodeine (**2b**, 68% overall yield from **2a**). Simon [296] was the first from the Makleit group to investigate extensively the application of the Mitsunobu reaction in the field of morphine alkaloids.

In 1991, Simon et al. [297] thereby synthesized numerous isocodeine (**262a–c**, Figure 62) and isomorphine (**262g–j**) derivatives via the Mitsunobu reaction for the preparation of 6-benzoate esters (**261a–j**) and their subsequent hydrolysis.

This elegant two-step method [297] made available for the first time novel isocodeine isomorphine derivatives and previously known compounds of the iso series with acceptable yields. In the first step, codeine (**2a**), $N^{17}$-substituted codeine derivatives (**260b**, **260c**, *n*Pr, allyl), 3-*O*-ethylmorphine (**260d**), 3-*O*-benzylmorphine (**260e**), 3-*O*-morpholinylethylmorphine (**260f**), 3-*O*-acetylmorphine (**55**) or $N^{17}$-substituted-3-*O*-acetylmorphine derivatives (**260h–j**, *n*Pr, allyl, cyclopropylmethyl) were reacted with benzoic acid as the acidic pronucleophile (H-Nu, **243**). The Mitsunobu reactions were conducted in the presence of diethyl azodicarboxylate (DEAD) and triphenylphosphine (TPP, **245**), resulting in the corresponding 6-*O*-benzoyl-isocodeine (**261a–j**) derivatives. The latter compounds were treated with a 10% aqueous potassium hydroxide solution to give the isomorphine and isocodeine derivatives (**262a–j**) with a free 6β-hydroxyl group.

In 1994, Friedmann et al. [298] investigated the influence of C-6 configuration on the OR affinity of a large number of $N^{17}$-substituted-morphine derivatives (C-6α-hydroxy, $N^{17}$-substituent: CH₃ (**1a**), *n*-propyl (**260h**), allyl (**260i**), cyclopropylmethyl (**260j**) $N^{17}$-substituted-isomorphine (C-6β-hydroxy, **1b**, **262h–j**)) and their 7,8-dihydro analogs [297]. They used in vivo rat tail-flick, mouse hot-plate and in vitro isolated GPI assays for pharmacological characterization [298]. The OR agonist activity of the $N^{17}$-methyl derivatives (morphine (**1a**), isomorphine (**1b**), dihydromorphine (**35**) and dihydroisomorphine (**82**)) was determined by mouse hot-plate, rat hot-plate and rat tail-flick tests, in comparison with morphine (**1a**). The antinociceptive actions of the C-6α and C-6β derivatives did not differ significantly, having relative potencies 0.6–1.9-fold that of morphine (**1a**). In the isolated electrically stimulated GPI preparation, isomorphine (**1b**) was twice as potent as morphine (**1a**), but dihydroisomorphine (**82**) showed a potency only 1.18-fold that of dihydromorphine (**35**) relative to normorphine. The potencies relative to normorphine were in the range of 1.1–4.4. The epimerization of C-6α to C-6β derivatives had only slight effects on OR activities in vitro but influenced the antagonistic effect of

the $N^{17}$-cyclopropylmethyl and $N^{17}$-allyl compounds. $N^{17}$-Allyl-dihydronorisomorphine (AD$_{50}$ = 4.0 mg/kg, (s.c) (3.2–7.3), showed a 10-fold increase in antagonist potency compared to the parent $N^{17}$-allyl-normorphine (**260i**, 0.48 (0.4–0.57)) in the rat tail-flick test vs. morphine.



**260**
**a**: R$_1$ = CH$_3$, R$_2$ = CH$_3$ = **2a**
**b**: R$_1$ = CH$_3$, R$_2$ = *n*Pr
**c**: R$_1$ = CH$_3$, R$_2$ = allyl
**d**: R$_1$ = C$_2$H$_5$, R$_2$ = CH$_3$
**e**: R$_1$ = Bn, R$_2$ = CH$_3$
**f**: R$_1$ = (CH$_2$)$_2$NC$_4$H$_8$O, R$_2$ = CH$_3$
**g**: R$_1$ = Ac, CH$_3$ = **55**
**h**: R$_1$ = Ac, R$_2$ = *n*Pr
**i**: R$_1$ = Ac, R$_2$ = allyl
**j**: R$_1$ = Ac, R$_2$ = CPM

**261**
**a**: R$_1$ = CH$_3$, R$_2$ = CH$_3$
**b**: R$_1$ = CH$_3$, R$_2$ = *n*Pr
**c**: R$_1$ = CH$_3$, R$_2$ = allyl
**d**: R$_1$ = C$_2$H$_5$, R$_2$ = CH$_3$
**e**: R$_1$ = Bn, R$_2$ = CH$_3$
**f**: R$_1$ = (CH$_2$)$_2$NC$_4$H$_8$O, R$_2$ = CH$_3$
**g**: R$_1$ = Ac, CH$_3$
**h**: R$_1$ = Ac, R$_2$ = *n*Pr
**i**: R$_1$ = Ac, R$_2$ = allyl
**j**: R$_1$ = Ac, R$_2$ = CPM

**262**
**a**: R$_1$ = CH$_3$, R$_2$ = CH$_3$ = **2b**
**b**: R$_1$ = CH$_3$, R$_2$ = *n*Pr
**c**: R$_1$ = CH$_3$, R$_2$ = allyl
**d**: R$_1$ = C$_2$H$_5$, R$_2$ = CH$_3$
**e**: R$_1$ = Bn, R$_2$ = CH$_3$
**f**: R$_1$ = (CH$_2$)$_2$NC$_4$H$_8$O, R$_2$ = CH$_3$
**g**: R$_1$ = H, CH$_3$ = **1b**
**h**: R$_1$ = H, R$_2$ = *n*Pr
**i**: R$_1$ = H, R$_2$ = allyl
**j**: R$_1$ = H, R$_2$ = CPM

**Figure 62.** Synthesis of isocodeine and isomorphine derivatives via Mitsunobu reaction. *Reagents and conditions*: (i): 2 equiv. benzoic acid, 2 equiv. DEAD, 2 equiv. TPP, benzene, room temperature, 1 h, 29–75%; (ii): 10% KOH (aq.), ethanol, reflux, 10 min, 29–100%.

### 2.11.3. Reactions of Codeine Isomers and Neopine

In the previously presented experiments, the starting secondary alcohols carried the hydroxyl group at position 6α- of the C-ring of the morphinan skeleton. In 1993, Simon [296] investigated the Mitsunobu reaction of codeine isomers (isocodeine (**2b**), allopseudocodeine (**2c**) and pseudocodeine (**2d**)) with various pronucleophiles (H-Nu compounds) by the application of diethyl azodicarboxylate (DEAD) and triphenylphosphine (TPP). These reactions were performed under exactly the same conditions as those described above for 6α-hydroxyl derivatives [297].

Upon subjecting isocodeine (**2b**, 6β-OH, Figure 63) to the Mitsunobu reaction with benzoic acid or phthalimide, there was no conversion. A previous investigation of the nucleophile substitution reactions of isocodeine tosylate (**81**) by Makleit [115] found the formation of pseudocodeine derivatives due to allylic rearrangement. In the Mitsunobu reaction of pseudocodeine (**2d**, 8β-OH) with 4-nitrobenzoic acid or phthalimide, 6β-substituted derivatives (isocodeine series) were formed due to [3,3-sigmatropic] rearrangement. Presumably, the attack of the corresponding nucleophile from the α-side is sterically hindered in an S$_N$2-type reaction. Makleit, Somogyi and Bognár [129,130] had similar experiences during investigations of the nucleophile substitution reactions of pseudocodeine tosylate (**97**). They found the formation of 6-deoxy-6-substituted-isocodeines (**99**) or 8-deoxy-8-substituted-pseudocodeine derivatives (**98**), depending on the nature of the nucleophilic anion [129,130].

**Figure 63.** Reaction of isocodeine, allopseudocodeine, pseudocodeine and neopine with various reagents under Mitsunobu conditions. *Reagents and conditions*: (i): H-Nu = benzoic acid or phthalimide, DEAD, TPP; (ii): H-Nu = 4-NO$_2$-benzoic acid or phthalimide, DEAD, TPP; (iii): **A**: when H-Nu = benzoic acid or 4-NO$_2$-benzoic acid, DEAD, TPP, no reaction was observed, **B**: when H-Nu = phthalimide, DEAD, TPP, formation of 8β-phthalimido-derivative was observed; (iv): **A**: H-Nu = benzoic acid or phthalimide, DEAD, TPP; **B**: DEAD, TPP.

There was no observable reaction when allopseudocodeine (**2c**, 8α-OH) was treated with benzoic acid or 4-nitrobenzoic acid under Mitsunobu conditions [296]. Interestingly, when phthalimide was applied as pronucleophile, there was the formation of the 8β-phthalimido derivative (**98**, Nu = NPht, pseudocodeine series), a result corresponding to the Mitsunobu reaction mechanism (8α-hydroxyl (**2c**) → 8-phthalimido-pseudocodeine (**98**)). The authors proved the structure of the synthesized phthalimido compound (**98**) by NMR spectroscopy and by chemical reaction. The reaction of the 8β-phtalimido-compound (**98**, Nu = NPht) with hydrazine hydrate gave the same known 8β-amine (8-amino-pseudocodeine (**84**)) as that prepared earlier by Bognár and Makleit [117,118] via another route (codeine (**2a**) → codeine tosylate (**63a**) (or mesylate, **63b**) → 8-azidocodide (**83**) → 8-aminocodide (**84**)).

When neopine (**3a**) was chosen as a starting material, the replacement of the C-6α secondary alcohol using benzoic acid or phthalimide as a Mitsunobu pronucleophile failed [296], although in both cases, there was 6-demethoxythebaine (**105**) present in the product mixture. Likewise, when the reaction was performed in the absence of the pronucleophile (H-Nu), only the presence of the elimination product, 6-demethoxythebaine (**105**), could be detected. In the neopine (**3a**) molecule, the 6α-hydroxyl group occupies a position pseudo-axial to the 7β-proton, which represents a favorable steric condition for elimination. The elimination reactions of 6-*O*-mesyl-neopine (**100**) derivatives are well known from the literature [143,144,152,153,299].

### 2.11.4. Synthesis of 6β-aminomorphinans

The conversion of codeine 6-sulfonesters (**63a**, **63b**) to 6β-halo-substituted derivatives by nucleophilic substitution (S$_N$2) was achievable only for F$^\ominus$ and Cl$^\ominus$ anions [110–114]. The reaction of the sulfonesters with Br$^\ominus$ or I$^\ominus$ nucleophiles occurred via a complex mechanism (S$_N$2 + S$_N$i'), resulting in 8β-substituted products due to a [3,3] sigmatropic rearrangement.

We note that for the same reasons, the application of the $N_3^{\ominus}$ nucleophile and the subsequent reduction of the formed azide gave 8β-amino derivatives. Morphinan-6-ones were employed earlier for the production of 6-amino-4,5-epoxymorphinans via reductive amination, which resulted in 6α/6β-amino epimer mixtures [300–302]. The Makleit research group developed a stereoselective method for the preparation of 6β-aminomorphinans [303]. In 1992, they extended their investigations [303] to the synthesis of numerous $N^{17}$-substituted-6β-aminocodeine (**266a–d**) and $N^{17}$-substituted-6β-aminomorphine (**266e–h**, Figure 64) derivatives. The carefully selected starting morphinan derivatives (**263a–h**) all contained a $\Delta^{7,8}$ double bond in ring-C. By the treatment of codeine (**2a**), $N^{17}$-substituted-codeine (**263b–d**), 3-*O*-acetylmorphine (**55**) and 3-*O*-acetyl-$N^{17}$-substituted-morphine (**263f–h**) derivatives with phthalimide under Mitsunobu conditions (DEAD, TPP, benzene), the corresponding 6β-phthalimido-codeines (**264a–d**) (68–92%) and 6β-phthalimido-3-*O*-acetylmorphines (**264e–h**) (39–56%) were formed with an inversion of the configuration. Side reactions, e.g., allylic shifts, were not expected. 6β-Phthalimido-morphines (**265a–d**) were prepared by the 3-*O*-deacetylation of the compounds **264e–h** with hydroxylamine hydrochloride in aqueous ethanol (50 °C, 10 min). The 6β-phthalimido compounds (**264a–h**) were subjected to hydrazinolysis (see also Gabriel synthesis) to give the primary amine 6β-amino derivatives (**266a–h**) in 50–98% yield. For the preparation of 6β-amino-7,8-dihydro derivatives (**267a–f**), the selected $\Delta^{7,8}$ compounds (**266a,b,d,e,f,h**) were saturated under heterogenous catalytic conditions (H$_2$, 10% Pd-C, EtOH). 6β-Amino-dihydrocodeines (**267a–c**) and 6β-amino-dihydromorphines (**267d–f**) were obtained in 37–75% yield.

The Makleit group [304] accomplished the Mitsunobu reaction of $N^{17}$-demethyl-$N^{17}$-substituted-14-hydroxycodeines (**268a–d**, CH$_3$, *n*Pr, allyl, cyclopropylmethyl) as well as $N^{17}$-demethyl-$N^{17}$-substituted-3-*O*-acetyl-14-hydroxymorphines (**268e–h**, Figure 65) with phthalimide.

The 6β-phthalimido derivatives (**269a–h**) were prepared with yields in the range of 20–65%, without any observed allyl-migration. The treatment of these compounds with hydrazine hydrate in ethanol yielded 6β-amino-14-hydroxycodeine (**271a–d**) and 14-hydroxymorphine (**271e–h**) derivatives. Most of these 6β-amino derivatives were previously unavailable via the sulfonate ester → azide → amine route [54,55] or by the reductive amination of morphinan-6-ones [300,301].

Continuing their systematic investigations, the Makleit group extended the epimerization studies to compounds saturated in ring-C (7,8-dihydro compounds): dihydromorphines, dihydrocodeines and their 14-hydroxy analogs [305]. When benzoic acid was applied as a pronucleophile in the Mitsunobu reaction of dihydrocodeine (**67**), there was incomplete conversion. Interestingly, by the application of *p*-nitrobenzoic acid instead, the corresponding dihydroisocodeine *p*-nitrobenzoate was isolated in a yield of 90%. Accordingly, 14-hydroxydihydrocodeine (**68**) and $N^{17}$-substituted-14-hydroxydihydrocodeine derivatives (**273b–c**, Figure 66) were reacted under Mitsunobu conditions (TPP, DEAD) with 4-nitrobenzoic acid in anhydrous benzene to yield the corresponding *p*-nitrobenzoic esters (**274a–h**). Ester cleavage of these compounds was performed by alkaline hydrolysis, giving the desired 6β epimers (**275a–h**) with yields in the range of 37–90%. In this manner, the authors achieved a new stereoselective synthesis of the human metabolites of naloxone (β-naloxol (**275g**)) and naltrexone (**199**, β-naltrexol (**275h**)).

**Figure 64.** Synthesis of $N^{17}$-substituted-6β-aminocodeine and 6β-aminomorphine derivatives. *Reagents and conditions*: (i): 2 equiv. phthalimide, 2 equiv. DEAD, 2 equiv. TPP, benzene, 39–92%; (ii): hydroxylamine hydrochloride, $H_2O$, EtOH, 50 °C, 10 min; 35–79%; (iii): 98% hydrazine hydrate, EtOH, 50–98%; (iv): $H_2$, 10% Pd-C, EtOH, 1 Bar.



**Figure 65.** Synthesis of $N^{17}$-substituted-6β-amino-14-hydroxycodeine and 6β-amino-14-hydroxymorphine derivatives. *Reagents and conditions*: (i): 2 equiv. phthalimide, 2 equiv. DEAD, 2 equiv. TPP, anhydrous benzene, RT, 1 h, 30–65%; (ii): hydroxylamine hydrochloride, $H_2O$, EtOH, 50 °C, 10 min; 20–74%; (iii): 98% hydrazine hydrate, EtOH, 10–90%; (iv): $H_2$, 10% Pd-C, EtOH, 1 Bar.

273–274
**a**: $R_1$ = $CH_3$, $R_2$ = $CH_3$
**b**: $R_1$ = $CH_3$, $R_2$ = $n$Pr
**c**: $R_1$ = $CH_3$, $R_2$ = allyl
**d**: $R_1$ = $CH_3$, $R_2$ = CPM
**e**: $R_1$ = Ac, $R_2$ = $CH_3$
**f**: $R_1$ = Ac, $R_2$ = $n$Pr
**g**: $R_1$ = Ac, allyl
**h**: $R_1$ = Ac, $R_2$ = CPM

275
**a**: $R_1$ = $CH_3$, $R_2$ = $CH_3$
**b**: $R_1$ = $CH_3$, $R_2$ = $n$Pr
**c**: $R_1$ = $CH_3$, $R_2$ = allyl
**d**: $R_1$ = $CH_3$, $R_2$ = CPM
**e**: $R_1$ = H, $R_2$ = $CH_3$
**f**: $R_1$ = H, $R_2$ = $n$Pr
**g**: $R_1$ = H, allyl
**h**: $R_1$ = H, $R_2$ = CPM

**Figure 66.** Synthesis of 14-hydroxydihydroisocodeine and 14-hydroxyisomorphine derivatives. *Reagents and conditions*: (i): 2 equiv. 4-nitrobenzoic acid, 2 equiv. TPP, 2 equiv. DEAD, anhydrous benzene, RT, 1 h, 33–79%; (ii): 10% KOH aqueous solution, EtOH, reflux, 10 min, 37–90%.

In a second series of experiments [305], dihydrocodeine- (**67**), 3-*O*-acetyldihydromorphine-(**54**), 14-hydroxydihydrocodeine-(**68**, **276b–d**, X = OH) and 3-*O*-acetyl-14-hydroxydihydromorphine derivatives (**276e–h**, X = OH, Figure 67) were treated with phthalimide in benzene in the presence of triphenylphosphine and diethyl azodicarboxylate (DEAD) to yield the corresponding 6β-phthalimido compounds (**277a–h**). For the hydrolysis of the phenol esters (**277e–h**), the researchers used hydroxylamine hydrochloride in aqueous ethanol, giving the corresponding 6β-phthalimido-14-hydroxydihydomorphine derivatives (**278a–d**) with a free phenolic hydroxyl group in 58–70% yield. The treatment of the 6β-phthalimido derivatives (**277a–h**) with hydrazine hydrate led stereoselectively to the 6β-amino compounds (**279a–h**) in 51–90% yield. At the time, these investigations of stereoselective syntheses of 6β-oxymorphamine (**279e**, $R_2$ = $CH_3$), 6β-naloxamine (**279g**, $R_2$ = allyl) and 6β-naltrexamine (**279h**, $R_2$ = cyclopropylmethyl) were considered novel. Szilágyi et al. presented a detailed NMR analysis of the prepared new compounds [306], and Fürst et al. subsequently undertook their pharmacological characterization [298,307].



276–277
**a**: $R_1$ = $CH_3$, $R_2$ = $CH_3$
**b**: $R_1$ = $CH_3$, $R_2$ = $n$Pr
**c**: $R_1$ = $CH_3$, $R_2$ = allyl
**d**: $R_1$ = $CH_3$, $R_2$ = CPM
**e**: $R_1$ = Ac, $R_2$ = $CH_3$
**f**: $R_1$ = Ac, $R_2$ = $n$Pr
**g**: $R_1$ = Ac, allyl
**h**: $R_1$ = Ac, $R_2$ = CPM

278
**a**: $R_2$ = $CH_3$
**b**: $R_2$ = $n$Pr
**c**: $R_2$ = allyl
**d**: $R_2$ = CPM

279
**a**: $R_1$ = $CH_3$, $R_2$ = $CH_3$
**b**: $R_1$ = $CH_3$, $R_2$ = $n$Pr
**c**: $R_1$ = $CH_3$, $R_2$ = allyl
**d**: $R_1$ = $CH_3$, $R_2$ = CPM
**e**: $R_1$ = H, $R_2$ = $CH_3$
**f**: $R_1$ = H, $R_2$ = $n$Pr
**g**: $R_1$ = H, allyl
**h**: $R_1$ = H, $R_2$ = CPM

**Figure 67.** Synthesis of $N^{17}$-substituted-6β-amino-14-hydroxydihydrocodeine and 6β-amino-14-hydroxydihydromorphine derivatives. *Reagents and conditions*: (i): 2 equiv. phthalimide, 2 equiv. DEAD, 2 equiv. TPP, anhydrous benzene, RT, 1 h, 33–90%; (ii): hydroxylamine hydrochloride, $H_2O$, EtOH, 50 °C, 10 min; 25–70%; (iii): 98% hydrazine hydrate, EtOH, 35–98%.

### 2.11.5. Synthesis of 6β-Succinimido Derivatives

Upon reacting codeine (**2a**) with the succinimide pronucleophile (HSu) [303] under identical Mitsunobu conditions to those described above (DEAD, TPP, benzene), 6β-succinimido-codeine (**280a**, Figure 68) was obtained in 80% yield. In the case of 3-*O*-acetylmorphine (**55**), only the isolation of the deacetylated 6β-succinimido-morphine (**281b**) was feasible. The saturation of the $\Delta^{7,8}$ double bond under heterogenous catalytic conditions (H$_2$, 10% Pd-C, RT, atmospheric pressure) was only achievable for 6β-succinimido derivatives (**280a**, 73%, **280b**, 55%). In the case of the appropriate 6β-phthalimido compounds (**264a–h**), the reduction of the $\Delta^{7,8}$ double bond was not realizable under atmospheric pressure.



**Figure 68.** Synthesis of 6β-succinimido codeine and morphine derivatives. Reagents and conditions: (i): 2 equiv. succinimide, 2 equiv. DEAD, 2 equiv. TPP, benzene; (ii): H$_2$, 10% Pd-C, EtOH, atmospheric pressure.

### 2.11.6. Reaction of 14-Halogenocodeines

14-Halogenocodeines (**282a–b**, Figure 69) contain both an allyl alcohol (C$^8$=C$^7$-C$^6$-OH) and allyl halide (C$^7$=C$^8$-C$^{14}$-X) sub-structural unit within the same molecule. Thebaine (**4**) reacted with *N*-halosuccinimides (NCS, NBS) in acetic acid or acetone–water (2:1 (*v/v*)) gave 14-halocodeinones [155].

The reduction of codeinone derivatives (e.g., codeinone (**24**), 14-hydroxycodeinone (**132**), 1-bromocodeinone and 14-bromocodeinone (**109**)) with sodium borohydride led stereoselectively to the corresponding codeines (e.g., **282a–b**, 6α-hydroxy compounds). 14-Chlorocodeine (**282a**) [138,139] and 14-bromocodeine (**282b**) [155] are useful starting materials for the synthesis of neopine derivatives. The reduction of neopinone (**23**) with NaBH$_4$ results in a mixture of neopine (**3a**) and isoneopine (**3b**). Okuda et al. [160,308] found that the NaBH$_4$ reduction of 14-bromocodeinone (**109**) in methanol–water gave three isolated products: the main product neopine (**3a**, 46%), isoneopine (**3b**, 6%) and indolinocodeine (28%).

**Figure 69.** Mitsunobu reaction of 14-halogenocodeines with phthalimide and diphenylphosphoryl azide. *Reagents and conditions*: (i): phthalimide, DEAD, TPP, benzene, RT, 1 h; (ii): *N,N*-dimethylformamide, 100 °C, 1 h, [155]; (iii): methyl vinyl ketone, reflux, 1 h; (iv): DPPA, DEAD or DIAD, TPP; (v): DEAD, TPP, benzene, RT, 1 h, 70%.

In 1993, Simon et al. [309] investigated the Mitsunobu reaction of 14-halogenocodeines (**282a–b**, Figure 69) with phthalimide as a pronucleophile in the presence of triphenylphosphine (TPP) and dialkyl azodicarboxylates (DEAD or DIAD) or diphenyl azidophosphate (DPPA). The reaction of 14-chlorocodeine (**282a**) with phthalimide (TPP, DEAD, benzene) resulted in three products. The main product, a $\Delta^{6,8}$-conjugated diene (**285a**) containing a hydrazine dicarboxylic diethyl ester substituent in position-6, was obtained in 36% yield. Further products, namely 6β-phthalimido-14-chloro-6-deoxycodeine (**283**, 12%) formed by inversion and 6β,14-dichloro-6-deoxycodeine (**284a**, 13%), were isolated by column chromatography in a ratio of about 1:1. Interestingly, when 14-bromocodeine (**282b**) was reacted with phthalimide under identical conditions (TPP, DEAD, benzene, RT, 1 h), there was no observed formation of a 6β-phthalimido derivative, presumably due to steric hindrance by the bulky 14-bromo substituent. In this case, the main product was the thebaine analog (**285a**, 34%), followed by 6β,14-dibromo-6-deoxycodeine (**284b**, X = Br, 25%). To prove the structure of the $\Delta^{6,8}$-diene (**285a**) with the hydrazine dicarboxylic diethyl ester substituent in position-6, it was boiled with methyl vinyl ketone to yield the corresponding DA adduct thevinone analog (**286a**). In a second approach, 14-halogenocodeines (**282a–b**) were reacted under the above-mentioned conditions (TPP, DEAD) in the absence of a pronucleophile (H-Nu). The formation of 6β,14-dichloro-6-deoxycodeine (**284a**, 32%) and 6β,14-dibromo-6-deoxycodeine (**284b**, 25%) as well the $\Delta^{6,8}$-diene (**285a**; 32%, from **282a** and 25% from **282b**, respectively) was observed. The authors [309] proved the structure of 6β,14-dihalo-6-deoxycodeines (**284a–b**) by spectroscopy and chemical reactions. When these derivatives (**284a–b**) were allowed to react in *N,N*-dimethylformamide in the absence of a nucleophile [159], the same 6-halogeno-6-demethoxythebaine (**118a–**

**b**) derivatives were obtained as had been prepared earlier in the nucleophilic substitution reaction of 14-chlorocodeine tosylate (**119a**) with Cl$^\ominus$ and Br$^\ominus$ ions, respectively (see Section 2.8.6) [156,158]. The formation of the 6β,14-dihalo-6-deoxycodeines (**284a–b**) and Δ$^{6,8}$-dienes (**118a–b**) in this reaction was explained by the in situ liberation of hydrogen halides (HCl, HBr), which could then act as pronucleophiles in the Mitsunobu reaction. To substantiate the presence of the in situ-generated H-Nu compound, the hydrochloride salt of codeine (**2a**) was allowed to react under Mitsunobu conditions (TPP, DEAD), which gave α-chlorocodide (**59b**, Figure 69) in 70% yield. In another approach, 14-halogenocodeines (**282a–b**) were reacted with diphenylphosphorylazide (DPPA) under Mitsunobu conditions, giving the 6β-azido-14-halogeno-6-deoxycodeine derivatives (**287a**, X = Cl, 37%, **287b**, X = Br, 25%).

The reaction of morphine (**1a**) or codeine (**2a**) with thionyl chloride resulted in α-chloromorphide (**288a**) and α-chlorocodide (**59b**), respectively [110]. Notably, the reactions of codeine (**2a**) with thionyl bromide [110] or codeine tosylate (**63a**) with lithium bromide [110] both resulted in β-bromocodide (**65b**, Figure 17), the product of thermodynamic control. When hydrogen halide salts (hydrochloride or hydrobromide) of codeine (**2a**) or morphine (**1a**) were allowed to react under Mitsunobu conditions (DEAD, TPP, toluene) in the absence of other nucleophiles [310], 6β-halogen-substituted derivatives were isolated (e.g., from codeine hydrochloride → α-chlorocodide (**59b**), from codeine hydrobromide → α-bromocodide (**288c**), Figure 70). The importance of the above-mentioned results of Simon et al. [310] have to be emphasized, as this was the first isolation of α-bromocodide (**288c**), the product of kinetic control. Analog reactions starting from the hydrogen halide (HCl, HBr) salts of 14-hydroxy derivatives (14-hydroxycodeine (**66**), 14-hydroxymorphine (**289a**), 14-hydroxydihydrocodeine (**68**) and 14-hydroxydihydromorphine (**289b**)) led to the corresponding 6β-halogen (Cl, Br)-substituted compounds (**290a–d**). The reactions of Δ$^{7,8}$ unsaturated derivatives (**1a**, **2a**, **66**, **289a**) were complete within 1 h, but the conversion proceeded much slower (3–4 h) in the 7,8-dihydro series (**68**, **289b**).



**1a**: R = H, morphine
**2a**: R = CH$_3$, codeine

X = Cl, Br

**288a**: R = H, X = Cl, α-chloromorphide
**288b**: R = H, X = Br, α-bromomorphide
**59b**: R = CH$_3$, X = Cl, α-chlorocodide
**288c**: R = CH$_3$, X = Br, α-bromocodide

**289a–b**

**289a**: R = H, 7,8: CH=CH
**289b**: R = H, 7,8: CH=CH
**66**: R = CH$_3$, 7,8: CH$_2$-CH$_2$
**68**: R = CH$_3$, 7,8: CH$_2$-CH$_2$

**290a–d**

**290a**: R = H, 7,8: CH=CH
**290b**: R = H, 7,8: CH=CH
**290c**: R = CH$_3$, 7,8: CH$_2$-CH$_2$
**290d**: R = CH$_3$, 7,8: CH$_2$-CH$_2$

**Figure 70.** Reaction of the hydrogen halide salts of morphinans under Mitsunobu conditions. *Reagents and conditions*: (i): DEAD or DIAD, TPP, toluene or benzene, room temperature, 1–4 h.

### 2.11.7. Novel Applications

In this section, we present a few novel examples highlighting potential applications of Mitsunobu reactions in the field of semisynthetic morphinans, as informed by the results of the Makleit group in the 1990s. In 2014, Fujimura et al. [311] reported the pharmacological characteristics of the OR ligand TRK-130 (**278d**, naltalimide, *N*-[(5*R*,6*R*,14*S*)-17-cyclopropylmethyl-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]phthalimide, Figure 71). The compound TRK-130 (**278d**) proved to be a selective partial μOR agonist (K$_i$ for μOR = 0.268, δOR = 121 and κOR = 8.97 nM, respectively, δ/μ = 451, κ/μ = 33.5) [311] in radioligand-binding assays with human ORs. Naltalimide (**278d**) is used as a prophylactic agent against urinary incontinence, i.e., overactive bladder (OAB) [311]. The synthesis of naltalimide (**278d**) was achieved by the Simon et al. method [305] from 3-*O*-acetyl-*N*$^{17}$-cyclopropylmethyl-14-hydroxydihydromorphine (3-*O*-acetyl-α-naltrexol, **276h**, route: **276h** → **277h** → **278d**, X = OH, see also Figure 68) in a Mitsunobu reaction with phthalimide. Izumimoto et al. [312] developed an alternative synthesis route for naltalimide (**278d**) and its *N*$^{17}$-allyl analog (**278c**) from β-naltrexamine (**279h**) [305] and β-naloxamine (**279g**) [305], respectively. The corresponding 6β-amine (**279g**–**h**) was reacted with phthalic anhydride in DMF in the presence of triethylamine at 140 °C [312] to yield the 6β-phthalimido derivatives (**278c**–**d**) with yields of 34–58%.



**Figure 71.** Synthesis of naltalimide. *Reagents and conditions*: (i): 2 equiv. phthalimide, 2 equiv. DEAD, 2 equiv. TPP, anhydrous benzene, RT, 1 h; (ii): hydroxylamine hydrochloride, H$_2$O, EtOH, 50 °C, 10 min; (iii): 98% hydrazine hydrate, EtOH; (iv): phthalic anhydride, Et$_3$N, DMF; 140 °C, 4h.

To potentially treat substance dependence, the research group of Kenner C. Rice developed heroin vaccine haptens [313,314] (Heroin Hapten (MorHap, **291**, Figure 72)). One of the chosen hapten scaffolds was 6β-amino-6-desoxymorphine (**266e**). For its preparation, they applied the method described earlier by the Makleit group [303]. In brief, they selectively acetylated morphine to 3-*O*-acetylmorphine (**55**) by the Welsh method [99]. They treated this product with phthalimide under Mitsunobu conditions (TPP, DIAD, toluene, RT, 2 h) to yield 6β-phtalimido-3-*O*-acetylmorphine (**264e**, 88%). The stereochemistry of the phthalimido derivative (**264e**) was substantiated by X-ray crystallographic analysis. The cleavage of the phthalimido protecting group with hydrazine hydrate in ethanol (55 °C, 90min) led to 6β-amino-6-desoxymorphine (**266e**) in 81% yield. Subsequently, the free 6β-amine was acylated with the activated ester 2,5-dioxopyrrolidin-1-yl 3-(tritylthio)propanoate to the desired hapten (**291**, MorHap). Finally, the hapten (**291**, MorHap) was conjugated to the

carrier protein (tetanus toxoid (TT) or cross-reactive material 197 (CRM$_{197}$)). Antibodies formed due to the immunization effect of the TT-MorHap conjugate led to nearly complete protection against heroin dependence in mouse experiments.



**Figure 72.** Synthesis of heroin vaccine hapten (MorHap) from 6β-amino-desoxymorphine. *Reagents and conditions*: (i): phthalimide, DIAD, TPP, toluene, room temperature, 2 h, 88%; (ii): hydrazine hydrate, 95% EtOH, 55 °C, 90 min, 81%; (iii): 1.5 equiv. 2,5-dioxopyrrolidin-1-yl 3-(tritylthio)propanoate, CH$_2$Cl$_2$, 2 equiv. Et$_3$N, room temperature 48 h, 55%.

Scammels et al. [315] prepared fluorescently labeled morphinan-sulfo-Cy5 conjugates for the visualization of ORs in living cells. For these bioimaging investigations, they developed a fluorescent partial OR agonist ligand. For the synthesis of C-6 amide pre-congeners, first, 3-*O*-(4-methoxybenzyl)-6-amino-6-desoxymorphine (**296**, Figure 73) was synthesized from morphine (**1a**) in five steps. The phenolic hydroxyl group of **1a** was protected as PMB (*p*-methoxy-benzyl) ether. Next, 3-*O*-PMB-morphine (**292**) was reacted with benzoic acid under Mitsunobu conditions (DIAD, TPP, toluene) to form the benzoate ester (**293**). The latter compound (**293**) was converted into the 3-*O*-PMB-isomorphine (**294**) by saponification with 1M potassium hydroxide in aqueous ethanol solution. The 6-beta-hydroxyl function of **294** was transformed to a 6α-amino group via a second Mitsunobu reaction and subsequent phthalimide cleavage. 3-*O*-PMB-isomorphine (**294**) was reacted with phthalimide (DIAD, TPP, toluene) to give 6α-phthalimido-3-*O*-PMB-morphine (**295**). The treatment of this latter compound with hydrazine hydrate in ethanol resulted in 3-*O*-PMB-6-amino-6-desoxymorphine (**296**).



**Figure 73.** Precursors for the synthesis of fluorescently labeled morphinan-sulfo-Cy5 conjugates. *Reagents and conditions*: (i): PMB-Cl, 3M KOH, DMF, MeOH, room temperature, 4 h, 46%; (ii): 1.5 equiv. benzoic acid, 1.5 equiv. DIAD, 1.5 equiv. TPP, toluene, 0 °C to room temperature, 4 h; (iii): 1M potassium hydroxide, EtOH, H$_2$O, reflux, 20 min, 78% (ii + iii); (iv): 1.5 equiv. phthalimide, 1.5 equiv. DIAD, 1.5 equiv. TPP, toluene, 0 °C to room temperature, 4 h; (v): hydrazine hydrate, EtOH, reflux, 1 h, 34% (iv + v).

In 1998, the research group of Nagase [316] developed nalfurafine (**300**, TRK-820, 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6β-[*N*-methyl-*trans*-3-(3-furyl)-acrylamido]morphinan, Remith®®, Figure 74), a 4,5-epoxymorphinan-type OR ligand. TRK-820 (**300**) was a selective, very-high-affinity agonist for κ-ORs, and a partial agonist for μ-ORs and δ-ORs (K$_i$ (κ-OR) = 75 pM, K$_i$ (μ-OR) = 5.2 nM, K$_i$ (δ-OR) = 161 nM, μ/κ = 69.3, δ/κ = 2146) [317]. TRK-820 (**300**) is an approved pharmaceutical for the treatment of hemodialysis-related uremic pruritus and for patients with chronic liver diseases. Nalfurafine (**300**) was prepared from naltrexone (**199**) via *N*-methyl-β-naltrexamide (**298**). The secondary amine (**298**) was acylated with 3-(3-furyl)acryloylchloride (**299**) to yield **300**. Recently, Suzuki et al. [318] synthesized nalfurafine (**300**) and its 10α-hydroxy analogs from 3-*O*-acetyl-α-naltrexol (**276h**) via a modified synthesis route by the application of the Mitsunobu reaction.



**Figure 74.** Synthesis of nalfurafine (TRK-820) a selective κ-opioid receptor agonist. *Reagents and conditions*: (i): **A**. *N*-benzylmethylamine, benzoic acid, benzene, 110 °C, 8 h, **B**. NaBH$_3$CN, room temperature, 2 h; (ii): H$_2$, 10% Pd-C, EtOH, atmospheric pressure, room temperature, 24 h; (iii): (*E*)-3-(3-furyl)acrylic acid (**299**), Et$_3$N, DMF, CH$_2$Cl$_2$, room temperature, 16 h.

In the previous decade, 6β-acylaminomorphinans [319] and 6β-pyridinyl amidomorphinans were synthesized [320] starting with precursors arising from earlier work by the Makleit group [303].

## 2.12. Poppy Alkaloids as Starting Materials for Molecular Imaging

Molecular imaging by positron emission tomography (PET) or single-photon emission computed tomography (SPECT) enables the detection of one or more sub-types of ORs in healthy brains and in pathologies involving opioid neurotransmission [35,321–323]. OR PET radiochemistry development has benefited from the foundational work on opioid chemistry described above, which presented important lead compounds for radiolabeling. As with the lead compounds, some classes of OR PET ligands have incomplete sub-type selectivity and differ with respect to their agonist–antagonist binding profile. Furthermore, the extreme potency of some opioid agonists calls for particular attention to the molar activity of OR agonist tracers.

OR PET imaging began with development of the μ-OR-selective agonist 4-anilidopiperidine derivative carfentanil ([$^{11}$C]caf) [324] and the μ/κ OR-selective antagonist morphinan foxy ([$^{18}$F]**204a**, [$^{18}$F]foxy) and cyclofoxy derivatives ([$^{18}$F]**203a**, acetyl-[$^{18}$F]cyclofoxy; [$^{18}$F]**204c**, [$^{18}$F]cyclofoxy ([$^{18}$F]FcyF); [$^{11}$C]**204c**, [$^{11}$C]cyclofoxy ([$^{11}$C]cyF)) [243–248] (Figure 75). The synthesis of the [$^{18}$F]foxy and [$^{18}$F]cyclofoxy derivatives starts from the poppy alkaloid thebaine (**4**) [325] and proceeds with conversion to 14-hydroxycodeinone and the further synthetic manipulation of the C-ring to introduce the 6β-fluoro group by nucleophilic substitution [244] (see Figure 52).

**Figure 75.** Structures of selected labeled morphinan derivatives.

Following the synthesis of the δ-OR-selective antagonist *N*1'-([11C]methyl)naltrindole ([11C]MeNTI, (K$_i$ (μ) = 14 nM, K$_i$ (δ) = 0.02 nM, K$_i$ (κ) = 65 nM) [326], and *N*1'-(2-[18F]fluoroethyl)naltrindole ([18F]FE-NTI, BU97001, affinities) was prepared [327].

Researchers have developed a range of 11C- and 18F-labeled cyclofoxy derivatives (Figure 75), namely [11C]cyclofoxy ([11C]cyF [247]), [18F]foxy [243], [18F]acetylcyclofoxy [245,246] and [18F]cyclofoxy ([18F]FcyF) [243,248]. Among these, the μOR/κOR antagonist [18F]FcyF has served in a study of OR availability in methadone-treated former opioid addicts [248], revealing lower OR availability in the striatum as compared to healthy volunteers, in measurements of occupancy by methadone.

Notably, Pasternak et al. reported on the synthesis of radioiodinated iodobenzoyl derivatives of **279e**, **279g** and **279h**, 6β-oxymorphamine ([125I-BOxyA), 6β-naloxamine ([125IBNalA) and 6β-naltrexamine ([125IBNtxA) in 2011 [328], with potential application for SPECT imaging.

6,14-Ethenomorphinans (orvinols/Bentley compounds) [57,280,329] are ring-C bridged semisynthetic derivatives of the poppy alkaloid thebaine [325] and/or oripavine [330–332]. Their radiolabeled derivatives are the most frequently used tracers for OR molecular imaging,

e.g., the nonselective OR antagonist ^{11}C-diprenorphine ([^{11}C]DPN, **301a**, (K$_i$ (μ) = 0.07 nM, K$_i$ (δ) = 0.23 nM, K$_i$ (κ) = 0.02 nM, Figure 75) [333,334] and the partial μOR agonist and kappa antagonist ^{11}C-buprenorphine ([^{11}C]BPN, **301b**) [334,335] (K$_i$ (μ) = 1.5 nM, K$_i$ (δ) = 6.1 nM, K$_i$ (κ) = 2.5 nM, K$_i$ (NOP) = 77.4).

Following the development of the agonist ligand ^{11}C-phenethyl-orvinol (**302a**, [^{11}C]PEO) (K$_i$ (μ) = 0.18 nM, K$_i$ (δ) = 5.1 nM, K$_i$ (κ) = 0.12 nM) [336], Schoultz et al. reported its ^{18}F-fluorine-labeled version, ^{18}F-phenethyl-orvinol (**302b**, [^{18}F]FE-PEO, (K$_i$ (μ) = 0.10 nM, K$_i$ (δ) = 0.49 nM, K$_i$ (κ) = 0.08 nM) [337–339]. In 2000, Wester et al. reported the radiosynthesis of the antagonist ligand 6-*O*-(2-[^{18}F]fluoroethyl)-6-*O*-desmethyl-diprenorphine ([^{18}F]FE-DPN, **301c**, K$_i$ (μ) = 0.24 nM, K$_i$ (δ) = 8.00 nM, K$_i$ (κ) = 0.20 nM, Figure 75) [340] thorough an indirect [^{18}F]fluoroethylation procedure. Subsequently, Schoultz et al. [341] elaborated a more efficient method for the synthesis of [^{18}F]FE-DPN (**301c**) and [^{18}F]FEOTos, and they also extended their method to the radiosynthesis of 6-*O*-(2-[^{18}F]-fluoroethyl)-6-*O*-desmethyl-buprenorphine (**301d**, [^{18}F]FE-BPN, K$_i$ (μ) = 0.24 nM, K$_i$ (δ) = 2.10 nM, K$_i$ (κ) = 0.12 nM) [341]. More recently, Marton et al. [342] developed a novel precursor molecule, 6-*O*-(2-tosyloxyethyl)-6-*O*-desmethyl-3-*O*-trityl-diprenorphine (TE-TDDPN, «Henriksen precursor»), for the one-pot, two-step nucleophilic radiosynthesis of [^{18}F]FE-DPN ([^{18}F]**301c**). In 2023, the research group of Mikecz [343] optimized the radiosynthesis of [^{18}F]FE-DPN ([^{18}F]**301c**) from the new precursor. Despite its incomplete OR sub-type selectivity in vitro, 6-*O*-(2-fluoroethyl)-6-*O*-desmethyl-diprenorphine (FE-DPN, **301c**) preferentially binds to μ-ORs in living brains [344].

### *2.13. Other Semisynthetic Derivatives*

In the main sections of this review, we presented selected research topics from a huge body of work entailing more than five decades of scientific activity of the alkaloid research groups of the University of Debrecen and the Alkaloida Chemical Company. In this final section, we seek to highlight some additional important studies. The investigation of Horváth and Makleit [345,346] is noteworthy due to its importance in the field of the morphine total synthesis. The authors developed an efficient method for the conversion of 6-*O*-demethyl-salutaridine to salutaridine. In the early 1990s, the Makleit research group turned with great interest toward the Bentley compounds [221,280]. The main driving force was the finding of Lewis et al. [347] that buprenorphine, a 6,14-ethanomorphinan partial μOR agonist and κOR antagonist, serves as an alternative to methadone for the treatment of heroin/diamorphine dependence. Makleit et al. developed numerous novel synthesis routes for the efficient preparation of buprenorphine, diprenorphine and their $N^{17}$-substituted analogs [276,348–350]. Very recently, we provided an overview of their research in the field of C-ring bridged morphinans together with the Diels–Alder adducts of morphinan-6,8-dienes and their transformations dating back almost a century [57]. We cannot omit mentioning the investigations of Berényi, who established aporphine chemistry as a new direction for the Debrecen alkaloid research group. They expended enormous effort over the years in the synthesis of morphinan-6,8-dienes [57] and their rearrangements to potent dopaminergic aporphine derivatives [325,351]. We emphasize the efforts extending over many years of Hosztafi in methodological research for the *N*-demethylation of morphine alkaloids [352–355]. We also note the thorough investigations carried out by Seller et al. [356] for the refinement of poppy alkaloid extraction technology with the help of modern technical equipment and separation methods.

## 3. Summary and Conclusions

In considering the cause-and-effect relationships in the current opioid crisis [357–360], it is important to appreciate the enormous efforts in medicinal chemistry driven by the

dream of generations of scientists of finding the ideal analgesic with a reduced risk of dependence and overdose.

Here, the concept of biased pharmacology for several OR sub-types presents a model for obtaining therapeutic responses, with a lesser risk of dependence and side effects [51,52]. Comprehending the broad scope of this concerted search calls for consideration of the historical background of these investigations and its implications for the new generation of researchers and scholars.

In the present survey, we provide an overview of the organic chemical investigations of morphine alkaloids arising from a historical collaboration between Hungarian research groups in industry (Alkaloida Chemical Company) and academia (University of Debrecen), dating back to the 1950s. We emphasize the historical continuity of this endeavor, building continuously upon the pioneering work by Kabay, now recognized as having been one of the most important morphine alkaloid producers in the world [14]. The privatization of the Alkaloida Chemical Company following the political changes in Hungary in the 1990s brought to an abrupt end the five-decade-long close and fruitful collaboration between the Department of Organic Chemistry at the University of Debrecen and the Alkaloida Chemical Company in Tiszavasvári. Our review intends to enshrine and memorialize this exemplary history of industrial/academic collaboration. For list of abbreviations used in this survey and the members of the «University of Debrecen—Alkaloida» research team mentioned by name [361], see Supplementary Materials.

# References

1. Sertürner, F.W. Über das Morphium, eine neue salzfähige Grundlage, und die Mekonsäure, als Hauptbestandteile des Opiums. *Ann. Der Phys.* **1817**, *55*, 56–89.
2. Schmitz, R. Friedrich Wilhelm Sertürner and the Discovery of Morphine. *Pharm. Hist.* **1985**, *27*, 61–74.
3. Van Zee, A. The promotion and marketing of oxycontin: Commercial triumph, public health tragedy. *Am. J. Publ. Health* **2009**, *99*, 221–227. [CrossRef]
4. Kabay, J.J. *János Kabay, The Life of an Inventor*; National Library of Australia: Victoria, Australia, 1990; ISBN 0-646-01672-5.
5. Kabay, J.J. *Kabay János Magyar Feltaláló Élete*; Alkaloida Vegyészeti Gyár Részvénytársaság: Tiszavasvári, Hungary, 1992; ISBN 9-630-29978-x.
6. Hosztafi, S. Kabay János a magyar morfingyártás megalapítója. In *Kabay Jánosra Emlékezünk*; Évi Pályázat Díjnyertes Munkái; Galó, M., Ed.; Szabolcs-Szatmár-Bereg Megyei Tudományos Közalapítvány Kuratóriuma: Nyíregyháza, Hungary, 1996; Volume 8, pp. 27–53.
7. Hosztafi, S. János Kabay, the founder of morphine manufacture in Hungary. *Gyógyszerészet* **1997**, *41*, 25–37.
8. Móra, L.; Próder, I. *A Magyar Kémia és Vegyipar Kronológiája 1800–1950, Magyar Tudománytörténeti Intézet Tudományos Közleményei*; Gazda, I., Ed.; Magyar Tudománytörténeti Intézet: Budapest, Hungary, 2015; Volume 51, pp. 1–128.
9. Próder, I. Kabay János morfinelőállítási eljárása. *Magy. Kém. Lapja* **1998**, *53*, 169–172.
10. Kabay, J. Eljárás Ópiumalkaloidák Előállítására. Hungarian Patent 89,464, 1 May 1925.
11. Kabay, J. Eljárás Ópiumalkaloidák Előállítására. Hungarian Patent 109,788, 30 November 1931.
12. Bayer, I. Manufacture of alkaloids from the poppy plant in Hungary. *Bull. Narc.* **1961**, *1*, 21–28.
13. Szántay, C.; Nemes, A. A magyar alkaloidkémia története. *Magy. Kém. Foly.* **1994**, *100*, 423–442.

14. Bernáth, J. *Poppy, The Genus Papaver*; Harwood Academic Publishers: Amsterdam, The Netherlands, 1998; pp. 1–342.

15. Herczegh, P. Bognár Rezső szerves kémikus egyetemi tanár, akadémikus, tudománypolitikus (1913–1990). *Gerund. Egyetemtörténeti Közlemények* **2016**, *7*, 235–240.

16. Bognár, R.; Gaál, G.D.; Mészáros, Z.; Szabó, S.; Zeller, I. Eljárás Morphin Társalkaloidjainak Kinyerésére Máknövény Részeinek Kivonatolása Során Kapott Anyagból. Hungarian Patent 145,999, 3 July 1958.

17. Szlávik, L.; Bognár, R.; Bartók, A.; Gaál, G.; Kaskötő, Z.; Nagy, S.; Gyöngy, I.; Maczkó, G.; Kerekes, P.; Selmeci, G. Eljárás Ópiumalkaloidák Előállítására. Hungarian Patent 155,407, 12 July 1967.

18. Bognár, R.; Gaál, G.; Kerekes, P.; Szabó, S. On the accompanying alkaloids of morphine 1. Isolation of codeine, thebaine and narcotine. *Pharmazie* **1967**, *22*, 452–454.

19. Bognár, R.; Gaál, G.; Górecki, P.; Szabó, S. On the companion alkaloids of morphine. 2. Isolation of narcotoline and papaverine. *Pharmazie* **1967**, *22*, 525–526.

20. Górecki, P.; Bognár, R. On the accompanying alkaloids of morphine. 3. Modified preparation of codeine, thebaine and papaverine. *Pharmazie* **1968**, *23*, 590–593. [PubMed]

21. Blaskó, G.; Gula, D.J.; Shama, M. The phthtalideisoquinoline alkaloids. *J. Nat. Prod.* **1982**, *45*, 105–122. [CrossRef]

22. Bentley, K.W. *The Chemistry of Morphine Alkaloids*; Clarendon Press: Oxford, UK, 1954; pp. 1–453.

23. Casy, A.F.; Parfitt, R.T. Diels-Alder adducts of thebaine. In *Opioid Analgesics: Chemistry and Receptors*; Plenum Press: New York, NY, USA, 1986; pp. 69–84.

24. Szántay, C.; Dörnyei, G.; Blaskó, G. The morphine alkaloids. In *The Alkaloids: Chemistry and Physiology*; Academic Press Inc.: New York, NY, USA; London, UK, 1994; Volume 45, pp. 128–232.

25. Hosztafi, S. III. Chemistry-Biochemistry of Poppy, 1. Chemical Structures of Alkaloids. In *Poppy, The Genus Papaver*; Bernáth, J., Ed.; Harwood Academic Publishers: Amsterdam, The Netherlands, 1998; pp. 105–159.

26. Lee, S.; Park, N.I.; Park, Y.; Park, K.C.; Kim, E.S.; Son, Y.K.; Choi, B.S.; Kim, N.S.; Choi, I.Y. *O*- and *N*-Methyltransferases in benzylisoquinoline alkaloid producing plants. *Genes Genom.* **2023**, *46*, 367–378. [CrossRef]

27. Marques, I.A.; Brodelius, P.E. Elicitor-Induced l-Tyrosine Decarboxylase from Plant Cell Suspension Cultures: II. Partial Characterization. *Plant Physiol.* **1988**, *88*, 52–55. [CrossRef]

28. Lee, E.J.; Facchini, P.J. Tyrosine aminotransferase contributes to benzylisoquinoline alkaloid biosynthesis in opium poppy. *Plant Physiol.* **2011**, *157*, 1067–1078. [CrossRef] [PubMed]

29. Luk, L.Y.; Bunn, S.; Liscombe, D.K.; Facchini, P.J.; Tanner, M.E. Mechanistic studies on norcoclaurine synthase of benzylisoquinoline alkaloid biosynthesis: An enzymatic Pictet-Spengler reaction. *Biochemistry* **2007**, *46*, 10153–10161. [CrossRef]

30. Robin, A.Y.; Giustini, C.; Graindorge, M.; Matringe, M.; Dumas, R. Crystal structure of norcoclaurine-6-*O*-methyltransferase, a key rate-limiting step in the synthesis of benzylisoquinoline alkaloids. *Plant J.* **2016**, *87*, 641–653. [CrossRef]

31. Yu, M.; Facchini, P.J. cDNA cloning and characterization of (*S*)-*N*-methylcoclaurine 3′-hydroxylase (CYP80B1) from elicitortreated opium poppy cell suspension cultures (accession no. AF191772). *Plant Physiol.* **2000**, *122*, 1457.

32. Lannuzel, A.; Michel, P.P.; Caparros-Lefebvre, D.; Abaul, J.; Hocquemiller, R.; Ruberg, M. Toxicity of Annonaceae for dopaminergic neurons: Potential role in atypical parkinsonism in Guadeloupe. *Mov. Disord.* **2002**, *17*, 84–90. [CrossRef]

33. Fürst, S.; Hosztafi, S. Pharmacology of poppy alkaloids. In *Poppy—The Genus Papaver*; Bernáth, J., Ed.; Harwood Academic Publisher: Amsterdam, The Netherlands, 1998; pp. 291–318.

34. Aceto, M.D.; Harris, L.S.; Abood, M.E.; Rice, K.C. Stereoselective mu- and delta-opioid receptor-related antinociception and binding with (+)-thebaine. *Eur. J. Pharm.* **1999**, *365*, 143–147. [CrossRef]

35. Cumming, P.; Marton, J.; Lilius, T.O.; Olberg, D.E.; Rominger, A. A Survey of Molecular Imaging of Opioid Receptors. *Molecules* **2019**, *24*, 4190. [CrossRef]

36. Nyman, U.; Bruhn, J.G. Papaver bracteatum—A summary of current knowledge. *Planta Med.* **1979**, *35*, 97–117. [CrossRef] [PubMed]

37. Milo, J.; Levy, A.; Palevitch, D. An alternative raw-the cultivation and breeding of Papaver bracteatum. In *Poppy—The Genus Papaver*; Bernáth, J., Ed.; Harwood Academic Press: Amsterdam, The Netherlands, 1998; pp. 279–290.

38. Millgate, A.G.; Pogson, B.J.; Wilson, I.W.; Kutchan, T.M.; Zenk, M.H.; Gerlach, W.L.; Fist, A.; Larkin, P.J. Morphine-pathway block in top1 poppies. *Nature* **2004**, *431*, 413–414. [CrossRef] [PubMed]

39. Dastmalchi, M.; Chang, L.; Torres, M.A.; Ng, K.K.S.; Facchini, P.J. Codeinone reductase isoforms with differential stability, efficiency and product selectivity in opium poppy. *Plant J.* **2018**, *95*, 631–647. [CrossRef] [PubMed]

40. Bird, D.A.; Franceschi, V.R.; Facchini, P.J. A tale of three cell types: Alkaloid biosynthesis is localized to sieve elements in opium poppy. *Plant Cell* **2003**, *15*, 2626–2635. [CrossRef]

41. Onoyovwe, A.; Hagel, J.M.; Chen, X.; Khan, M.F.; Schriemer, D.C.; Facchini, P.J. Morphine biosynthesis in opium poppy involves two cell types: Sieve elements and laticifers. *Plant Cell* **2013**, *25*, 4110–4122. [CrossRef]

42. Lim, H.-Y.; Kwok, S.-F. *Differentiation and Comparison of Raw, Prepared and Dross Opium*; United Nations Office on Drugs and Crime: Vienna, Austria, 1981. Available online: https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1981-01-01_1_page006.html (accessed on 15 January 2025).

43. Stranska, I.; Skalicky, M.; Novak, J.; Matyasova, E.; Hejnak, V. Analysis of selected poppy (*Papaver somniferum* L.) cultivars: Pharmaceutically important alkaloids. *Ind. Crops Prod.* **2013**, *41*, 120–126. [CrossRef]

44. Carlin, M.G.; Dean, J.R.; Ames, J.M. Opium alkaloids in harvested and thermally processed poppy seeds. *Front. Chem.* **2020**, *8*, 737. [CrossRef]

45. Haber, I.; Pergolizzi, J., Jr.; LeQuang, J.A. Poppy Seed Tea: A Short Review and Case Study. *Pain Ther.* **2019**, *8*, 151–155. [CrossRef]

46. Bishop-Freeman, S.C.; Fox, L.; Winecker, R.E.; Hudson, J.S. Death from poppy tea consumption. *J. Anal. Toxicol.* **2020**, *44*, 734–740. [CrossRef]

47. Steentoft, A.; Kaa, E.; Worm, K. Fatal intoxications in Denmark following intake of morphine from opium poppies. *Z. Rechtsmed.* **1988**, *101*, 197–204. [CrossRef] [PubMed]

48. Penafiel, R.; Yoo, D.; Turner, C.; Brown, J.A.; McDonald, C.; Tran, J.; Shaw, V.; Roberts, D.M. Toxicokinetics of thebaine in those consuming non-food grade poppy seeds as a tea. *Clin. Toxicol.* **2023**, *61*, 644–648. [CrossRef] [PubMed]

49. Benyhe, S.; Zádor, F.; Ötvös, F. Biochemistry of opioid (morphine) receptors: Binding, structure and molecular modelling. *Acta Biol.* **2015**, *59* (Suppl. 1), 17–37.

50. Tanguturi, P.; Streicher, J.M. The role of opioid receptors in modulating Alzheimer's Disease. *Front. Pharmacol.* **2023**, *14*, 1056402. [CrossRef]

51. Che, T.; Dwivedi-Agnihotri, H.; Shukla, A.K.; Roth, B.L. Biased ligands at opioid receptors: Current status and future directions. *Sci. Signal.* **2021**, *14*, 677. [CrossRef]

52. De Neve, J.; Barlow, T.M.A.; Tourwé, D.; Bihel, F.; Simonin, F.; Ballet, S. Comprehensive overview of biased pharmacology at the opioid receptors: Biased ligands and bias factors. *RSC Med. Chem.* **2021**, *12*, 828–870. [CrossRef]

53. DePriest, A.Z.; Puet, B.L.; Holt, A.C.; Roberts, A.; Cone, E.J. Metabolism and disposition of prescription opioids: A review. *Forensic Sci. Rev.* **2015**, *27*, 115–145.

54. Makleit, S.; Bognár, R. Amino-morfidok és amino-kodidok előállításának és térkémiájának vizsgálatáról. *Kém. Közl.* **1968**, *30*, 289–295.

55. Bognár, R.; Makleit, S. Conversions of tosyl and mesyl derivatives of the morphine group II. Aminomorphides and aminocodides. *Acta Chim. Acad. Sci. Hung.* **1968**, *58*, 203–205.

56. Crabbendam, P.R.; Lie, T.S.; Linders, J.T.M.; Maat, L. Synthesis of 6, 14-ethenoisomorphinans and 6, 14-ethenomorphinans based on Diels–Alder adducts of 6-demethoxythebaine and 6-demethoxy-β-dihydrothebaine; pharmacology of the isomorphinans (Chemistry of Opium Alkaloids, Part XIX). *Recl. Trav. Chim. Pays-Bas* **1984**, *103*, 296–300. [CrossRef]

57. Marton, J.; Fekete, A.; Cumming, P.; Hosztafi, S.; Mikecz, P.; Henriksen, G. Diels–Alder adducts of morphinan-6, 8-dienes and their transformations. *Molecules* **2022**, *27*, 2863. [CrossRef]

58. Rodionov, V.M. L'importance des ethers alcoyliques des acides sulfoaromatiquea pour l'alcoylation des composes organiques. *Bull. Soc. Chim. Fr.* **1926**, *39*, 305–325.

59. Heumann, W.R. The manufacture of codeine from morphine. *Bull. Narcotics* **1958**, *10*, 15–17.

60. Gyöngy, I.; Makleit, S.; Mészáros, Z.; Szlávik, L. Eljárás Folcodin (Morfolinil-Etil-Morfin) Előállítására. Hungarian Patent 144,637, 5 April 1956.

61. Mertes, P.M.; Petitpain, N.; Tacquard, C.; Delpuech, M.; Baumann, C.; Malinovsky, J.M.; Longrois, D.; Gouel-Cheron, A.; Quang, D.L.; Demoly, P.; et al. Pholcodine exposure increases the risk of perioperative anaphylaxis to neuromuscular blocking agents: The ALPHO case-control study. *Br. J. Anaesth.* **2023**, *131*, 150–158. [CrossRef] [PubMed]

62. Mahase, E. UK withdraws pholcodine-containing cough and cold medicines over anaphylaxis risk in surgery. *BMJ Brit. Med. J.* **2023**, *380*, 609. [CrossRef]

63. Szabó, S.; Bognár, R. Eljárás N-allil-normorfin tisztítására. Hungarian Patent 1483, 30 May 1956.

64. McCawley, E.L.; Hart, E.R.; Marsh, D.F. The Preparation of *N*-Allylnormorphine. *J. Am. Chem. Soc.* **1941**, *63*, 314. [CrossRef]

65. von Braun, J. Die Einwirkung von Bromcyan auf tertiäre Amine. *Berichte* **1900**, *33*, 1438–1452. [CrossRef]

66. Berényi, S.; Hosztafi, S.; Makleit, S.; Szeifert, I. A New route for the preparation of *N*-substituted *N*-demethylapocodeine derivatives. *Acta Chim. Acad. Sci. Hung.* **1982**, *110*, 363–369.

67. Berényi, S.; Hosztafi, S.; Makleit, S.; Molnár, I. Preparation of demethoxyoripavine and its conversion into *N*-substituted *N*-demethylapomorphine derivatives. *Acta Chim. Hung.* **1983**, *113*, 51–60.

68. Bognár, R.; Makleit, S. A new preparation of dihydro-6-deoxymorphine. *Chem. Ind.* **1956**, 1239.

69. Bognár, R.; Makleit, S. Eine neue Darstellung des Dihydro-6-desoxymorphins. *Arzneim. Forsch./Drug. Res.* **1958**, *8*, 323–325.

70. Bognár, R.; Makleit, S. A dihidro-6-desoxymorphin új előállítása. *Acta Univ. Debreceniensis Ludovico Kossuth Nomin.* **1958**, *5*, 225–229.

71. Holmes, H.L. The Morphine Alkaloids I. In *The Alkaloids, Chemistry and Physiology*; Manske, R.H.F., Holmes, H.L., Eds.; Academic Press Inc.: New York, NY, USA, 1952; Volume 2, pp. 2–162.

72. Holmes, H.L.; Stok, G. The Morphine Alkaloids II. In *The Alkaloids, Chemistry and Physiology*; Manske, R.H.F., Holmes, H.L., Eds.; Academic Press Inc.: New York, NY, USA, 1952; Volume 2, pp. 162–219.

73. Small, L.; Browning, G.L. Reduction studies in the morphine series. VII. Thebaine. *J. Org. Chem.* **1939**, *3*, 618–637. [CrossRef]

74. Stork, G. The reduction of thebaine. *J. Am. Chem. Soc.* **1952**, *74*, 768–773. [CrossRef]

75. Bentley, K.W.; Robinson, R. Some notes on the reduction of thebaine and related topics. *Experientia* **1950**, *65*, 353–354. [CrossRef] [PubMed]

76. Bentley, K.W.; Robinson, R.; Wain, A.E. The reduction of thebaine and dihydrothebaine by sodium and ammonia. *J. Chem. Soc.* **1952**, 958–966. [CrossRef]

77. Razdan, R.K.; Portlock, D.E.; Dalzell, H.C.; Malmberg, C. Synthesis of β-dihydrothebaine. *J. Org. Chem.* **1978**, *43*, 3604–3606. [CrossRef]

78. Schmid, H.; Karrer, P. Über das β-Dihydro-thebain. *Helv. Chim. Acta* **1950**, *33*, 863–873. [CrossRef]

79. Bentley, K.W.; Lewis, J.W.; Taylor, J.B. Reduction of thebaine with mixed hydride reducing agents. *J. Chem. Soc. C* **1969**, *15*, 1945–1946. [CrossRef]

80. Linders, J.T.M.; Adriaansens, R.J.O.; Lie, T.S.; Maat, L. Scission of the epoxy ring in 4.5α-epoxymorphinans: A convenient synthesis of β-dihydrothebaine, 6-demethoxy-β-dihydrothebaine and desoxycodeine-A. (Chemistry of Opium Alkaloids, Part 21). *Recl. Trav. Chim. Pays-Bas* **1986**, *105*, 27–29. [CrossRef]

81. Robinson, R. Address of the President Sir Robert Robinson, at the anniversary meeting, 1 December 1947. *Proc. Roy. Soc. Lond. Ser. B Biol. Sci.* **1947**, *135*, 5–19.

82. Robinson, R. An essay in correlation arising from alkaloid chemistry. *Nature* **1947**, *160*, 815–817. [CrossRef] [PubMed]

83. Small, L.F. The reduction of thebaine. Neopine methyl ether. *J. Org. Chem.* **1955**, *20*, 953–958. [CrossRef]

84. Bognár, R.; Szabó, S. A tebain hidrogénezéséről. *Magy. Kém. Foly.* **1953**, *59*, 321–325.

85. Szabó, S. Újabb Adatok a Tebain Redukciós Termékeinek Kémiájához. C.Sc. Dissertation, Kossuth Lajos Tudományegyetem (KLTE), Debrecen, Hungary, 1967.

86. Schöpf, C. Die Konstitution der Morphiumalkaloide. *Justus Liebigs Ann. Chem.* **1927**, *452*, 211–267. [CrossRef]

87. Florez, D.H.Â.; dos Santos Moreira, A.M.; da Silva, P.R.; Brandão, R.; Borges, M.M.C.; de Santana, F.J.M.; Borges, K.B. Desomorphine (Krokodil): An overview of its chemistry, pharmacology, metabolism, toxicology and analysis. *Drug Alcohol Depend.* **2017**, *173*, 59–68. [CrossRef] [PubMed]

88. Alves, E.A. DARK classics in chemical neuroscience: Krokodil. *ACS Chem. Neurosci.* **2020**, *11*, 3968–3978. [CrossRef]

89. Mella-Raipan, J.; Romero-Parra, J.; Recabarren-Gajardo, G. DARK classics in chemical neuroscience: Heroin and desomorphine. *ACS Chem. Neurosci.* **2020**, *11*, 3905–3927. [CrossRef]

90. Rapoport, H.; Bonner, R.M. $\Delta^7$-Desoxymorphine. *J. Am. Chem. Soc.* **1951**, *73*, 5485. [CrossRef]

91. Cunningham, C.W.; Mercer, S.L.; Hassan, H.E.; Traynor, J.R.; Eddington, N.D.; Coop, A. Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3-and 6-substituted morphine analogs. *J. Med. Chem.* **2008**, *51*, 2316–2320. [CrossRef]

92. Eddy, N.B.; Halbach, H.; Braenden, O.J. Synthetic substances with morphine-like effect: Relationship between analgesic action and addiction liability, with a discussion of the chemical structure of addiction-producing substances. *Bull. World Health Org.* **1956**, *14*, 353–402. [PubMed]

93. Braenden, O.J.; Eddy, N.B.; Halbach, H. Synthetic substances with morphine-like effect: Relationship between chemical structure and analgesic action. *Bull. World Health Org.* **1955**, *13*, 937–998. [PubMed]

94. Reden, J.; Reich, M.F.; Rice, K.C.; Jacobson, A.E.; Brossi, A.; Streaty, R.A.; Klee, W.A. Deoxymorphines: Role of the phenolic hydroxyl in antinociception and opiate receptor interactions. *J. Med. Chem.* **1979**, *22*, 256–259. [CrossRef]

95. Alves, E.A.; Grund, J.P.C.; Afonso, C.M.; Netto, A.D.P.; Carvalho, F.; Dinis-Oliveira, R.J. The harmful chemistry behind krokodil (desomorphine) synthesis and mechanisms of toxicity. *Forensic Sci. Int.* **2015**, *249*, 207–213. [CrossRef] [PubMed]

96. Katselou, M.; Papoutsis, I.; Nikolaou, P.; Spiliopoulou, C.; Athanaselis, S. A "Krokodil" emerges from the murky waters of addiction. Abuse trends of an old drug. *Life Sci.* **2014**, *102*, 81–87. [CrossRef]

97. Small, L.F.; Morris, D.E. The desoxymorphines. *J. Am. Chem. Soc.* **1933**, *55*, 2874–2885. [CrossRef]

98. Small, L.F.; Yuen, K.C.; Eilers, L.K. The catalytic hydrogenation of the halogenomorphides: Dihydrodesoxymorphine-D. *J. Am. Chem. Soc.* **1933**, *55*, 3863–3870. [CrossRef]

99. Welsh, L.H. $O^3$-Monoacetylacetylmorphine. *J. Org. Chem.* **1954**, *19*, 1409–1415. [CrossRef]

100. Schmid, H.; Karrer, P. Über die Umsetzungsprodukte von Toluolsulfonsäureestern mit Lithiumaluminiumhydrid. *Helv. Chim. Acta* **1949**, *32*, 1371–1378. [CrossRef]

101. Makleit, S.; Berényi, S.; Bognár, R. Conversions of tosyl and mesyl derivatives of the morphine group, XIV. A new method for the preparation of "deoxymorphine E and dihydrodeoxymorphine D". *Acta Chim. Acad. Sci. Hung.* **1976**, *88*, 409–411.

102. Srimurugan, S.; Su, C.J.; Shu, H.C.; Murugan, K.; Chen, C. A facile and improved synthesis of desomorphine and its deuterium-labeled analogue. *Monatsh. Chem.* **2012**, *143*, 171–174. [CrossRef]

103. Gahr, M.; Freudenmann, R.W.; Hiemke, C.; Gunst, I.M.; Connemann, B.J.; Schönfeldt-Lecuona, C. Desomorphine goes "crocodile". *J. Addict. Dis.* **2012**, *31*, 407–412. [CrossRef] [PubMed]

104. Neves, J.F.; Alves, E.A.; Soares, J.X.; Cravo, S.M.; Silva, A.M.; Pereira Netto, A.D.; Carvalho, F.; Dinis-Oliveira, R.J.; Afonso, C.M. Data analysis of "krokodil" samples obtained by street-like synthesis. *Data Brief* **2015**, *6*, 83–88. [CrossRef] [PubMed]

105. Babapoor-Farrokhran, S.; Caldararo, M.D.; Rad, S.N.; Laborde, F.N.; Rehman, R.; Mejia, J. New case of krokodil (desomorphine) use. *Int. J. Case Rep. Images* **2018**, *9*, 1–4.

106. Soares, J.X.; Alves, E.A.; Silva, A.M.N.; de Figueiredo, N.G.; Neves, J.F.; Cravo, S.M.; Rangel, M.; Netto, A.D.P.; Carvalho, F.; Dinis-Oliveira, R.J.; et al. Street-like synthesis of krokodil results in the formation of an enlarged cluster of known and new morphinans. *Chem. Res. Toxicol.* **2017**, *30*, 1609–1621. [CrossRef]

107. Smith, M.B. Reactions, Mechanisms, and Structure, Chapter 10. Aliphatic substitution nucleophilic and organometallic. In *March's Advanced Organic Chemistry*, 7th ed.; John Wiley & Sons Inc.: Hoboken, NJ, USA, 2013; pp. 373–568. ISBN 978-0-470-46259-1.

108. Hamlin, T.A.; Swart, M.; Bickelhaupt, F.M. Nucleophilic substitution ($S_N2$): Dependence on nucleophile, leaving group, central atom, substituents, and solvent. *ChemPhysChem* **2018**, *19*, 1315–1330. [CrossRef]

109. Jacobson, O.; Kiesewetter, D.O.; Chen, X. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. *Bioconjugate Chem.* **2015**, *26*, 1–18. [CrossRef]

110. Stork, G.; Clarke, F.H. The $S_N2'$ reaction. III. Structure and $S_N2'$ reactions of the halocodides. *J. Am. Chem. Soc.* **1956**, *78*, 4619–4624. [CrossRef]

111. Bognár, R.; Makleit, S.; Radics, L. Tozil-, ill. mezilszármazékok reakcióinak vizsgálata a morfinsorban, VIII. A 6-dezoxi-6-fluor-izo-kodein új előállítása és vizsgálata. *Magy. Kém. Foly.* **1970**, *76*, 461–464.

112. Bognár, R.; Makleit, S.; Radics, L. Conversions of tosyl and mesyl derivatives of the morphine group, VIII. A new synthesis and investigations of 6-deoxy-6-fluoroisocodeine. *Acta Chim. Acad. Sci. Hung.* **1971**, *67*, 63–69.

113. Makleit, S.; Mile, T.; Bognár, R. Tozil-, ill. mezilszármazékok vizsgálata a morfinsorban, XVI. Újabb adatok az allilátrendeződés mechanizmusához. *Magy. Kém. Foly.* **1975**, *81*, 564–565.

114. Makleit, S.; Mile, T.; Bognár, R. Conversions of tosyl and mesyl derivatives in the morphine group, XVI. New data to the mechanism of allylic rearrangement. *Acta Chim. Acad. Sci. Hung.* **1976**, *89*, 275–277. [CrossRef]

115. Makleit, S. Az un Morfin-Sor (Morfin, Kodein, Dihidromorfin, Dihidrokodein, 14-Hidroxi-Kodein és 14-Hidroxi-Dihidrokodein) 6-O-Tozil, ill, 6-O-Mezil-Származékai Előállítása és Nukleofil Szubsztitúciós Reakcióinak Tanulmányozása, Part I (1971), Part 2 (1972). D.Sc. Dissertation, Kossuth Lajos University, Debrecen, Hungary, 1972.

116. Gaál, G.; Makleit, S. 2.1. Mákalkaloidok izolálása és kémiai átalakítása. In *Kutatási eredmények 1950–1973, Jubileumi Kötet Bognár Rezső Hatvanadik Születésnapjára*; Gaál, G., Ed.; Kossuth Lajos Tudományegyetem Szerves Kémiai Tanszéke; Alföldi Nyomda: Debrecen, Hungary, 1973; pp. 57–118.

117. Bognár, R.; Makleit, S. Tozil-, ill. mezilszármazékok reakcióinak vizsgálata a morfinsorban, III. Azido- és amino-kodidok előállítása. *Magy. Kém. Foly.* **1968**, *74*, 523–526.

118. Bognár, R.; Makleit, S. Conversions of tosyl and mesyl derivatives of the morphine group, III. Preparation of azido- and aminocodides. *Acta Chim. Acad. Sci. Hung.* **1969**, *59*, 373–378.

119. Bognár, R.; Makleit, S.; Mile, T. Tozil-, ill. mezilszármazékok reakciónak vizsgálata a morfinsorban, IV. Azido-és amino-morfidok előállítása. *Magy. Kém. Foly.* **1968**, *74*, 526–530.

120. Bognár, R.; Makleit, S.; Mile, T. Conversions of tosyl and mesyl derivatives of the morphine group, IV. Preparation of "azido- and aminomorphides". *Acta Chim. Acad. Sci. Hung.* **1969**, *59*, 379–385.

121. Makleit, S.; Radics, L.; Bognár, R.; Mile, T.; Oláh, É. Tozil-, illetve mezilszármazékok reakcióinak vizsgálata a morfinsorban, X. 14-Hidroxi-morfin-származékok, I. Azido- és aminovegyületek. *Magy. Kém. Foly.* **1972**, *78*, 223–228.

122. Makleit, S.; Radics, L.; Bognár, R.; Mile, T.; Oláh, É. Conversions of tosyl and mesyl derivatives of the morphine group, X. 14-Hydroxymorpine derivatives, I. Azido and amino derivatives. *Acta Chim. Acad. Sci. Hung.* **1972**, *74*, 99–113.

123. Makleit, S.; Bognár, R. Tozil-, ill. mezilszármazékok reakcióinak vizsgálata a morfinsorban, V. Izo-kodein és dihidro-izo-kodein új előállítása. *Magy. Kém. Foly.* **1969**, *75*, 235.

124. Makleit, S.; Bognár, R. Conversions of tosyl and mesyl derivatives of the morphine group, V. A new method for the preparation of isocodeine and dihydroisocodeine. *Acta Chim. Acad. Sci. Hung.* **1969**, *59*, 387–388.

125. Bognár, R.; Makleit, S.; Mile, T. Tozil-, ill. mezil-származékok reakcióinak vizsgálata a morfin-sorban. Acetil-merkapto és merkaptoszármazékok előállítása. *Magy. Kém. Foly.* **1969**, *75*, 330–332.

126. Bognár, R.; Makleit, S.; Mile, T. Conversions of tosyl and mesyl derivatives of the morphine group. Synthesis of acetylmercapto and mercapto derivatives. *Acta Chim. Acad. Sci. Hung.* **1969**, *59*, 161–164.

127. Bognár, R.; Makleit, S.; Mile, T.; Radics, L. Tozil ill. mezilszármazékok reakcióinak vizsgálata a morfinsorban, VI. Acetilmerkapto és merkaptoszármazékok előállítása. *Magy. Kém. Foly.* **1970**, *76*, 102–105.

128. Bognár, R.; Makleit, S.; Mile, T.; Radics, L. Conversions of tosyl and mesyl derivatives of the morphine group, VI. Synthesis of acetylmercapto and mercapto derivatives. *Acta Chim. Acad. Sci. Hung.* **1970**, *64*, 273–279.

129. Makleit, S.; Somogyi, G.; Bognár, R. Tozil, illetve mezilszármazékok vizsgálata a morfinsorban, XV.: A pszeudokodein-tozilát nukleofil szubsztitúciós reakcióinak tanulmányozása. *Magy. Kém. Foly.* **1975**, *81*, 517–519.

130. Makleit, S.; Somogyi, G.; Bognár, R. Conversions of tosyl and mesyl derivatives in the morphine group XV. Nucleophilic substitution reactions of pseudocodeine tosylate. *Acta Chim. Acad. Sci. Hung.* **1976**, *82*, 173–179. [CrossRef]

131. Makleit, S.; Bognár, R. Tozil-, illetve mezilszármazékok vizsgálata a morfinsorban, VII. Izo-morfin és dihidro-izo-morfin új előállítása. *Magy. Kém. Foly.* **1970**, *76*, 112–113.

132. Makleit, S.; Bognár, R. Conversions of tosyl and mesyl derivatives of the morphine group, VII. A new method for the preparation of isomorphine and dihydroisomorphine. *Acta Chim. Acad. Sci. Hung.* **1970**, *64*, 281–283.

133. Bognár, R.; Makleit, S.; Mile, T.; Radics, L. Tozil-, ill. mezilszármazékok reakcióinak vizsgálata a morfinsorban, IX. *Magy. Kém. Foly.* **1972**, *78*, 163–166.

134. Bognár, R.; Makleit, S.; Mile, T.; Radics, L. Reaktionen von Tosyl- bzw. Mesyl-Derivaten in der Morphin-Reihe, 9. Mitt. *Monatsh. Chem.* **1972**, *103*, 143–149. [CrossRef]

135. Small, L.F.; Lutz, R.E. *Chemistry of the Opium Alkaloids*; US Treasury Department Public Health Reports; US Treasury Department: Washington, DC, USA, 1932; Volume 103, pp. 1–374.

136. Inoue, H.; Takeda, M.; Kugita, H. Synthesis of B/C trans-fused morphine structures. IV. Synthesis of B/C *trans*-isomorphine. *Chem. Pharm. Bull.* **1970**, *18*, 1569–1575. [CrossRef]

137. Kugita, H.; Takeda, M.; Inoue, H. Synthesis of B/C trans-fused morphine structures. V. Pharmacological summary of trans-morphine derivatives and an improved synthesis of trans-codeine. *J. Med. Chem.* **1970**, *13*, 973–975. [CrossRef] [PubMed]

138. Makleit, S.; Berényi, S.; Bognár, R. Új, hatékony módszer neopin előállítására. *Magy. Kém. Foly.* **1977**, *83*, 478–479.

139. Makleit, S.; Berényi, S.; Bognár, R. A new and efficient method for the preparation of neopine. *Acta Chim. Acad. Sci. Hung.* **1977**, *94*, 165–168.

140. Berényi, S.; Makleit, S. Az izoneopin előállítása. *Magy. Kém. Foly.* **1980**, *86*, 335–336.

141. Berényi, S.; Makleit, S. Synthesis of isoneopine. *Acta Chim. Acad. Sci. Hung.* **1980**, *104*, 97–99.

142. Berényi, S.; Makleit, S.; Dobány, Z. Morphine alkaloids Part 105. Isolation of neopine from poppy head. *Herba Hung.* **1986**, *25*, 87–89.

143. Berényi, S.; Makleit, S.; Bognár, R.; Tegdes, A. Tozil-, illetve mezilszármazékok vizsgálata a morfinsorban, XXII. A 6-*O*-mezil-neopin néhány nukleofil szubsztitúciós reakciója. *Magy. Kém. Foly.* **1979**, *85*, 499–501.

144. Berényi, S.; Makleit, S.; Bognár, R.; Tegdes, A. Conversions of tosyl and mesyl derivatives of the morphine group, XXII. Some nucleophilic substitution reactions of 6-*O*-mesylneopine. *Acta Chim. Acad. Sci. Hung.* **1980**, *103*, 365–369. [CrossRef]

145. Crabbendam, P.R.; Maat, L.; Beyerman, H.C. Chemistry of opium alkaloids. Part XV. Preparation of 6-demethoxythebaine from neopine and its Diels-Alder reaction with ethyl acrylate. *Recl. Trav. Chim. Pays-Bas* **1981**, *100*, 293–294. [CrossRef]

146. Hutchins, C.W.; Cooper, G.K.; Puerro, S.; Rapoport, H. 6-Demethoxythebaine and its conversion to analgesics of the 6,14-ethenomorphinan type. *J. Med. Chem.* **1981**, *24*, 773–777. [CrossRef] [PubMed]

147. Beyerman, H.C.; Crabbendam, P.R.; Lie, T.S.; Maat, L. Convenient conversions of codeine into 6-demethoxythebaine via bond rearrangement (Chemistry of Opium Alkaloids, Part XVIII). *Recl. Trav. Chim. Pays-Bas* **1984**, *103*, 112–114. [CrossRef]

148. Hauser, F.M.; Chen, T.-K.; Carroll, F.I. 14-Hydroxycodeinone. Improved synthesis. *J. Med. Chem.* **1974**, *17*, 1117. [CrossRef]

149. Iijima, I.; Minamikawa, J.; Jacobson, A.E.; Brossi, A.; Rice, K.C.; Klee, W.A. Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone. *J. Med. Chem.* **1978**, *21*, 398–400. [CrossRef] [PubMed]

150. Currie, A.C.; Gillon, J.; Newbold, G.T.; Spring, F.S. Some reactions of 14-hydroxycodeine. *J. Chem. Soc.* **1960**, 773–781. [CrossRef]

151. Seki, I. Studies on the morphine alkaloids and its related compounds. XIII. On the nucleophilic substitution reactions of the 14-hydroxylated morphine alkaloids. *Chem. Pharm. Bull.* **1966**, *14*, 445–453. [CrossRef] [PubMed]

152. Simon, C.; Berényi, S.; Makleit, S.; Fekete, V. Tozil és mezilszármazékok vizsgálata a morfinsorban, XXV. A 6-O-mezil-7α-klór(bróm)-neopin nukleofil szubsztitúciós reakcióinak vizsgálata. *Magy. Kém. Foly.* **1986**, *92*, 402–406.

153. Simon, C.; Berényi, S.; Makleit, S.; Fekete, V. Conversions of tosyl and mesyl derivatives of the morphine group, XXV. Studies of the nucleophilic substitution reactions of 6-*O*-mesyl-7α-chloro(bromo)neopine. *Acta Chim. Hung.* **1987**, *124*, 497–503.

154. Abe, K.; Nakamura, Y.; Onda, M.; Okuda, S. Studies on morphine alkaloids—VIII. Some reactions of 14β-bromocodeine and related compounds. *Tetrahedron* **1971**, *27*, 4495–4509. [CrossRef]

155. Conroy, H. Neopinone. *J. Am. Chem. Soc.* **1955**, *77*, 5960–5966. [CrossRef]

156. Berényi, S. A 8,14-es Helyzetben Kettős Kötést és Kettősen Allil-Rendszert Tartalmazó Morfinszármazékok SN Típusú Reakciói; C.Sc. Dissertation, Kossuth Lajos Tudományegyetem Debrecen, Debrecen, Hungary, 1984.

157. Berényi, S.; Makleit, S.; Szilágyi, L. Tozil- és mezilszármazékok vizsgálata a morfinsorban, XXIII. Új 6-szubsztituált-6-demetoxi-tebain származékok előállítása. *Magy. Kém. Foly.* **1984**, *90*, 154–157.

158. Berényi, S.; Makleit, S.; Szilágyi, L. Conversions of tosyl and mesyl derivatives of the morphine group, XXIII. Preparation of new 6-substtituted-6-demethoxythebaine derivatives. *Acta Chim. Hung.* **1984**, *117*, 307–312.

159. Berényi, S.; Makleit, S.; Sepsi, Á. Morphine Alkaloids. Part 106. Reactions of morphine derivatives containing double allylic system. Part 2. Studies of nucleophilic substitution reactions of dihalo derivatives. *Acta. Chim. Hung.* **1989**, *126*, 275–279. [CrossRef]

160. Okuda, S.; Yamaguchi, S.; Tsuda, K. Studies on morphine alkaloids. II. Indolinocodeine. I. A new skeletal rearrangement of 14-bromocodeine. *Chem. Pharm. Bull.* **1965**, *13*, 1092–1103.

161. Patai, S. The chemistry of the azido group. In *The Chemistry of Functional Groups*; Interscience Publishers a division of John Wiley & Sons Ltd.: London, UK; New York, NY, USA; Sydney, Australia; Toronto, ON, Canada, 1971; pp. 1–626, ISBN 10:0471669253.

162. Braese, S.; Gil, C.; Knepper, K.; Zimmermann, V. Organic azides: An exploding diversity of a unique class of compounds. *Angew. Chem. Int. Ed.* **2005**, *44*, 5188–5240. [CrossRef]

163. Pinho e Melo, T.M.V.D. Part 1. Synthesis and safety, Chapter 3. Synthesis of azides. In *Organic Azides. Syntheses and Applications*; Braese, S., Banert, K., Eds.; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2010; pp. 53–94.

164. Xie, S.; Sundhoro, M.; Houk, K.N.; Yan, M. Electrophilic azides for materials synthesis and chemical biology. *Acc. Chem. Res.* **2020**, *53*, 937–948. [CrossRef]

165. Aimi, T.; Meguro, T.; Kobayashi, A.; Hosoya, T.; Yoshida, S. Nucleophilic transformations of azido-containing carbonyl compounds via protection of the azido group. *Chem. Commun.* **2021**, *57*, 6062–6065. [CrossRef] [PubMed]

166. Griffin, R.J. Chapter 3. The medicinal chemistry of the azido group. In *Progress in Medicinal Chemistry*; Ellis, G.P., Luscombe, D.K., Eds.; Elsevier Science: Amsterdam, The Netherlands, 1994; Volume 31, pp. 121–232.

167. Cocker, J.D.; Cowley, B.R.; Cox, J.S.G.; Eardley, S.; Gregory, G.I.; Lazenby, J.K.; Long, A.G.; Sly, J.C.P.; Somerfield, G.A. 922. Cephalosporanic acids. Part II. Displacement of the acetoxy-group by nucleophiles. *J. Chem. Soc.* **1965**, 5015–5031. [CrossRef]

168. Willner, D.; Holdrege, C.T.; Baker, S.R.; Cheney, L.C. 7-(α-aminophenylacetamido)-3-azidomethyl-3-cephem-4-carboxylic acid. *J. Antibiot.* **1972**, *25*, 64–67. [CrossRef]

169. Lister, R.G.; Nutt, D.J. Is Ro 15-4513 a specific alcohol antagonist? *Trends Neurosci.* **1987**, *10*, 223–225. [CrossRef]

170. Bach, P.; de Timary, P.; Gründer, G.; Cumming, P. Molecular imaging studies of alcohol use disorder. In *Current Topics in Behavioral Neurosciences*; Springer: Berlin/Heidelberg, Germany, 2023. [CrossRef]

171. Halldin, C.; Farde, L.; Litton, J.E.; Hall, H.; Sedvall, G. [$^{11}$C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding. Preparation, autoradiography and positron emission tomography. *Psychopharmacology* **1992**, *108*, 16–22. [CrossRef] [PubMed]

172. Winter, B.A.; Goldstein, A. A photochemical affinity-labelling reagent for the opiate receptor (s). *Mol. Pharmacol.* **1972**, *8*, 601–611. [CrossRef] [PubMed]

173. Fürst, S.; Hosztafi, S.; Friedmann, T. Structure-activity relationships of synthetic and semisynthetic opioid agonists and antagonists. *Curr. Med. Chem.* **1995**, *1*, 423–440. [CrossRef]

174. Fürst, S.; Hosztafi, S. The chemical and pharmacological importance of morphine analogues. *Acta Physiol. Hung.* **2008**, *95*, 3–44. [CrossRef]

175. Knoll, J. Azidomorphine and rymazolium an approach to the ideal analgesic. *Pharmacol. Res. Commun.* **1973**, *5*, 175–191. [CrossRef]

176. Knoll, J. Azidomorphines: A new family of potent analgesics with low dependence capacity. *Prog. Neuropsychopharmacol.* **1979**, *3*, 95–108. [CrossRef]

177. Knoll, J.; Fürst, S.; Mészáros, Z.; Nagy, G.; Dávid, Á.; Bognár, R.; Makleit, S.; Valovics, G. Pharmaceutical Composition Having Synergistic Analgesic Activity and Containing Azidomorphine or Azidocodeine, Chinoin Pharmaceutical and Chemical Works Ltd.: Budapest, Hungary. U.S. Patent 4,035,491, 29 June 1976.

178. Knoll, J.; Fürst, S.; Kelemen, K. The pharmacology of azidomorphine and azidocodeine. *J. Pharm. Pharmacol.* **1973**, *25*, 929–939. [CrossRef] [PubMed]

179. Bulaev, V.M.; Chichenkov, O.N. Effect of morphine and azidomorphine on cortical unit activity. *Bull. Exp. Biol. Med.* **1977**, *83*, 828–830. [CrossRef]

180. Bulaev, V.M.; Zakusov, V.V.; Knoll, J.; Chichenkov, O.N. Pharmacology of azidomorphine. *Bull. Exp. Biol. Med.* **1978**, *85*, 749–751. [CrossRef]

181. Knoll, J.; Zsilla, G.; Makleit, S. The metabolism of azidomorphine in the rat. *Med. Biol.* **1975**, *53*, 501–504.

182. Knoll, J.; Fürst, S.; Vizi, E.S. Kinetic parameters of a new narcotic agonist, azidomorphine. *Pharmacology* **1973**, *10*, 354–362. [CrossRef] [PubMed]

183. Horváth, K.; Wollemann, M. Azidomorphine is an agonist of high-affinity opioid receptor binding sites. *Neurochem. Res.* **1986**, *11*, 1565–1569. [CrossRef]

184. Knoll, J.; Fürst, S.; Makleit, S. The pharmacology of 14-hydroxy-azidomorphine. *J. Pharm. Pharmacol.* **1974**, *27*, 99–105. [CrossRef] [PubMed]

185. Cone, E.J. The metabolism of azidomorphine in a human subject. *Xenobiotica* **1978**, *8*, 301–304. [CrossRef]

186. Sasvári, K.; Simon, K.; Bognár, R.; Makleit, S. The crystal and molecular structure of 6-deoxy-6-azidodihydroisomorphine, $C_{17}H_{20}N_4O_2$. *Acta Cryst. B* **1974**, *30*, 634–641. [CrossRef]

187. Kálmán, A.; Ignáth, Z.; Simon, K.; Bognár, R.; Makleit, S. The crystal and molecular structure of 6-deoxy-6-azido-14-hydroxydihydroisomorphine, $C_{17}H_{20}N_4O_3$. *Acta Cryst. B* **1976**, *32*, 2667–2670. [CrossRef]

188. Tamás, J.; Mák, M.; Makleit, S. Mass spectrometric studies on azidomorphine derivatives. *Org. Mass Spectrom.* **1974**, *9*, 847–853. [CrossRef]

189. Dinya, Z.; Makleit, S.; Szabó, S.; Mile, T.; Bognár, R. A morfinszármazékok C-gyűrűjének térszerkezeti adottságai és az infravörös spektrumaik közötti összefüggések vizsgálata. *Magy. Kém. Foly.* **1971**, *77*, 265–274.

190. Dinya, Z.; Makleit, S.; Bognár, R. A morfinszármazékok elektron és térszerkezetének vizsgálata és összefüggésük a farmakológiai hatással. *Kém. Közl.* **1973**, *39*, 141–172.

191. Dinya, Z.; Makleit, S.; Bognár, R.; Jékel, P. Quantum-chemical calculations for morphine alkaloids. *Acta Chim. Acad. Sci. Hung.* **1972**, *71*, 125–126.

192. Makleit, S.; Knoll, J.; Bognár, R.; Berényi, S.; Kiss, G. Tozil-, ill. mezilszármazékok vizsgálata a morfinsorban, XVII. "Azidomorfin"-származékok, I. *Magy. Kém. Foly.* **1976**, *82*, 430–431.

193. Makleit, S.; Knoll, J.; Bognár, R.; Berényi, S.; Kiss, G. Conversions of tosyl and mesyl derivatives of the morphine group, XVII. "Azidomorphine" derivatives I. *Acta Chim. Acad. Sci. Hung.* **1977**, *93*, 165–168.

194. Bognár, R.; Makleit, S.; Kiss, G.; Berényi, S.; Mile, T.; Knoll, J.; Elek, S.; Gyökér, I.; Zoltai, A.; Tóth, G.; et al. 6-Deoxy-6-Azido-14-Hydroxy-7,8-Dihydro Isomorphine or a Pharacetuically Acceptable Salt Thereof. US Patent 4,144,236, 10 May 1977.

195. Bognár, R.; Makleit, S.; Knoll, J.; Berényi, S.; Horváth, G. Tozil-, illetve mezilszármazékok reakcióinak vizsgálata a morfinsorban, XIII. Morfin-alkaloidok azidoszármazékai. *Kém. Közl.* **1975**, *44*, 1–10.

196. Bognár, R.; Makleit, S.; Knoll, J.; Berényi, S.; Horváth, G. Conversions of tosyl and mesyl derivatives of the morphine group. XIII. Azido derivatives of morphine alkaloids. *Bulg. Chem. Commun.* **1975**, *8*, 203–215.

197. Makleit, S.; Knoll, J.; Bognár, R.; Berényi, S.; Somogyi, G.; Kiss, G. Tozil-, ill. mezilszármazékok vizsgálata a morfinsorban, XVIII. "Azidomorfin"-származékok II. *Magy. Kém. Foly.* **1976**, *82*, 432–437.

198. Makleit, S.; Knoll, J.; Bognár, R.; Berényi, S.; Somogyi, G.; Kiss, G. Conversions of tosyl and mesyl derivatives of the morphine group, XVIII. "Azidomorphine" derivatives, II. *Acta Chim. Acad. Sci. Hung.* **1977**, *93*, 169–174.

199. Bognár, R.; Gaál, G.; Kerekes, P.; Horváth, G.; Kovács, M.T. Hydroxyl group elimination in the morphine series. *Org. Prep. Proced. Int.* **1974**, *6*, 305–311. [CrossRef]

200. Makleit, S.; Berényi, S.; Bognár, R.; Elek, S. Tozil-, illetve mezilszármazékok vizsgálata a morfinsorban, XX. A mezilészterek előállításáról. *Magy. Kém. Foly.* **1977**, *83*, 190–191.

201. Makleit, S.; Berényi, S.; Bognár, R.; Elek, S. Conversions of tosyl and mesyl derivatives of the morphine group, XX. Synthesis of mesyl esters. *Acta Chim. Acad. Sci. Hung.* **1977**, *94*, 161–163.

202. Knoll, J.; Makleit, S.; Friedmann, T.; Hársing, L.G.; Hadházy, P. Circulatory, respiratory and antitussive effects of azidomorphine and related substances. *Arch. Int. Pharmacodyn. Ther.* **1974**, *210*, 241–249.

203. Bognár, R.; Makleit, S.; Kiss, G.; Berényi, S.; Mile, T.; Knoll, J.; Elek, S.; Gyökér, I.; Zoltai, A.; Tóth, G.; et al. 7,8-Dihydroisomorphine derivative, namely azidoethylmorphine. U.S. Patent 4,167,636, 29 March 1978.

204. Makleit, S.; Knoll, J.; Bognár, R.; Berényi, S.; Somogyi, G.; Kiss, G. Tozil-, ill. mezilszármazékok vizsgálata a morfinsorban, XIX. "Azidomorfin"-származékok. *Magy. Kém. Foly.* **1976**, *82*, 434–437.

205. Makleit, S.; Knoll, J.; Bognár, R.; Berényi, S.; Somogyi, G.; Kiss, G. Conversions of tosyl and mesyl derivatives of the morphine group, XIX. "Azidomorphine" derivatives III. *Acta Chim. Acad. Sci. Hung.* **1977**, *93*, 175–181.

206. Knoll, J.; Fürst, S.; Makleit, S. The pharmacology of *N*-substituted azidomorphines. *Arch. Int. Pharmacodyn. Ther.* **1977**, *228*, 268–292. [PubMed]

207. Fürst, S.; Wagner, T.A.; Knoll, J. Azidomorphines and heterogenous opiate receptors. *Pol. J. Pharmacol. Pharm.* **1988**, *40*, 627–634.

208. Fürst, S.; Friedmann, T.; Kovács, A.; Wagner, T. Comparison of the opioid activity of CAM and κ agonists. In *NIDA Research Monograph 75, Proceedings of the 1986 INRC Progress in Opioid Research, International Narcotics Research Conference, San Francisco, CA, USA, 6–11 July 1986*; Holaday, J.W., Law, P.-Y., Herz, A., Eds.; National Institute on Drug Abuse: Rockville, MD, USA, 1986; pp. 224–227.

209. Knoll, J.; Makleit, S.; Berényi, S.; Hosztafi, S.; Fürst, S.; Knoll, B.; Kiss, G.; Gyulai, Z. Eljárás N-Szubsztituált-N-Demetil-Azidoetilmorfin-Származékok Előállítására. Hungarian Patent 199,843, 27 December 1985.

210. Gulyás, G.; Berényi, S.; Makleit, S. Morfinvázas alkaloidok új epoxiszármazékainak előállítása és átalakításai. *Magy. Kém. Foly.* **1986**, *92*, 508–513.

211. Gulyás, G.; Berényi, S.; Makleit, S. Morphine alkaloids, 104. Synthesis and conversions of new epoxy derivatives. *Acta. Chim. Hung.* **1988**, *125*, 255–265.

212. Gulyás, G.; Makleit, S. A 8β,14β-epoxi-kodid reakcióinak tanulmányozása. *Magy. Kém. Foly.* **1988**, *94*, 517–519.

213. Gulyás, G.; Makleit, S. Investigation of the reactions of 8,14β-epoxycodide. *Acta Chim. Hung.* **1990**, *127*, 99–102.

214. Seki, I. Studies on the morphine alkaloids and its related compounds. XV. Isolations of 8β,14β-epoxy-codide and 14-hydroxy-dihydropseudocodeine from some nucleophilic substitution reaction products of tosylate of 14-hydroxy-codeine or its isomers. *Chem. Pharm. Bull.* **1969**, *17*, 1549–1554. [CrossRef]

215. Seki, I.; Takagi, H. Studies on the morphine alkaloids and its related compounds. XVI. Synthesis of 14-hydroxy-allopseudocodeine 8-ethers and its derivatives. *Chem. Pharm. Bull.* **1969**, *17*, 1555–1559. [CrossRef]

216. Bognár, R.; Makleit, S.; Radics, L.; Mile, T. Tozil, illetve mezilszármazékok reakcióinak vizsgálata a morfinsorban, XI.: 14-Hidroxi-morfin-származékok, II. Halogénvegyületek. *Magy. Kém. Foly.* **1972**, *78*, 228–229.

217. Makleit, S.; Radics, L.; Mile, T.; Bognár, R. Conversions of tosyl and mesyl derivatives of morphine group. XI.: 14-Hydroxymorphine derivatives. II. Halogen compounds. *Acta Chim. Acad. Sci. Hung.* **1972**, *74*, 111–113.

218. Bentley, K.W.; Hardy, D.G. Novel analgesics and molecular rearrangements in the morphine-thebaine group I. Ketones derived from 6,14-endo-ethenotetrahydrthebaine. *J. Am. Chem. Soc.* **1967**, *89*, 3267–3273. [CrossRef]

219. Linders, J.T.M.; Maat, L. Face selectivity of the Diels-Alder reaction of thebaine-like morphinandienes, A computational approach (Chemistry of opium alkaloids, Part XXXI). *Bull. Soc. Chim. Belg.* **1989**, *98*, 265–276. [CrossRef]

220. Maat, L. Novel thebainelike morphinan-dienes and their Diels-Alder adducts. In *NIDA Research Monograph Series, Drugs of Abuse: Chemistry, Pharmacology, Immunology, and AIDS*; Pham, P.T.K., Rice, K.C., Eds.; National Institutes of Health: Washington, DC, USA, 1990; pp. 35–49.

221. Lewis, J.W.; Husbands, S.M. The orvinols and related opioids—High affinity ligands with diverse efficacy profiles. *Curr. Pharm. Des.* **2004**, *10*, 717–732. [CrossRef]

222. Berényi, S.; Gulyás, G.; Batta, G.; Gunda, T.; Makleit, S. Steric factors in the azidolysis–thermolysis of some 5-tosyloxymethylbicyclo [2.2.2] oct-2-enes to yield 4-azatetracyclo [4.4.0.0$^{2.4}$.0$^{3.8}$]decanes. *J. Chem. Soc. Perkin Trans.* **1991**, *1*, 1139–1142. [CrossRef]

223. Berényi, S.; Gulyás, G.; Batta, G.; Makleit, S. Synthesis of a new azatetracyclodecane ring system via intramolecular addition of azide on double bond. *Org. Prep. Proced. Int.* **1991**, *23*, 111–113. [CrossRef]

224. Batta, G.; Gunda, T.E.; Szabó, Z.; Berényi, S.; Gulyás, G.; Makleit, S. C-19 Configurational assignments in some morphine derivatives by homonuclear NOE. *Magn. Reson. Chem.* **1992**, *30*, 96–104. [CrossRef]

225. Sepsi, Á.; Berényi, S.; Makleit, S.; Tóth, Z. Morphine Alkaloids, CXVII: Investigation of the azidolysis of tertiary alcohols of thebaine derivatives with bridged ring C. *Arch. Pharm.* **1993**, *326*, 313–317. [CrossRef]

226. Pancrazi, A.; Khuong-Huu, Q. Alcaloides steroidiques—CLXVII: Synthese d'azides tertiaires en serie alicyclique—III. *Tetrahedron* **1974**, *30*, 2337–2343. [CrossRef]

227. Cone, E.J.; Gorodetzky, C.W.; Darwin, W.D.; Buchwald, W.F. Stability of the 6,14-endo-ethanotetrahydrooripavine analgesics: Acid-catalyzed rearrangement of buprenorphine. *J. Pharm. Sci.* **1984**, *73*, 243–246. [CrossRef]

228. Husbands, S.M.; Breeden, S.W.; Grivas, K.; Lewis, J.W. Ring constrained analogues of the orvinols: The furanomorphides. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 831–834. [CrossRef]

229. Csutorás, C.; Berényi, S.; Czakó, B.; Makleit, S. Syntheses and transformations of novel nitrogen and sulfur containing morphinandienes. *Monatsh. Chem.* **1997**, *128*, 1267–1273. [CrossRef]

230. Gates, M.; Tschudi, G. The synthesis of morphine. *J. Am. Chem. Soc.* **1956**, *78*, 1380–1393. [CrossRef]

231. Gates, M.; Shepard, M.S. The closure of the oxide bridge in the morphine series. *J. Am. Chem. Soc.* **1962**, *84*, 4125–4130. [CrossRef]

232. Weller, D.D.; Rapoport, H. Practical synthesis of codeine from dihydrothebainone. *J. Med. Chem.* **1976**, *19*, 1171–1175. [CrossRef]

233. Rice, K.C. Synthetic opium alkaloids and derivatives. A short total synthesis of (±)-dihydrothebainone, (±)-dihydrocodeinone, and (±)-nordihydrocodeinone as an approach to a practical synthesis of morphine, codeine and congeners. *J. Org. Chem.* **1980**, *45*, 3135–3137. [CrossRef]

234. Tóth, G.; Mallareddy, J.R. Tritiated opioid receptor ligands as radiotracers. *Curr. Pharm. Design* **2013**, *19*, 7461–7472. [CrossRef]

235. Filer, C.N. Morphinan alkaloids labeled with tritium: Synthesis and applications. *J. Label. Compd. Radiopharm.* **2013**, *56*, 639–648. [CrossRef]

236. Gillis, E.P.; Eastman, K.J.; Hill, M.D.; Donnelly, D.J.; Meanwell, N.A. Applications of fluorine in medicinal chemistry. *J. Med. Chem.* **2015**, *58*, 8315–8359. [CrossRef]

237. Sandulenko, I.V.; Ambartsumyan, A.A.; Moiseev, S.K. Fluorinated and [$^{18}$F]fluorinated morphinan based opioid ligands. *Org. Biomol. Chem.* **2020**, *18*, 5533–5557. [CrossRef]

238. Makleit, S.; Berényi, S.; Hoszafi, S.; Simon, C. Synthesis and chemical transformation of halogen-containing morphine derivatives. *Magy. Kém. Lapja* **1997**, *52*, 282–289.

239. Somogyi, G.; Makleit, S.; Bognár, R. Tozil-, illetve mezilszármazékok vizsgálata a morfinsorban, XXI. A dihidrokodein C-6-halogénszármazékai. *Magy. Kém. Foly.* **1977**, *83*, 327–330.

240. Somogyi, G.; Makleit, S.; Bognár, R. Conversions of tosyl and mesyl derivatives of the morphine group, XXI. C-6 Halogen derivatives of dihydrocodeine. *Acta Chim. Acad. Sci. Hung.* **1978**, *97*, 339–344.

241. Boswell, G.A.; Henderson, R.M. Fluoro Analogs of Hydrocodone and Oxycodone Useful as Analgesics, Narcotic Antagonists or Both. U.S. Patent 4,241,065, 2 July 1979.

242. Ganti, V. Analgesic, Antagonist, and/or Anorectic 14-Fluoromorphinans. US Patent 4,451,470, 6 July 1982.

243. Rice, K.C.; Pert, C.B.; Burke, T.R.; Larson, S.M.; Eckelman, W.C.; Channing, M.A. Synthesis and Utilization of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy-6β-fluoromorphinans (foxy and cyclofoxy) as 18F-Labeled Opioid Ligands for Positron Emission Transaxial Tomography (PETT). U.S. Patent 4,775,759, 27 November 1984.

244. Burke, T.R.; Rice, K.C.; Pert, C.B. Probes for narcotic receptor mediated phenomena. 11. Synthesis of 17-methyl and 17-cycloporopylmethyl-3,14-dihydroxy-4,5α-epoxy-6β-fluoromorphinans (foxy and cyclofoxy) as a model of opioid ligands suitable for positron emission transaxial tomography. *Heterocycles* **1985**, *23*, 99–106.

245. Pert, C.B.; Danks, J.A.; Channing, M.A.; Eckelman, W.C.; Larson, S.M.; Bennett, J.M.; Burke, T.R., Jr.; Rice, K.C. S-[18F]Acetylcyclofoxy: A useful probe for the visualization of opiate receptors in living animals. *FEBS Letters* **1984**, *177*, 281–286. [CrossRef]

246. Channing, M.S.; Eckelman, W.C.; Bennett, J.M.; Burke, T.R.; Rice, K.C. Radiosynthesis of (S)[18F]F-3-acetylcyclofoxy: A high affinity opiate antagonist. *Int. J. Appl. Radiat. Isot.* **1985**, *36*, 429–433. [CrossRef]

247. Newman, A.; Channing, M.; Finn, R.; Dunn, B.; Simpson, N.; Carson, R.; Ostrowski, N.; Cohen, R.; Burke, T.; Larson, S.; et al. Ligands for Imaging Opioid Receptors in Conscious Humans by Positron Emission Tomography (PET). In *NIDA Research Monograph, Problems of Drug Dependence*; National Institutes of Health: Washington, DC, USA, 1988; pp. 117–121.

248. Kling, M.A.; Carson, R.E.; Borg, L.; Zametkin, A.; Matochik, J.A.; Schluger, J.; Herscovitch, P.; Rice, K.C.; Ho, A.; Eckelman, W.C.; et al. Opioid receptor imaging with positron emission tomography and [18F]cyclofoxy in long-term, methadone-treated former heroin addicts. *J. Pharm. Exp. Ther.* **2000**, *295*, 1070–1076. [CrossRef]

249. Woudenberg, R.H.; Maat, L. Synthesis and biological activity of new etorphine analogues from 7-chloro-6-demethoxythebaine and 7-chloro-5β-methyl-6-demethoxythebaine (Chemistry of Opium Alkaloids, part XXXVII). *Recl. Trav. Chim. Pays-Bas* **1993**, *112*, 113–122. [CrossRef]

250. Maat, L.; Woudenberg, R.H.; Meuzelaar, G.J.; Linders, J.T.M. Chemistry of opium alkaloids. Part 44: Synthesis and opioid receptor binding profile of substituted ethenoisomorphinans and ethenomorphinans. *Bioorg. Med. Chem.* **1999**, *7*, 529–541. [CrossRef]

251. Marton, J.; Szabó, Z.; Csorvássy, I.; Simon, C.; Hosztafi, S.; Makleit, S. Reaction of morphinan-6, 8-dienes with azadienophiles. *Tetrahedron* **1996**, *52*, 2449–2464. [CrossRef]

252. Jeong, I.H.; Kim, Y.S.; Cho, K.Y.; Kim, K.J. Unexpected effect of fluorine in Diels-Alder reaction of 2-fluoroacrolein with thebaine. *Bull. Korean Chem. Soc.* **1990**, *11*, 178–179.

253. Jeong, I.H.; Kim, Y.S.; Cho, K.Y.; Kim, K.J. Reaction of thebaine with trifluoromethyl substituted acetylenic dienophiles. *Bull. Korean Chem. Soc.* **1990**, *11*, 258–260.

254. Kim, K.J.; Kim, S.M. Synthesis of fluorinated new thebaine derivatives as analgesics. *Yakhak Hoechi* **1998**, *42*, 257–264.

255. Berényi, S.; Hosztafi, S.; Makleit, S. A new efficient method for the preparation of 2-fluoro-*N*-propyl-norapomorphine. *J. Chem. Soc. Perkin Trans.* **1992**, *1*, 2693–2694. [CrossRef]

256. Csutorás, C.; Berényi, S.; Neumeyer, J.L. Investigation of the acid-catalyzed rearrangement of morphinans. *Lett. Org. Chem.* **2007**, *4*, 409–413. [CrossRef]

257. Berényi, S.; Tóth, Z.; Sepsi, Á.; Zékány, A.; Gyulai, S.; Makleit, S. Synthesis and biological evaluation of some halogenated 6,14-ethenomorphinan derivatives. *Med. Chem. Res.* **1995**, *5*, 26–32.

258. Savić-Vujović, K.R.; Vučković, S.; Srebro, D.; Ivanović, M.; Došen-Mićović, L.; Vučetić, Č.; Džolijić, E.; Prostran, M. A comparison of the antinociceptive and temperature responses to morphine and fentanyl derivatives in rats. *Arch. Pharm. Res.* **2013**, *36*, 501–508. [CrossRef]

259. Magnus, P.; Ghavimi-Alagha, B. Chemical Transformations of (-)-Codeine to Afford Derivatives Codeine and Morphine Thereof. WO 2013/184,902, 7 June 2012.

260. Ramsby, S.; Neumeyer, J.L.; Grigoriadis, D.; Seeman, P. 2-Haloaporphines as potent dopamine agonists. *J. Med. Chem.* **1989**, *32*, 1198–1201. [CrossRef]

261. Baldessarini, R.J.; Kula, N.S.; Gao, Y.; Campbell, A.; Neumeyer, J.L. R-(-)-2-Fluoro-*N*-*n*-propylnorapomorphine: A very potent and D$_2$-selective dopamine agonist. *Neuropharmacology* **1991**, *30*, 97–99. [CrossRef]

262. Hosztafi, S.; Makleit, S. Synthesis of new morphine derivatives containing halogen in the aromatic ring. *Synth. Commun.* **1994**, *24*, 3031–3045. [CrossRef]

263. Hosztafi, S.; Makleit, S. Synthesis of new apomorphine derivatives containing halogen (CI and Br) in ring-D. *Synth. Commun.* **1996**, *26*, 3909–3918. [CrossRef]

264. Filer, C.N.; Ahern, D.G. Preparation of (-)-[8,9-3H]apomorphine at high specific activity. *J. Org. Chem.* **1980**, *45*, 3918–3919. [CrossRef]

265. Filer, C.N. Radiopharmaceutical and Methods of Synthesis and Use Thereof. US. Patent 7,323,566, 20 April 2005.

266. Lousberg, R.J.J.C.; Weiss, U. The analgesic action of 1-fluorocodeine. *Experientia* **1974**, *30*, 1440–1441. [CrossRef]

267. Makleit, S.; Dubina, V. A gram scale preparation of 1-fluorocodeine and 1-fluorodihydrocodeine. *ACH-Models Chem.* **2000**, *137*, 447–449.

268. Hosztafi, S.; Marton, J. Synthesis of 1-fluoro-substituted codeine derivatives. *Chem. Pap.* **2016**, *70*, 973–982. [CrossRef]

269. Hosztafi, S.; Kraszni, M.; Tóth, G.; Marton, J. Synthesis of 1-Iodo-substituted codeine derivatives. *Lett. Org. Chem.* **2018**, *15*, 1012–1020. [CrossRef]

270. Sandulenko, I.V.; Kovaleva, E.S.; Peregudov, A.S.; Kalinin, V.N.; Moiseev, S.K. 21,21,21-Trifluorothevinone: The straightest way to fluorinated thevinols and orvinols. *ChemistrySelect* **2016**, *1*, 1004–1005. [CrossRef]

271. Zelentsova, M.; Sandulenko, I.V.; Ambartsumyan, A.; Danshina, A.; Moiseev, S.K. C (21)-Di-and monofluorinated scaffold for thevinol/orvinol-based opioid receptor ligands. *Org. Biomol. Chem.* **2023**, *21*, 9091–9100. [CrossRef]

272. Zelentsova, M.; Moiseev, S.K. Synthesis of aryl-21,21,21-triflurothevinols. *Adv. Chem. Chemical Technol. (Uspekhi V Khimii I Khimicheskoi Tekhnologii)* **2018**, *32*, 32–34.

273. Zelentsova, M.V.; Sandulenko, I.V.; Melnikova, E.K.; Moiseev, S.K. $^{19}$F NMR determination of the C20 absolute configuration of C21-fluorinated arylthevinols. *Mendeleev Commun.* **2022**, *32*, 97–99. [CrossRef]

274. Sandulenko, I.V.; Belozertseva, I.V.; Zvartau, E.E.; Zelentsova, M.V.; Ambartsumyan, A.A.; Smol'yakov, A.F.; Moiseev, S.K. C (21)-fluorinated thevinol scaffold for opioid ligands. 21, 21, 21-Trifluoro-6-O-nororvinols: Design, synthesis and analgesic activity. *Eur. J. Med. Chem.* **2023**, *252*, 115296. [CrossRef]

275. Szűcs, E.; Marton, J.; Szabó, Z.; Hosztafi, S.; Kékesi, G.; Tuboly, G.; Bánki, L.; Horváth, G.; Szabó, P.T.; Tömböly, C.; et al. Synthesis, biochemical, pharmacological characterization and in silico profile modelling of highly potent opioid orvinol and thevinol derivatives. *Eur. J. Med. Chem.* **2020**, *191*, 112145. [CrossRef] [PubMed]

276. Marton, J.; Hosztafi, S.; Berényi, S.; Simon, C.; Makleit, S. Herstellung von 6, 14-Ethenomorphinan-derivaten. *Monatsh. Chem.* **1994**, *125*, 1229–1239. [CrossRef]

277. Sandulenko, I.V.; Kovaleva, E.S.; Zelentsova, M.V.; Ambartsumyan, A.A.; Gorlov, S.N.; Danshina, A.A.; Aysin, R.R.; Moiseev, S.K. Control of the diastereoselectivity at C (20) in the formation of C (21)-fluorinated thevinols. *Org. Biomol. Chem.* **2023**, *21*, 1440–1449. [CrossRef]

278. Bentley, K.W.; Hardy, D.G.; Meek, B. Novel analgesics and molecular rearrangements in the morphine-thebaine group. II. Alcohols derived from 6, 14-endo-etheno-and 6, 14-endo-ethanotetrahydrothebaine. *J. Am. Chem. Soc.* **1967**, *89*, 3273–3280. [CrossRef] [PubMed]

279. Kumar, V.; Ridzwan, I.E.; Grivas, K.; Lewis, J.W.; Clark, M.J.; Meurice, C.; Jimenez-Gomez, C.; Pogozheva, I.; Mosberg, H.; Traynor, J.R.; et al. Selectively promiscuous opioid ligands: Discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity. *J. Med. Chem.* **2014**, *57*, 4049–4057. [CrossRef]

280. Husbands, S.M. Buprenorphine and related orvinols. In *Research and Development of Opioid-Related Ligands*; ACS Symposium Series; American Chemical Society: Washington, DC, USA, 2013; pp. 127–144.

281. Sandulenko, I.V.; Zelentsova, M.V.; Tyutyunov, A.A.; Moiseev, S.K. Thevinoic acid fluoroalkyl esters. *Russ Chem. Bull.* **2022**, *71*, 2754–2756. [CrossRef]

282. Finke, A.O.; Krasnov, V.I.; Rybalova, T.V.; Chirkova, V.Y.; Belenkaya, S.V.; Volosnikova, E.A.; Shcherbakov, D.N.; Shults, E.E. A straightforward trifluoromethylation at the C6 position of morphinane alkaloids, their modification and evaluation of inhibition of the SARS-CoV-2 main protease. *J. Fluor. Chem.* **2023**, *271*, 110189. [CrossRef]

283. Mitsunobu, O.; Yamada, M. Preparation of esters of carboxylic and phosphoric acid via quaternary phosphonium salts. *Bull. Chem. Soc. Jpn.* **1967**, *40*, 2380–2382. [CrossRef]

284. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. *Synthesis* **1981**, *1*, 1–28. [CrossRef]

285. Fletcher, S. The Mitsunobu reaction in the 21st century. *Org. Chem. Front.* **2015**, *2*, 739–752. [CrossRef]

286. Simon, C.; Hosztafi, S.; Makleit, S. Application of the Mitsunobu reaction in the field of alkaloids. *J. Heterocycl. Chem.* **1997**, *34*, 349–365. [CrossRef]

287. Robson, L.E.; Kosterlitz, H.W. Specific protection of the binding sites of D-Ala$^2$-D-Leu$^5$-enkephalin (δ-receptors) and dihydromorphine (μ-receptors). *Proc. Royal Soc. Lond. B. Biol. Sci.* **1979**, *205*, 425–432.

288. Smith, J.R.; Simon, E.J. Selective protection of stereospecific enkephalin and opiate binding against inactivation by N-ethylmaleimide: Evidence for two classes of opiate receptors. *Proc. Natl. Acad. Sci. USA* **1980**, *71*, 281–284. [CrossRef]

289. Bowen, W.D.; Hellewell, S.B.; Kelemen, M.; Huey, R.; Stewart, D. Affinity labeling of δ-opiate receptors using [D-Ala$^2$, Leu$^5$, Cys$^6$] enkephalin. Covalent attachment via thiol-disulfide exchange. *J. Biol. Chem.* **1987**, *262*, 13434–13439. [CrossRef]

290. Fujii, I.; Togame, H.; Yamamoto, M.; Kanematsu, K.; Takayanagi, I.; Konno, F. Design and synthesis of sulfur-containing morphine and an opioid receptor probe. *Chem. Pharm. Bull.* **1988**, *36*, 2282–2285. [CrossRef] [PubMed]

291. Okuda, S.; Yamaguchi, S.; Kawazoe, Y.; Tsuda, K. Studies on Morphine Alkaloids. I. Nuclear magnetic resonance spectral studies on morphine alkaloids. I. *Chem. Pharm. Bull.* **1964**, *12*, 104–112. [CrossRef]

292. Kanematsu, K.; Naito, R.; Shimohigashi, Y.; Ohno, M.; Ogasawara, T.; Kurono, M.; Yagi, K. Design synthesis of an opioid receptor probe: Mode of binding of S-Activated (-)-6-β-sulfhydryldihydromorphine with the SH group in the mu-opioid receptor. *Chem. Pharm. Bull.* **1990**, *38*, 1438–1440. [CrossRef]

293. Kanematsu, K.; Yoshiyasu, T.; Yoshida, M. Molecular srtucture of (-)-3-acetyl-6-beta-(acetylthio)-*N*-(cyclopropylmethyl) normorphine and its 14-hydroxy congeners. *Chem. Pharm. Bull.* **1990**, *38*, 1441–1443. [CrossRef]

294. Fleischhacker, W.; Richter, B. Claisen-Reaktionen an Codeinen. 8-Alkyl-8, 14-dihydro-6-desmethoxythebaine und-oripavine. *Chem. Ber.* **1980**, *113*, 3866–3880. [CrossRef]

295. Kirby, G.W.; Massey, S.R. An efficient preparation of isocodeine from codeine. *J. Chem. Soc. C* **1971**, 3047–3048. [CrossRef] [PubMed]

296. Simon, C. A Mitsunobu-Reakció Alkalmazása a Morfin-Alkaloidok Körében. C.Sc. Dissertation, Kossuth Lajos Tudományegyetem Debrecen, Debrecen, Hungary, 1993.

297. Simon, C.; Hosztafi, S.; Makleit, S. Application of the Mitsunobu reaction for the preparation of isomorphine and isocodeine derivatives. *Synth. Commun.* **1991**, *21*, 407–412. [CrossRef]

298. Friedmann, T.; Tóth, Z.; Hosztafi, S.; Simon, C.; Makleit, S.; Fürst, S. Influence of spatial orientation of the C-6-OH group in ring C of morphine derivatives on opioid activity. *Arch. Int. Pharmacodyn. Thér.* **1994**, *328*, 16–25.

299. Maat, L.; De Groot, J.A.; Beyerman, H.C. Synthesis of 6β-Halogenodeoxyneopine from Neopine. *Synth. Commun.* **1979**, *9*, 713–718. [CrossRef]

300. Jiang, J.B.; Hanson, R.N.; Portoghese, P.S.; Takemori, A.E. Stereochemical studies on medicinal agents. 23. Synthesis and biological evaluation of 6-amino derivatives of naloxone and naltrexone. *J. Med. Chem.* **1977**, *20*, 1100–1102. [CrossRef]

301. Sayre, L.M.; Portoghese, P.S. Stereospecific synthesis of the 6α- and 6β-amino derivatives of naltrexone and oxymorphone. *J. Org. Chem.* **1980**, *45*, 3366–3368. [CrossRef]

302. Mohamed, M.S.; Portoghese, P.S. Stereoselectivity of the reduction of naltrexone oxime with borane. *J. Org. Chem.* **1986**, *51*, 105–106. [CrossRef]

303. Simon, C.; Hosztafi, S.; Makleit, S. Application of the Mitsunobu reaction for morphine compounds. Preparation of 6β-aminomorphine and codeine derivatives. Morphine Alkaloids Part 115. *Synth. Commun.* **1992**, *22*, 913–921. [CrossRef]

304. Simon, C.; Hosztafi, S.; Makleit, S. Applicaltion of the Mitsunobu reaction in the morphine series. Preparation of 6β-amino-14β-hydroxymorphine and 14-hydroxycodeine derivatives. *Heterocycles* **1994**, *38*, 1347–1354.

305. Simon, C.; Hosztafi, S.; Makleit, S. Stereoselective synthesis of β-naltrexol, β-naloxol β-naloxamine, β-naltrexamine and related compounds by the application of the Mitsunobu reaction. *Tetrahedron* **1994**, *50*, 9757–9768. [CrossRef]

306. Szilágyi, L.; Makleit, S.; Hosztafi, S.; Simon, C. Substituent-dependent conformational changes in 6β-substituted codeine derivatives. *Magn. Reson. Chem.* **1992**, *30*, 552–557. [CrossRef]

307. Riba, P.; Tóth, Z.; Hosztafi, S.; Friedmann, T.; Fürst, S. Structure-activity relationships of *N*-cyclopropylmethyl morphine derivatives in isolated organs. *Analgesia* **1995**, *1*, 785–788. [CrossRef]

308. Abe, K.; Onda, M.; Okuda, S. Studies on Morphine Alkaloids. V. Reaction Mechanism of the Reduction of 14β-Bromocodeinone with Sodium Borohydride. *Chem. Pharm. Bull.* **1969**, *17*, 1847–1853. [CrossRef]

309. Simon, C.; Hosztafi, S.; Makleit, S. Application of the Mitsunobu reaction in the morphine series: The reaction of 14β-chloro and 14β-bromocodeine with phthalimide and diphenylphosphoryl azide. *Tetrahedron Lett.* **1993**, *34*, 6475–6478. [CrossRef]

310. Simon, C.; Hosztafi, S.; Makleit, S. The first preparation of 6β-bromo codeine and morphine derivatives. Kinetic vs. thermodynamic control. *J. Chem. Res.* **1997**, *12*, 2734–2742. [CrossRef]

311. Fujimura, M.; Izumimoto, N.; Momen, S.; Yoshikawa, S.; Kobayashi, R.; Kanie, S.; Hirakata, M.; Komagata, T.; Okanishi, S.; Hashimoto, T.; et al. Characteristics of TRK-130 (Naltalimide), a novel opioid ligand, as a new therapeutic agent for overactive bladder. *J. Pharmacol. Exp. Ther.* **2014**, *350*, 543–551. [CrossRef]

312. Izumimoto, N.; Kawai, K.; Kawamura, K.; Fujimura, M.; Komagata, T. Remedies or Preventives for Urinary Frequency or Urinary Incontinence and Morphinan Derivatives Having Nitrogen-Containing Heterocyclic Group. U.S. Patent 7,320,984, 8 October 2003.

313. Matyas, G.R.; Rice, K.C.; Cheng, K.; Li, F.; Antoline, J.F.; Iyer, M.R.; Jacobson, A.E.; Mayorov, A.V.; Beck, Z.; Torres, O.B.; et al. Facial recognition of heroin vaccine opiates: Type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine. *Vaccine* **2014**, *32*, 1473–1479. [CrossRef] [PubMed]

314. Jalah, R.; Torres, O.B.; Mayorov, A.V.; Li, F.; Antoline, J.F.; Jacobson, A.E.; Rice, K.C.; Deschamps, J.R.; Beck, Z.; Alving, C.R.; et al. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers. *Bioconjugate Chem.* **2015**, *26*, 1041–1053. [CrossRef]

315. Lam, R.; Gondin, A.B.; Canals, M.; Kellam, B.; Briddon, S.J.; Graham, B.; Scammells, P.J. Fluorescently labeled morphine derivatives for bioimaging studies. *J. Med. Chem.* **2018**, *61*, 1316–1329. [CrossRef]

316. Nagase, H.; Hayakawa, J.; Kawamura, K.; Kawai, K.; Takezawa, Y.; Matsuura, H.; Tajima, C.; Endo, T. Discovery of a structurally novel opioid κ-agonist derived from 4,5-epoxymorphinan. *Chem. Pharm. Bull.* **1998**, *46*, 366–369. [CrossRef] [PubMed]

317. Wang, Y.; Tang, K.; Inan, S.; Siebert, D.; Holzgrabe, U.; Lee, D.Y.; Huang, P.; Li, J.G.; Cowan, A.; Liu-Chen, L.Y. Comparison of pharmacological activities of three distinct κ ligands (Salvinorin A, TRK-820 and 3FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. *J. Pharm. Exp. Ther.* **2005**, *312*, 220–230. [CrossRef] [PubMed]

318. Suzuki, S.; Sugawara, Y.; Tsuji, R.; Tanimura, R.; Kaneko, C.; Yuzawa, N.; Yagi, M.; Kawai, K. Discovery of highly selective κ-opioid receptor agonists: 10α-Hydroxy TRK-820 derivatives. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 3920–3924. [CrossRef]

319. Váradi, A.; Hosztafi, S.; Le Rouzic, V.; Tóth, G.; Urai, Á.; Noszál, B.; Pasternak, G.W.; Grinnell, S.G.; Majumdar, S. Novel 6β-acylaminomorphinans with analgesic activity. *Eur. J. Med. Chem.* **2013**, *69*, 786–789. [CrossRef]

320. Urai, A.; Váradi, A.; Szőcs, L.; Komjáti, B.; Le Rouzic, V.; Hunkele, A.; Pasternak, G.W.; Majumdar, S.; Hosztafi, S. Synthesis and pharmacological evaluation of novel selective MOR agonist 6β-pyridinyl amidomorphines exhibiting long-lasting antinociception. *MedChemComm* **2017**, *8*, 152–157. [CrossRef]

321. Lever, J.R. PET and SPECT imaging of the opioid system: Receptors, radioligands and avenues for drug discovery and development. *Curr. Pharm. Design* **2007**, *13*, 33–49. [CrossRef]

322. Henriksen, G.; Willoch, F. Imaging of opioid receptors in the central nervous system. *Brain* **2008**, *131*, 1171–1196. [CrossRef] [PubMed]

323. Dannals, R.F. Positron emission tomography radioligands for the opioid system. *J. Label. Compd. Radiopharm.* **2013**, *56*, 187–195. [CrossRef]

324. Dannals, R.F.; Ravert, H.T.; Frost, J.J.; Wilson, A.A.; Burns, H.D.; Wagner, H.N. Radiosynthesis of an opiate receptor binding radiotracer: [$^{11}$C]carfentanil. *Int. J. Appl. Radiat. Isot.* **1985**, *36*, 303–306. [CrossRef] [PubMed]

325. Berényi, S.; Csutorás, C.; Sipos, A. Recent developments in the chemistry of thebaine and its transformation products as pharmacological targets. *Curr. Med. Chem.* **2009**, *16*, 3215–3242. [CrossRef]

326. Lever, J.R.; Kinter, C.M.; Ravert, H.T.; Musachio, J.L.; Mathews, W.B.; Dannals, R.F. Synthesis of *N*1′-([$^{11}$C]methyl)naltrindole ([$^{11}$C]MeNTI): A radioligand for positron emission tomographic studies of delta opioid receptors. *J. Label. Compd. Radiopharm.* **1995**, *36*, 137–145. [CrossRef]

327. Mathews, W.B.; Kinter, C.M.; Palma, J.; Daniels, R.V.; Ravert, H.T.; Dannals, R.F.; Lever, J.R. Synthesis of *N*1′-([$^{18}$F]fluoroethyl)naltrindole ([$^{18}$F]FEtNTI): A radioligand for positron emission tomographic studies of delta opioid receptors. *J. Label. Compd. Radiopharm.* **1999**, *42*, 43–54. [CrossRef]

328. Majumdar, S.; Burgman, M.; Haselton, N.; Grinnell, S.; Ocampo, J.; Pasternak, A.R.; Pasternak, G.W. Generation of novel radiolabeled opiates through siete-selective iodination. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4001–4004. [CrossRef]

329. Bentley, K.W. The morphine alkaloids. In *The Alkaloids: Chemistry and Physiology*; Manske, R.H.F., Ed.; Academic Press Inc.: New York, NY, USA; London, UK, 1971; Volume 13.

330. Coop, A.; Lewis, J.W.; Rice, K.C. Direct and simple *O*-demethylation of thebaine to oripavine. *J. Org. Chem.* **1996**, *61*, 6774. [CrossRef]

331. Coop, A.; Janetka, J.W.; Lewis, J.W.; Rice, K.C. L-Selectride as a general reagent for the *O*-demethylation and *N*-decarbomethoxylation of opium alkaloids and derivatives. *J. Org. Chem.* **1998**, *63*, 4392–4396. [CrossRef]

332. Hosztafi, S. Recent Advances in the Chemistry of Oripavine and Its Derivatives. *Adv. Biosci. Biotechnol.* **2014**, *5*, 704–717. [CrossRef]

333. Lever, J.R.; Dannals, R.F.; Wilson, A.A.; Ravert, H.T.; Wagner, H.N., Jr. Synthesis of carbon-11 labeled diprenorphine: A radioligand for positron emission tomographic studies of opiate receptors. *Tetrahedron Lett.* **1987**, *28*, 4015–4018. [CrossRef]

334. Luthra, S.K.; Brady, F.; Turton, D.R.; Brown, D.J.; Dowsett, K.; Waters, S.L.; Jones, A.K.P.; Matthews, R.W.; Crowder, J.C. Automated radiosyntheses of [6-*O*-methyl-$^{11}$C]diprenorphine and [6-*O*-methyl-$^{11}$C]buprenorphine from 3-*O*-trityl protected precursors. *Appl. Radiat. Isot.* **1994**, *45*, 857–873. [CrossRef]

335. Lever, J.R.; Mazza, S.M.; Dannals, R.F.; Ravert, H.T.; Wilson, A.A.; Wagner, J.H.N. Facile synthesis of [$^{11}$C]buprenorphine for positron emission tomographic studies of opioid receptors. *Int. J. Radiat. Appl. Instrum. Part A. Appl. Radiat. Isot.* **1990**, *41*, 745–752. [CrossRef]

336. Marton, J.; Schoultz, B.W.; Hjørnevik, T.; Drzezga, A.; Yousefi, B.H.; Wester, H.-J.; Willoch, F.; Henriksen, G. Synthesis and evaluation of a full-agonist orvinol for PET-Imaging of opioid receptors: [$^{11}$C]PEO. *J. Med. Chem.* **2009**, *52*, 5586–5589. [CrossRef]

337. Marton, J.; Henriksen, G. Design and synthesis of an $^{18}$F-labeled version of phenylethyl orvinol ([$^{18}$F]FE-PEO) for PET-imaging of opioid receptors. *Molecules* **2012**, *17*, 11554–11569. [CrossRef] [PubMed]

338. Riss, P.J.; Hong, Y.T.; Marton, J.; Caprioli, D.; Williamson, D.J.; Ferrari, V.; Saigal, N.; Roth, B.L.; Henriksen, G.; Fryer, T.D.; et al. Synthesis and evaluation of $^{18}$F-FE-PEO in rodents: An $^{18}$F-labeled full agonist for opioid receptor imaging. *J. Nucl. Med.* **2013**, *54*, 299–305. [CrossRef] [PubMed]

339. Schoultz, B.W.; Hjørnevik, T.; Reed, B.J.; Marton, J.; Coello, C.S.; Willoch, F.; Henriksen, G. Synthesis and evaluation of three structurally related $^{18}$F-labeled orvinols of different intrinsic activities: 6-*O*-[$^{18}$F]Fluoroethyl-diprenorphine ([$^{18}$F]FDPN), 6-*O*-[$^{18}$F]fluoroethyl-buprenorphine ([$^{18}$F]FBPN), and 6-*O*-[$^{18}$F]fluoroethyl-phenethyl-orvinol ([$^{18}$F]FPEO). *J. Med. Chem.* **2014**, *57*, 5464–5469. [PubMed]

340. Wester, H.-J.; Willoch, F.; Tölle, T.R.; Munz, F.; Herz, M.; Øye, I.; Schadrack, J.; Schwaiger, M.; Bartenstein, P. 6-*O*-(2-[18F]Fluoroethyl-6-*O*-desmethyldiprenorphine ([18F]DPN): Synthesis, biologic evaluation, and comparison with [11C]DPN in humans. *J. Nucl. Med.* **2000**, *41*, 1279–1286.

341. Schoultz, B.W.; Reed, B.J.; Marton, J.; Willoch, F.; Henriksen, G. A fully automated radiosynthesis of [18F]fluoroethyl-diprenorphine on a single module by use of SPE cartridges for preparation of high quality 2-[18F]fluoroethyl tosylate. *Molecules* **2013**, *18*, 7271–7278. [CrossRef]

342. Marton, J.; Cumming, P.; Bauer, B.; Henriksen, G. A new precursor for the radiosynthesis of 6-*O*-(2-[18F]fluoroethyl)-6-*O*-desmethyl-diprenorphine ([18F]FE-DPN) by nucleophilic radiofluorination. *Lett. Org. Chem.* **2021**, *18*, 344–352. [CrossRef]

343. Németh, E.; Gyuricza, B.; Forgács, V.; Cumming, P.; Henriksen, G.; Marton, J.; Bauer, B.; Mikecz, P.; Fekete, A. Optimization of a Nucleophilic Two-Step Radiosynthesis of 6-*O*-(2-[18F]fluoroethyl)-6-*O*-desmethyl-diprenorphine ([18F] FE-DPN) for PET Imaging of Brain Opioid Receptors. *Int. J. Mol. Sci.* **2023**, *24*, 13152. [CrossRef]

344. Levinstein, M.R.; Ventriglia, E.N.; Gomez, J.L.; Budinich, R.C.; Marton, J.; Henriksen, G.; Holt, D.P.; Dannals, R.F.; Pomper, M.G.; Zarate, C.A.; et al. 6-*O*-(2-[18F]Fluoroethyl)-6-*O*-desmethyl-diprenorphine ([18F]FE-DPN) preferentially binds to mu opioid receptors in vivo. *Mol. Imag. Biol.* **2023**, *25*, 384–390. [CrossRef]

345. Horváth, G.; Makleit, S. Vizsgálatok a morfin szintézisével összefüggésben, II. Az *O*6-demetil-szalutaridin átalakítása szalu-taridinné. *Magy. Kém. Foly.* **1980**, *86*, 260–263.

346. Horváth, G.; Makleit, S. Studies related to the synthesis of morphine, II. Conversion of *O*6-demethylsalutaridine into salutaridine. *Acta Chim. Acad. Sci. Hung.* **1981**, *106*, 37–42. [CrossRef]

347. Lewis, J.W.; Walter, D. Buprenorphine—Background to its development as a treatment for opioid dependence. In *NIDA Research Monograph 121, Buprenorphine: An Alternative Treatment for Opioid Dependence*; Blaine, J.D., Ed.; US Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIDA: Rockville, MD, USA, 1992; Volume 121, pp. 5–11.

348. Berényi, S.; Hosztafi, S.; Makleit, S.; Simon, C.; Marton, J. New Process for Producing N-Substituted-6,14-endo-ethanotetrahydrothebaine and -Oripavine Derivatives and Their Salts. Hungarian Patent 210,158, 15 January 1991.

349. Marton, J.; Simon, C.; Hosztafi, S.; Berényi, S.; Makleit, S.; Kabai, S.; Kolozsi, S.; Kovács, Z.; Nagy, I. New Process for Producing 6,14-ethenomorphinan Derivatives and Salts Thereof. Hungarian Patent 76,478, 10 July 1995.

350. Marton, J.; Szabó, Z.; Hosztafi, S. Herstellung von 6,14 Ethenomorphinan-Derivaten. *Liebigs Ann. Chem.* **1993**, *8*, 915–919. [CrossRef]

351. Antus, S. Invetsigation of biologically active compounds at the Department of Organic Chemistry of University of Debrecen between 1992–2009, I. *Acta Pharm. Hung.* **2009**, *79*, 95–103. [PubMed]

352. Hosztafi, S.; Makleit, S.; Bognár, R. Morfin-alkaloidok *N*-demetilezése. A nor-neopin előállítása. *Magy. Kém. Foly.* **1980**, *86*, 15–17.

353. Hosztafi, S.; Makleit, S.; Bognár, R. *N*-Demethylation of morphine alkaloids. Preparation of norneopine. *Acta Chim. Acad. Sci. Hung.* **1980**, *103*, 371–375.

354. Hosztafi, S. Reactions of azodicarboxylic esters with amines. *Sci. Pharm.* **1987**, *55*, 61–75.

355. Hosztafi, S. Morfinváz C Gyűrűjében Módosított Vegyületek Szintézise. D.Sc. Dissertation, Semmelweis University, Budapest, Hungary, 2020.

356. Seller, S.; Szabó, M.; Palincza, J.; Imre, L.; Cselenyák, Z.; Tompa, J. Process for Separation of Opium Alkaloids. Hungarian Patent 225,038, 15 November 2002.

357. Volkow, N.D.; Blanco, C. The changing opioid crisis: Development, challenges and opportunities. *Mol. Psychiatry* **2021**, *26*, 218–233. [CrossRef] [PubMed]

358. Pieters, T. The imperative of regulation: The co-creation of a medical and non-medical US opioid crisis. *Psychoactives* **2023**, *2*, 317–336. [CrossRef]

359. Dennen, A.C.; Blum, K.; Braverman, R.E.; Bowirrat, A.; Gold, M.; Elman, I.; Thanos, K.P.; Baron, D.; Gupta, A.; Edwards, D.; et al. How to Combat the Global Opioid Crisis. *CPQ Neurol. Psychol.* **2023**, *5*, 93.

360. Engi, Z.; Benkő, R.; Soós, G.; Szok, D.; Csenki, M.; Csüllög, E.; Balog, A.; Csupor, D.; Viola, R.; Doró, P.; et al. Trends in opioid utilization in Hungary, 2006–2020: A nationwide retrospective study with multiple metrics. *Eur. J. Pain* **2022**, *26*, 1896–1909. [CrossRef]

361. Berényi, S. A debreceni mákalkaloidkutatás 50 éve—50 years on the Research of Poppy Alkaloids in Debrecen. *MKL–Magy. Kém. Lapja.* **1999**, *54*, 548–549.